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ABSTRACT 
 
The Chemistry of Atherogenic High Density Lipoprotein. (May 2011) 
D’Vesharronne J. Moore, B.S., Texas Southern University 
Chair of Advisory Committee: Dr. Ronald Macfarlane 
 
 An array of analytical methods including density gradient ultracentrifugation, 
capillary electrophoresis, and matrix-assisted laser desorption ionization mass 
spectrometry (MALDI-MS), were utilized to analyze serum high density lipoprotein 
(HDL) subfractions from two cohorts of normolipidemic individuals, which included 
subjects with diagnosed coronary artery disease (CAD), and angiographically proven 
non-CAD controls.  These methods collectively provided characteristic information 
about the two populations of individuals including composition, electrophoretic 
mobilities, molecular weights, isoforms, and post-translational modifications of HDL 
apolipoproteins.  This information proved useful in identifying potential biomarkers for 
CAD risk and understanding the biological functions of a novel atherogenic HDL 
phenotype in individuals with CAD. 
Through the implementation of the aforementioned methodologies, new isoforms 
of apoC-I were identified.  MALDI-MS detected a shifting of approximately 90 Da in 
the mass to charge ratios corresponding to apoC-I peaks in the serum subfractions from 
all CAD cohort patients.  This shifting was not observed in the non-CAD cohort which 
displayed apoC-I peaks in accordance with the known mass of this protein.  In addition 
to the shifting observed in the CAD cohort, some CAD patients showed further 
modifications of apoC-I that were indicative of oxidative processes.   
Interestingly, one patient, who has not been diagnosed with CAD and has a 
family history of the disease, contained the apoC-I isoforms.  This feature could underlie 
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this subject’s known family history of CAD and serve as an initial screening that could 
indicate the future development of CAD in this individual.  
 Through collaborative work with Johns Hopkins University, it was initially 
observed that apoC-I enriched HDL induced apoptosis of aortic smooth muscle cells.  
Conversely, apoC-I depleted HDL induced minimal to no apoptosis which led to the 
hypothesis that apoC-I is a contributor to atherogenic HDL and is a potential risk factor 
for CAD.  Further collaborative work with Johns Hopkins assessed the apoptosis levels 
induced by HDL from both cohorts of patients.  A distinct difference in apoptosis was 
identified between the two cohorts.  High density lipoprotein subfractions from subjects 
in the CAD cohort, all of which contained the apoC-I isoforms, induced marked 
apoptosis compared to the non-CAD controls.  These results further supported the 
hypothesis that apoC-I compromises the functionality of HDL and showed that through 
the induction of apoptosis, apoC-I can contribute to the destabilization of atherosclerotic 
plaque and the acceleration of CAD. 
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CHAPTER I 
 
INTRODUCTION 
 
 
 HDL in Health and Disease 
 
High Density Lipoprotein Cholesterol and Coronary Artery Disease 
 Coronary artery disease (CAD) is the leading cause of morbidity and mortality in 
the developed world.
1
  It is well established that there is a powerful inverse correlation 
between circulating high density lipoprotein cholesterol (HDL-C) levels and CAD risk.
2
 
High density lipoprotein cholesterol is determined as the amount of cholesterol in high 
density lipoprotein (HDL) particles per 100mL of plasma.
3
  High density lipoprotein 
cholesterol levels greater than or equal to 60 mg/dL are considered protective, while 
those below 40mg/dL in men and below 50mg/dL in women, are independent risk 
factors for future cardiovascular events.
4
  There is an elevation in CAD risk of 
approximately 3% in women and 2% in men for each decrement of 0.0259mM (1mg/dL) 
in HDL-C.
5,6
 With this established relationship between HDL-C and CAD risk, the 
medical community has historically tailored diagnosis, treatment, and prevention around 
HDL-C levels.    
 
Atheroprotective Properties of HDL 
 In addition to the correlation between HDL-C levels and CAD risk, HDL is also 
known for its many anti-atherogenic or atheroprotective properties.  The primary 
atheroprotective property of HDL is its ability to promote the efflux of cholesterol from 
macrophage and peripheral cells in a process known as reverse cholesterol transport.
7, 8
   
Peripheral cells are unable to catabolize cholesterol, thus the mechanism of reverse 
cholesterol transport provides the pathway by which excess cholesterol in the vessel wall 
and in macrophages, can be scavenged and returned to the liver for removal.
9
  This  
____________ 
This dissertation follows the style of Analytical Chemistry. 
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mechanism beneficially prevents systemic vascular cholesterol retention and 
accumulation.9  High density lipoprotein displays a number of atheroprotective 
properties independent of reverse cholesterol transport, including antioxidant
10
, anti-
inflammatory
11
, and anti-thrombotic properties.
12, 13
  The antioxidant properties of HDL 
are typically observed as the inhibition of low density lipoprotein (LDL) oxidation.
14, 15
  
High density lipoprotein associated proteins and enzymes contribute to its antioxidant 
functions.  These associated proteins and enzymes can prevent or delay LDL oxidation 
by the removal of oxidized phospholipids from LDL and artery wall cells, and by 
hydrolyzing LDL-derived oxidized phospholipids.
15
  The anti-inflammatory properties 
of HDL include decreasing cytokine-induced expression of adhesion molecules on 
endothelial cells, the inhibition of monocyte adhesion to these cells, and altering other 
aspects of endothelial function.
16, 17
  The anti-thrombotic properties of HDL are observed 
as inhibitory actions on factors that promote blood coagulation and may be related to 
HDL particle phospholipids containing potent anticoagulant properties.
 18,
 
19
 High 
density lipoprotein has also been shown to possess anti-apoptotic, vasodilatory, and anti-
infectious properties.
 20, 21
 High density lipoprotein potently inhibits apoptosis in 
endothelial cells induced by oxidized LDL,
22, 23 
this effect is also accompanied by 
decreased generation of reactive oxygen species suggesting a relation to the intracellular 
anti-oxidative properties of HDL.
24
  High density lipoprotein vasodilatory properties 
may be related to the stimulation of nitric oxide release by endothelial cells.
25, 26
  
Likewise, increased production of nitric oxide may form a basis for the inhibitory 
properties of HDL on platelet aggregation.
27
  The multifaceted functions and properties 
of HDL demonstrate its complexity and provide insight as to why its functionality and 
role in health and disease has not been completely elucidated. 
 
Atherogenic High Density Lipoprotein
 
Given the complexity of HDL, it is not unforeseen that a single assay of plasma 
steady-state HDL-C levels does not absolutely correlate with HDL function.  Although 
high serum levels of HDL-C have been correlated with longevity and decreased CAD 
3 
 
 
 
risk,
28, 29
 recent evidence suggests that elevated HDL-C levels may also portend 
increased risk for CAD and related events.
30
  There is also evidence that low HDL-C 
levels are associated with no increase or even reduced CAD risk.
30
  The apolipoprotein 
A-I (apoA-I) Milano mutation for example,  is a rare, naturally occurring genetic point 
mutation in apoA-I that leads to low HDL-C levels but does not confer an increased 
CAD risk.3
, 31
  Despite the many atheroprotective properties of HDL, there have been 
several populations of individuals identified with disease despite elevated levels of 
HDL-C such as the clinical trials involving cholesterol ester transfer protein (CETP) 
deficiencies.
32, 33
  The recently published results of outcome trials with CETP inhibitor 
torcetrapib
34, 35, 36, 37
 showed no apparent impact on atherosclerosis and increased 
morbidity and mortality despite significant raising of HDL-C levels.
34
  Trials were 
terminated prematurely due to a 25% increase in major CAD events and a 40% increase 
in death from CAD causes in the active treatment arm.
37
  These adverse events occurred 
despite a 72% increase in HDL-C and a 25% reduction in LDL-C.
34  
 Contrary to its 
many atheroprotective properties, it is seen that dysfunctional or atherogenic HDL 
contains properties that add to CAD risk and development.  In many patients with 
atherosclerosis, the hardening of arteries which occurs along with the progression of 
CAD, it appears that HDL is not only ineffectual as an antioxidant, but paradoxically 
increases lipid peroxide formation.
38
  In the setting of systemic inflammation, the anti-
atherogenicity of HDL can markedly diminish, to the extent where it even becomes 
proinflammatory.
39, 40  
This inflammatory situation can lead to a proinflammatory 
phenotype of HDL that increases LDL oxidation, increases vascular inflammation, 
promotes expression of cellular adhesion molecules, and is less, if at all, effective in 
reverse cholesterol transport.
17, 41  
The many studies reporting CAD despite elevated  
HDL-C levels as well as longevity and health despite low HDL-C levels, suggest that the 
anti-atherogenicity of elevated HDL-C is strongly influenced by specific genetic and 
metabolic backgrounds. 
 
 
4 
 
 
 
Therapeutic Strategies to Improve High Density Lipoprotein 
Strategies to increase HDL-C levels have been the target of HDL therapeutics, 
given the strong epidemiological associations between HDL-C and CAD. Substantial 
experimental evidence suggest that augmenting the levels and or functions of HDL and 
its associated components can have major vascular protective effects, independent of 
total or non-HDL-C levels.
 42
  A number of therapeutic strategies are being developed to 
target elevated HDL-C levels in an attempt to inhibit the progression or induce 
regression of atherosclerosis, reduce CAD events, normalize the intravascular 
metabolism and physicochemical properties of HDL, and improve anti-atherogenic 
efficacy.
 43
  Nicotinic acid, also known as niacin, is the most effective HDL-C raising 
agent currently available and can increase HDL-C by up to 35%.4  Several clinical 
studies have demonstrated niacin’s ability to reduce CAD events and slow the 
progression of atherosclerosis in patients with CAD and lower HDL-C levels.
44  
Niacin 
reduces triglyceride hydrolysis in adipose tissue by inhibition of hormone-sensitive 
lipase via HM74 receptors.
 45
  Plasma levels of triglyceride-rich lipoproteins and LDL-C 
are decreased and levels of HDL-C are raised primarily as a result of diminished hepatic 
uptake of HDL with enhanced lipidation of apoA-I.
46
  Cholesterol ester transfer protein 
(CETP), is a plasma protein that mediates transfer of cholesteryl esters from HDL to 
apoB-containing lipoproteins in exchange for triglycerides.
47
  The interest in CETP 
inhibition was sparked after the discovery of Japanese individuals with extremely high 
levels of HDL-C who were genetically deficient in CETP.
48, 49  
This genetic association 
led to the concept that pharmacological inhibition of CETP might be an approach to 
raise HDL-C.  Unfortunately, trials involving CETP inhibitor torcetrapib provided 
surmountable challenges in the search for effective strategies, and were terminated 
prematurely due to substantial mortality rates in the active treatment arm.
37
  Fibrates are 
peroxisome proliferative-activated receptor α agonists that exert multiple effects on lipid 
metabolism, increasing plasma HDL-C by 10% and decreasing triglycerides by 36% 
(averages for 53 randomized trials).
50
  Though the primary use of fibrates target 
lowering triglyceride levels, the modest HDL-C raising effect of these agents may also 
5 
 
 
 
translate into a reduction in clinical CAD events.
51, 52
  Statins’ major effect is to decrease 
the number of atherogenic apoB-containing lipoprotein particles.  In addition, these 
agents raise levels of HDL-C typically by 5 – 10%, reduce CETP activity and possess 
pleiotropic effects, which include anti-inflammatory and anti-oxidative activities.
53 
 
While statin treatment is associated with a limited effect on HDL-C concentration, 
changes in HDL’s anti-inflammatory or inflammatory properties may be greater.  
Consistent with these data, treatment of CAD patients with simvastatin increases HDL 
functionality, rendering HDL anti-inflammatory.
38
  Recently, reconstituted HDL, 
consisting of apoA-I and phospholipids, is stimulating significant therapeutic interest.
 54
  
Intravenous injection of reconstituted HDL is followed by a rapid elevation in HDL-C 
levels, facilitation of reverse cholesterol transport, as well as multiple anti-atherogenic 
effects.
55
  Short apoA-I mimicking peptides equally increase HDL levels, reduce 
atherosclerosis, activate reverse cholesterol transport, and exhibit other anti-atherogenic 
properties.
56
   Other drug classes in development include novel PPAR alpha agonists, 
liver-X receptor agonists, ABCA1 upregulators, SR-B1 inhibitors, protein mimetics and 
gene therapy.
43
  All of these approaches will require proof of long-term safety as well as 
clinical efficacy.  Different HDL-C raising agents may function complementarily or in 
series, and have additive effects, thus, combined use of such agents has also been 
proposed.
44
  For example, nicotinic acid combined with simvastatin potently elevates 
plasma HDL-C, lowers triglycerides, reduces the frequency of CAD events and slows 
the progression of CAD in patients with low HDL-C levels.
45  
Actions of statins on HDL 
functionality involve cooperation with CETP inhibitors,
57,58
 and apoA-I mimetic 
peptides.
59
  Table 1 reports information on HDL raising drugs.  There are currently many 
therapeutic hypotheses and agents under investigation.  The success of each however, 
will depend on the biological variability of those to which they are administered, and the 
outcomes of extensive clinical trials. 
 
 
 
6 
 
 
 
Table 1. HDL raising drugs 
Drug Class Mechanism of Action 
for HDL Elevation 
Elevation of 
HDL-C 
Nicotinic acid Suppresses triglyceride hydrolysis in adipose tissue by 
inhibition by hormone-sensitive lipase, thereby 
decreasing VLDL-triglyceride levels; stimulates 
cholesterol efflux by activating ABCA1. 
Up to 35% 
Fibrates Upregulation of apoA-I, apoA-II, lipoprotein lipase, 
SR-B1 and ABCA1 expression through binding and 
activation of PPARα; increase lipolysis of VLDL, 
with enhanced release of surface fragments to HDL, 
via increase in lipoprotein lipase activity. 
Up to 16% 
Statins Lower plasma CETP concentration; reduce CETP-
mediated transfer of cholesteryl esters to apoB-
containing lipoproteins via reductions in acceptor 
particle number; enhance hepatic apoA-I production. 
Up to 15% 
CETP Inhibitor 
Torcetrapib 
Inhibition of CETP by enhancing its association with 
its lipoprotein substrates; preferential elevation of 
large HDL. 
Up to 106% 
Reconstituted 
HDL 
Rapid formation of small HDL; apoA-IMilano, elevated 
efficiency as a cellular cholesterol acceptor through 
Arg173Cys substitution. 
Transient 
ApoA-I 
mimetics 
Rapid formation of small HDL particles, which 
subsequently mature to large HDL particles. 
Transient 
 
 
Apoptosis and Coronary Artery Disease 
Apoptosis is the highly regulated, energy requiring process by which cells are 
terminated in the human body.  In this form of cell death, damaged cells are removed 
without causing inflammation or damage to surrounding tissue.
60
  Apoptosis was 
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initially characterized by its morphological characteristics which include chromatin 
condensation, DNA fragmentation, plasma membrane blebbing, formation of apoptotic 
bodies, and cell shrinkage due to reduction in cytoplasm and organelles.
61
  Membrane 
bound apoptotic bodies containing cytosol and processed organelles are formed and 
subsequently removed by macrophages via phagocytosis.
62
  In relation to CAD, studies 
have shown that apoptosis plays a key role in pathogenesis.
63
  Apoptosis occurs in 
myocardial tissue samples from patients suffering from myocardial infarction or heart 
disease, dilated cardiomyopathy, and end stage heart failure.
64
  Apoptosis is activated by 
various stressors that are commonly seen in CAD such as cytokine production,
65
 
increased oxidative stress,
66
 and DNA damage.
67
  Apoptosis can be initiated by 
mitochondria, which release cytochrome c into the cytosol in response to extrinsic 
stimuli such as oxidative insults.
68
  Alternatively, the apoptotic pathway can be initiated 
via endogenous death receptors, leading to internal death signaling that promotes 
coordinated and specific cell death.
69
  Both pathways converge on a common 
downstream pathway, which mediates the final morphological and biochemical 
alterations that are characteristic of apoptosis.  Due to the limitations on the regenerative 
capacity of the myocardium, there is intense interest in the prevention of cardiomyocyte 
loss in coronary artery disease to prevent development of heart failure.
63
 
When it comes to the topic of HDL in health and disease, there are several 
unanswered questions that will take years to investigate.  The evidence supports the need 
to increase HDL-C in patients at risk for CAD events.9  High density lipoprotein 
cholesterol however, does not directly assess the rate of centripetal cholesterol flux from 
peripheral foam cells to the liver, which is influenced by factors other than HDL-C 
alone.  Additionally, HDL-C values fail to provide information regarding the anti-
inflammatory, antioxidant, anti-thrombotic, and endothelial function promoting benefits 
of HDL, despite increasing evidence supporting the clinical significance of these 
functions.  Biochemically innovative approaches to raising HDL-C, controlling HDL 
particle size and functionality, atherogenicity, and preventing the formation of 
dysfunctional HDL, offer greater insight and direction for reducing the risk of CAD than 
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currently available drug therapy.  The multiple actions and properties of HDL make it a 
complex therapeutic target albeit one with an abundance of anti-atherogenic potential. 
 
 
 
 
 High Density Lipoprotein Particles 
  
Lipoprotein Particles 
Lipoproteins are biochemical assemblies of lipids and proteins which serve to 
carry nonpolar lipids throughout the body in aqueous blood and extracellular fluid.  
These particles facilitate lipid exchange between lipoprotein classes and cells, and are 
instrumental in the metabolism and transportation of triglycerides, phospholipids, 
cholesteryl esters, and cholesterol.  These water-soluble macromolecules are composed 
of a surface monolayer made of amphipathic phospholipids, free cholesterol, and 
apolipoproteins surrounding a central core containing nonpolar lipids, mainly 
triglycerides and cholesteryl esters (Figure 1).
70
   
 
 
 
Figure 1.  Lipoprotein structure and composition. 
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These particles are classified based upon their hydrated densities, and comprise a 
heterogeneous spectrum of particles that differ in size, density, lipid, and apolipoprotein 
composition. This system of classification gives way to the five lipoprotein subclasses: 
low density lipoprotein (LDL), very low density lipoprotein (VLDL), intermediate 
density lipoprotein (IDL), high density lipoprotein (HDL), and chylomicrons (Table 2).
71
 
 
  
Table 2.  Lipoprotein characteristics 
Lipoprotein 
Class 
Density  
(g/mL) 
Size  
(nm) 
Major  
Lipids 
Major 
Apolipoproteins 
Chylomicrons >0.93 100 – 500 Dietary TAG B-48, C-II, E 
VLDL 0.93 – 1.006 30 – 80 Endogenous TAG B-100, C-II, E 
IDL 1.006 – 1.019 25 – 50 CE and TAG B-100, E 
LDL 1.019 – 1.063 18 – 28 CE and TAG B-100 
HDL 1.063 – 1.210 5 – 15 CE and PL A-I, A-II, C-II, E 
  
 
High Density Lipoprotein Particles 
 High density lipoprotein (HDL) particles are the most dense lipoprotein subclass 
and have been classically defined as a group of pseudomicellar, quasi-spherical, protein 
and lipid complexes with hydrated densities between 1.063 – 1.210g/mL.71  High density 
lipoprotein particles can vary tremendously in size, density, composition, and functional 
properties, potentially affecting their relationship to CAD.  These particles are 
characterized by their structural and metabolic heterogeneity, caused by their diverse 
metabolic origin and continuous remodeling by lipolytic enzymes, lipid transporters, and 
furthermore by lipid and apolipoprotein exchange with other circulating tissues and 
lipoproteins.3
, 70
  High density lipoprotein particles can be further divided into two 
distinct subfractions, HDL2 and HDL3.  HDL2 spans the density range between 1.063 – 
1.125g/mL while HDL3 spans the range between 1.125 – 1.210g/mL.
 72
  The larger and 
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more buoyant HDL2 is formed by enzymatic action upon the smaller and denser HDL3.  
Overall, HDL is protein rich compared to other lipoprotein subclasses, with a protein to 
lipid ratio ranging from 1:2 in HDL2 to 10:1 in HDL3.
73
  Progressive reduction in HDL 
particle size with increasing hydrated density is associated with elevation in protein 
content and in surface to core ratio accompanied by reduction in core lipid content, 
consistent with the predominance of surface components in small, dense HDL3.
74
  A 
lower HDL2 to HDL3 ratio, typically involving decreased HDL2 with constant or 
increased HDL3 has been associated with increased CAD risk.
75
  Coronary artery disease  
patients were also found to have less HDL with apoA-I within the more buoyant HDL2 
subclass, and more HDL with apoA-I and apoA-II within the denser HDL3 subclass 
compared with healthy controls.
76, 77
  Within the population of individuals with CAD, 
HDL subclasses also show prediction regarding disease.  The HDL2b subclass is 
inversely related to disease severity on coronary angiograms and progression of coronary 
lesions between repeated angiographies.
78, 79
  HDL3b also has been associated with a 
lipoprotein profile indicative of increased risk of CAD independent of HDL2b.
76
  
 
High Density Lipoprotein Metabolism 
Lipoprotein metabolism involves the collaborative work of all five lipoprotein 
subclasses, and involves the transportation of dietary or exogenous fat, endogenous fat, 
and reverse cholesterol transport.  Reverse cholesterol transport and HDL metabolism 
are two pathways with significant overlap, only the final step of reverse cholesterol 
transport, bile acid formation and excretion, is unrelated to HDL.  The metabolism of 
HDL, involves a variety of factors regulating HDL synthesis, intravascular remodeling, 
and catabolism.  In HDL metabolism, the individual lipid and apolipoprotein 
components of HDL are mostly assembled following secretion, frequently exchanged 
with or transferred to other lipoproteins, actively remodeled within the plasma 
compartment, and cleared at least in part independent from each other.  HDL metabolism 
begins with cholesterol efflux.  This process underlies the formation of HDL from lipid-
free apoA-I and cellular lipids, cholesterol, and or phospholipids.  Cholesterol efflux 
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occurs at the plasma membranes of cells as a result of the action of ATP binding cassette 
A-I (ABCA1),
80
 resulting in small, lipid-poor, discoidal HDL particles.
81
  These nascent 
particles are effective acceptors of cellular cholesterol, although other pathways 
involving ABCG1 and scavenger receptor B1 (SR-B1) mediate this step which results in 
large, lipid-rich discoidal particles.
80
  Upon reaching the appropriate size and 
composition, discoidal HDL particles become a substrate for lecithin:cholesterol 
acyltransferase (LCAT).  Lecithin:cholesterol acyltransferase esterifies free cholesterol 
and forms the hydrophobic core, transforming HDL from discoidal to spherical particles.  
These particles acquire additional cholesterol and apolipoproteins from other 
lipoproteins in the plasma and fuse with each other.  The products of this step are 
mature, large, cholesterol-rich, spherical particles.
82
  These spherical particles, upon 
reaching the appropriate size and composition, become substrates for a number of 
enzymes and transfer factors.  These include SR-B1 and the LDL-receptor related 
protein (LRP) at the surfaces of hepatocytes, which ensure delivery of HDL-C to the 
liver either by selective cholesteryl ester uptake or through HDL holoparticle uptake, 
respectively.
83
  Additionally, cholesterol ester transfer protein (CETP) facilitates the 
exchange of HDL cholesteryl esters for triglycerides in apoB-containing lipoproteins.
84
  
Other factors include phospholipid transfer protein (PLTP)
85
 and endothelial and hepatic 
lipases,
86
 which transfer and hydrolyze HDL phospholipids and triglycerides.  The rate 
of HDL remodeling and the proportion of cholesterol delivered to the liver versus that 
delivered to apoB-containing lipoproteins depends on the activities of SR-B1 and LRP, 
and the levels of triglycerides and activity of CETP.  The products of this step are small, 
lipid-poor spherical HDL particles and lipid-free apoA-I released during remodeling.  
The lipid poor spherical HDL particles join the cycle at the stage of maturation, while 
the lipid-free apoA-I can undergo a new cycle of lipidation and HDL formation. 
 
High Density Lipoprotein Associated Apolipoproteins 
Apolipoproteins attach to the surface of lipoprotein particles and facilitate the 
formation of lipoproteins, modulate the activity of enzymes and lipid transfer factors 
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involved in lipoprotein remodeling in circulation, and modulate receptor-mediated 
binding and endocytosis of lipoproteins and or their remnants.
 87
  High density 
lipoprotein associated apolipoproteins have a domain structure with amphipathic α-
helices that orient themselves with their nonpolar, lipid-binding surfaces interacting with 
polar and nonpolar regions of the particle surface lipids, while the opposite surfaces, rich 
in charged amino acid side chains, are in contact with the aqueous environment.  The 
major apolipoproteins of HDL are apoA-I and apoA-II, while others including apos A-
IV, A-V, C-I, C-II, C-III, D, E, F, H, J, L, M, O, and P are also attached. Recent studies 
have identified up to 75 distinct proteins associated with centrifugally-isolated HDL.
88 
 
The plasma abundance of these associated proteins however is insufficient to permit one 
copy per HDL particle, indicating that specific proteins may be bound to distinct particle 
species which are differentially distributed across the HDL density spectrum.  The 
potential for distinct particle subpopulations is consistent with the fact that HDL exerts 
various biological activities.  
ApoA-I is present in the majority of HDL particles and constitutes approximately 
70% of the apolipoprotein content of HDL particles; consequently, plasma apoA-I 
concentrations correlate closely with plasma HDL-C.
 89 
  ApoA-I is secreted 
predominantly by the liver and intestine as lipid-poor apoA-I and nascent phospholipid-
rich cholesterol poor HDL particles.  ApoA-I is a 28kDa protein found in plasma at a 
concentration of 100 – 150 mg/dL.89   Research studies have shown that overexpression 
of apoA-I leads to enhanced macrophage-specific reverse cholesterol transport,
 90
 
increases HDL-C, reduces atherosclerosis progression, and can even induce plaque 
regression.
91, 92  
ApoA-I infusion studies have shown temporary increases in total plasma 
apoA-I concentrations without any adverse effects,
93
 as well as rapid increases in plasma 
apoA-I and HDL followed by increases in HDL cholesteryl esters and apoA-I.
94
  An 
additional approach uses apoA-I mimetics, peptides that are structurally related to apoA-
I and mimic its effects.  Currently, several small amphipathic peptides containing 18 – 
22 amino acids have been created and shown to significantly reduce the progression of 
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aortic atherosclerosis and reduced inflammation when injected into cholesterol fed mice 
without causing significant changes in lipoprotein levels.
95
  
 ApoC-I is an HDL associated apolipoprotein which is emerging as a potential 
atherogenic component of HDL.  ApoC-I is a 6.6kDa serum protein, found in plasma at 
a concentration of 6mg/dL, and consists of 57 amino acids. 
96
  Synthesized in the liver 
and intestine, apoC-I is secreted following a co-translational cleavage of a 26-residue 
signal peptide from the N-terminal end, and does not contain a propeptide upon 
secretion.
97
  Due to its high lysine content, human apoC-I has the highest isoelectric 
point of all apolipoproteins, approximately 6.5, a feature often used for the purification 
of the protein from other apolipoproteins.
98
  ApoC-I contains alpha-helix regions 
contributing to lipid binding,
99
 and has been shown to activate LCAT in vitro resulting in 
increased formation of cholesteryl esters.
100, 101 
 Thus, it has the potential to participate in 
the esterification of the cholesterol that is transferred to HDL as a part of the excess 
surface components generated during lipolysis of VLDL and chylomicrons or that is 
transferred to HDL from cells.  The ability of apoC-I to activate LCAT may account for 
the normal serum levels of esterified cholesterol in individuals with apoA-I deficiencies.  
ApoC-I has also been shown to inhibit cholesteryl ester transfer protein (CETP).
102, 103
 
ApoC-I is important in the regulation of cholesterol transport; and is presently a possible 
independent risk factor for premature coronary artery disease.
  
Prior studies also 
demonstrated the existence of an elevated large HDL particle enriched in apoC-I found 
in infants of lower birth weight and younger gestational age.
104 
 Although this apoC-I 
enriched particle disappears soon after birth, these infants have increased risk of heart 
disease in adulthood.
105 
 The molecular mechanism behind this association remains to be 
elucidated, however, studies also indicate that apoC-I plays a role in apoptosis of 
vascular smooth muscle cells via recruitment of neutral sphingomyelinase.
106   
The amino acid sequences of apoC-I and its truncated form apoC-Iꞌ, derived from 
the DNA sequence are shown in Figure 2.  The mature forms of these apolipoproteins 
are capable of binding lipids due to the presence of two dynamic class A amphipathic 
helices.
107
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Prepeptide 
MRLFLSLPVL VVVLSIVLEG PAPAQG 
 
Mature ApoC-I 
1  10   20            30   40 
TPDVSSALDK LKEFGNTLED KARELISRIK QSELSAKMRE 
WFSETFQKVK EKLKIDS 
 
Truncated ApoC-I 
DVSSALDKLK EFGNTLEDKA RELISRIKQS  ELSAKMREWF 
SETFQKVKEK LKIDS 
 
Figure 2.  Amino acid sequence of apolipoprotein C-I and its pre-peptide.
108
  The single 
letter amino acid notations are defined as: A=Ala, R=Arg, N=Asn, D=Asp, C=Cys, 
E=Glu, Q=Gln, G=Glyc, H=His, I=Ile, L=Leu, K=Lys, M=Met, F=Phe, P=Pro, S=Ser, 
T=Thr, W=Tryp, Y=Tyr, V=Val. 
 
 
Residues 7-24 and 35-53 of apoC-I consist of amphipathic helices which are connected 
by a short linker region, contribute to lipid binding, and are stabilized by interhelical 
interactions.
109, 110
  The flexible linker region, allows helices to adopt many orientations.  
The non-polar face contains hydrophobic amino acids and interacts with fatty acid lipid 
chains.  The polar face contains hydrophilic amino acids that extend toward lipid groups 
and aqueous milieu.  Hydrophobic interactions between nonpolar residues of the 
amphipathic protein and lipid fatty acid chains are hypothesized to stabilize lipoprotein 
association.  The ability of apoC-I to associate with lipids is due to hydrophobic clusters 
formed by side chains of leucine and isoleucine as well as aromatic residues of 
tryptophan and phenylalanine.
111
 
The genes coding for human apoC-I are members of a 48-kb gene cluster on 
chromosome 19 which also includes the APOE and APOC2 gene,
112
 and is located either 
4.3
113
 or 5.3
114
kb downstream from the APOE gene in the same transcriptional 
orientation.  Mostly expressed in the liver, APOC1 is also expressed in the lung, skin, 
testes, adipose tissue, brain, and spleen.
114
  The pseudo-APOC1 gene resulted from the 
duplication of APOC1 and is located 7.5kb downstream from APOC1, between APOC1 
and  APOC4 genes.
114
  The regulation of human APOC1 gene expression, is under the 
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control of an array of elements found throughout the whole gene cluster.  The hepatic 
control region (HCR), located approximately 9kb downstream from the APOC1 gene 
was found to regulate the expression of the gene in the liver.
115
  The majority of 
apolipoprotein genes are comprised of four exons and three introns, with the first exon 
being non coding.  Exon 2 of human apoC-I encodes 20 of the 26 residues in the 26 
amino acid signal sequence and exon 3 encodes the remaining segment of the signal 
sequence plus the first 39 amino acids of the mature protein.  Exon 4 encodes the final 
segment of the mature protein.  There is not substantial information known regarding 
naturally occurring mutations in the APOC1 gene.  There has been a study reporting the 
case of apoC-I deficiency in patients with familial chylomicronemia, which may not 
directly implicate apoC-I as patients had both apoC-II and apoC-I deficiency.
116
   
Restriction fragment length polymorphisms (RFLPs) in or around the human APOC 
genes have been identified that are associated with lipoprotein disorders or altered 
plasma lipid concentrations in humans.  Human studies have not shown polymorphisms 
in the APOC1 gene leading to functional variants, an HpaI polymorphism in the 
promoter region has been shown to lead to 57% increased expression of this gene.
117,118  
 
 
High Density Lipoprotein Associated Enzymes 
Many enzymes are associated with HDL particles and facilitate the synthesis and 
functionality of this heterogeneous group of particles.  Lecithin:cholesterol 
acyltransferase (LCAT) plays a significant role in the maturation of HDL. This enzyme 
catalyzes the transfer of 2-acyl groups from lecithin to free cholesterol, generating 
cholesteryl esters and lysolecithin.
119
  Hydrophobic cholesteryl esters are retained in the 
HDL core forming larger mature HDL.  The activity of LCAT is critical to normal HDL 
metabolism.  In humans, genetic LCAT deficiency syndromes are associated with 
markedly reduced HDL-C and apoA-I levels,
82
 and rapid catabolism of cholesteryl ester 
poor apoA-I.
120
  Overexpression of LCAT in animal studies increases HDL-C levels, 
leading to decreased atherosclerosis in rabbits
121
 whereas in LDL-deficient mice, LCAT 
overexpression was reported to increase atherosclerosis unless co-expressed with 
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CETP.
122
  Although activation of LCAT would be expected to increase HDL-C, the 
effectiveness of this approach remains unspecific.   
Cholesteryl ester transfer protein (CETP), is a hydrophobic glycoprotein 
synthesized in the liver, spleen, small intestine, and adipose tissue, that circulates 
attached to lipoproteins.
123
  It promotes the redistribution and equilibration of 
hydrophobic cholesteryl esters and triglycerides packaged within the lipoprotein core 
between HDL and apoB containing lipoproteins, chylomicrons, and remnants.
 124
  The 
net effect of CETP action on HDL is depletion of cholesteryl esters and enrichment with 
triglycerides, with an overall net reduction in HDL particle size.  CETP is found in 
circulation with a normal serum concentration ranging from 0.18 – 0.27 mg/dL; CETP 
concentration correlates directly with LDL-C and negatively with HDL-C.
123
  Detected 
in foam cells in atherosclerotic lesions, the enzyme may promote cholesterol efflux from 
the lesions.
134
  Increased concentration of CETP has been found in individuals with 
chylomicronemia and dysbetalipoproteinemia.
125
  Decreased levels of CETP activity 
however, are associated with the risk of CAD despite higher HDL levels.
126
  Low CETP 
levels increase the proportion of triglycerides in VLDL and LDL and promote the 
formation of small atherogenic and oxidized LDL particles.
127
 
Phospholipid transfer protein (PLTP) is an enzyme associated with HDL and 
LDL particles, responsible for the transfer of phospholipids between lipoproteins, and 
synthesized in liver and adipose tissue.
128
  PLTP mediates the transfer of phospholipids 
from triglyceride rich lipoproteins to HDL following the hydrolysis of triglyceride rich 
lipoproteins by lipoprotein lipase.
129
  The activity of the enzyme increases during 
inflammation to maintain homeostasis by transferring and neutralizing inflammatory 
mediator, lipopolysaccharide.
130
  Normal serum levels for this protein range between 1.2 
– 1.5 mg/dL.128  PLTP may also serve a protective role in HDL metabolism specifically 
during an acute phase response.
131
  
In total, HDL associated enzymes, including paraoxonase 1, platelet-activating 
factor acetylhydrolase and lecithin:cholesterol acyltransferase, can become 
dysfunctional, depleted or both under inflammatory conditions in CAD.
38
  Reduced 
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function of HDL apolipoproteins and enzymes might result from covalent modification, 
such as oxidation by arterial wall cells and nonenzymatic glycation in the presence of 
high levels of glucose.
132
  It is hypothesized that modified HDL leads to changes in its 
anti-atherogenic properties and possibly results in the promotion of atherogenic 
events.
133
  Recent data suggest that HDL can be modified and lose its anti-atherogenic 
properties through several mechanisms.  Examples of some of these hypothesized 
mechanisms include oxidative modification due to the presence of free radicals and free 
metal ions in the atherosclerotic plaques
134
; enzyme-induced modification including 
myeloperoxidase, chymase-tryptase, matrix metalloproteinases, PMN-associated enzyme 
and endothelial lipase which degrade or oxidize apolipoproteins without substantial 
changes in lipid moiety or alternatively induce apolipoprotein cross-linking and lipid 
oxidation
135
; and acute phase reactants-induced modification during inflammation.
136
  
Overall, HDL represents a complex and diverse class of biomolecules.  The physical 
characteristics, functions, and metabolism of these particles display various implications 
in health and disease.  Progress in understanding the properties will aid in identifying 
biomarkers for heart disease. 
 
 
Analytical Chemistry to Investigate Coronary Artery Disease 
 The physical and chemical properties of HDL particles provide clues regarding 
their atherogenic potential.  Analytical methods can be used to identify various 
properties of HDL particles including but not limited to density, charge, size, and 
electrophoretic mobility.  The collaborative results of such methods serve as invaluable 
tools in the discovery of biomarkers for CAD and further characterization of the 
heterogeneous HDL lipoprotein subclass. 
 
Ultracentrifugation of Lipoproteins 
Ultracentrifugation is regarded as the gold standard of lipoprotein subclass 
separation, as these particles are classified and defined based upon their densities.  This 
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method relies on the ability of lipoprotein subclasses to separate when subjected to high 
gravitational forces and is useful as lipoproteins are relatively less dense than other 
serum proteins due to their lipid content.  Ultracentrifugation techniques facilitate an 
analysis of density properties of lipoprotein particles, which may provide clues regarding 
their atherogenic properties.  Sequential flotation
137
 and density gradient
138
 
ultracentrifugation are two commonly used preparatory ultracentrifugation techniques 
for the separation of lipoprotein subclasses.   
In sequential flotation, lipoprotein classes, sequentially float to the top of the 
sample tube after adjusting the solvent density to the lower limit of the fraction required 
using sodium chloride, potassium bromide, or mixtures of these salts.
139
  Each major 
lipoprotein class may be sequentially isolated by adjusting the density of the resulting 
infranatant solution to successively higher values.
139
  The reports of deLalla, Gofman, 
and Lindgren led to the key publications of Havel, Eder, and Bragdon describing how 
sequential ultracentrifugation of human plasma or serum in solutions of neutral salts 
such as KBr and NaI can be used to obtain defined lipoprotein subfractions.
71, 140 
Modifications of this procedure have been used globally in lipoprotein research and are 
commonly used for isolation of lipoprotein classes and subclasses.  During 
ultracentrifugation in neutral salts, however, HDL and other lipoprotein classes are 
exposed to ionic strengths of 5 to 20 times above those of human plasma and lymph.  
This condition subsequently has the potential to alter the lipoprotein complement by 
dissociation of molecules bound by charge-charge interactions.  This occurrence of 
possible modification of lipoprotein apolipoproteins and associated proteins by high salt 
concentration as also shown in increased lipoprotein density, has been documented and 
recognized in several studies.
141, 142   
Other disadvantages of sequential flotation 
ultracentrifugation include long spin times which can take up to several days for 
complete preparative fractionation.  To minimize the possibility of protein stripping by 
high ionic strength, several laboratories have developed differential and isopycnic 
gradient ultracentrifugation procedures in buffers of deuterium oxide (D2O) and sucrose, 
which maintain the lipoproteins at physiological ionic strength and pH.  These solutions 
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allow isolation of homogeneous lipoprotein classes with reproducible content of 
apolipoproteins, associated proteins, and lipid content and composition.
143, 144
   
Density gradient ultracentrifugation (DGU), has been the standard analytical 
method for lipoprotein profiling and uses solvent density gradients which are formed 
during ultracentrifugation.  Compared to other methods such as sequential flotation 
ultracentrifugation, DGU allows lipoproteins to be fractionated in one spin rather than 
multiple steps.  Density gradient ultracentrifugation techniques are more time efficient 
and expose lipoprotein particles to less centrifugal force which may lessen distortion in 
structure and composition.  Though DGU offers several advantages over many 
ultracentrifugation techniques, it has also been deemed tedious and time-consuming 
compared to other profiling methods.
145
 An additional disadvantage of DGU has been 
the difficulty in obtaining reproducible gradient forming solutes to generate a sufficient 
gradient from a homogenous solution.  For example, alkali metal halide salts have been 
used for separations but require extensive centrifugation times and a pre-formed 
gradient.
146
  Likewise, sucrose has been used as a gradient but is accompanied by 
decreased separation due to its high viscosity.
147
  As an improvement to the 
aforementioned gradients, Nycodenz and Iodixanol, derivatives of triiodobenzoic acid 
were shown to provide for the quicker formation of a density gradient.
148
  Yee and 
colleagues reported a novel iodixanol density gradient for composition, density, and 
phenotype analysis.
138
  Unlike traditional sequential flotation ultracentrifugation, the use 
of iodixanol as a density gradient does not require extensive ultracentrifugation time, salt 
density adjustments or dialysis.  Additionally, this novel gradient provides advantages of 
improved resolution of lipoproteins and their separation from plasma proteins as well as 
the ability to sub-fractionate individual lipoprotein density classes when compared to 
sequential flotation ultracentrifugation.  Though the triiodobenzoic acid derivatives 
provided a better option than sucrose and alkali halide salts, they are accompanied by 
disadvantages including high concentration, large partial volume, and low diffusion 
force.
149
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In a response to the need for improved gradients for DGU, Hosken and 
colleagues in the Laboratory for Cardiovascular Chemistry at Texas A&M University, 
found a useful solution in a novel class of solutes based on metal ion complexes.
149
  
Complexing a heavy metal ion to a highly soluble organic ligand provided a compact but 
high molecular weight solute.  Additionally, the modification of the metal ion, ligand, or 
counter ion provides a customizable gradient for specific separations.  What resulted was 
a drastic improvement in DGU with novel tunable gradients with advantages including 
high solubility, low concentration, rapid gradient formation, high molecular weight, 
small partial volume, low viscosity, and high resolution. From this work, Hosken and 
colleagues first identified a cesium salt of bismuth ethylenediaminetetraacetic acid 
(BiEDTA) as an ideal gradient forming solute.
149  
Despite its high UV absorbance and 
ability to be overloaded by high serum volumes, CsBiEDTA offered a significant 
improvement to the field by improving the quantity of information obtained from 
previous DGU separations while simultaneously simplifying sample preparation and 
analysis times.  Shortly thereafter, Johnson and colleagues in the Laboratory for 
Cardiovascular Chemistry at Texas A&M University, expanded on the concept of metal 
ion complexes of EDTA as solutes for DGU by investigating the differences observed 
from changing both complexing and counter ions.
150
  By measuring and comparing the 
density profiles of EDTA complexes of copper, iron, cadmium, lead, and bismuth using 
cesium and sodium counter ions, the link between solute molecular weight and the shape 
of the density gradient curve was understood.  This useful work aided in the 
establishment of a group of density gradients that could highlight specific regions of a 
lipoprotein density profile.  In addressing the issue of high UV absorbance, which 
prevents the measurement of protein at 280nm, it was observed that cadmium complexes 
had comparatively low UV absorbance, with a single maximum absorbance between 204 
and 206nm.
150
  Likewise, since the cadmium EDTA complexes are doubly charged and 
have a relatively low absorptivity it was perceived that they may serve as better density-
gradient forming solutes, particularly for preparative work which uses larger serum 
volumes.  It was also seen that NaBiEDTA provided a near-baseline separation among 
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all profile lipoprotein regions and would be an ideal gradient for analytical work or 
lipoprotein profiling.
150
  Through the expanded work of Johnson and colleagues, 
preferential separation of lipoprotein subclasses by modifying the metal ions in the 
density gradient was achieved, adding even more flexibility and improvement to the 
field of lipoprotein profiling.   
The current lipoprotein separation and profiling method in the laboratory is an 
isopycnic ultracentrifugation technique, which uses a homogenous solution composed of 
the density gradient solute, encompassing the range of densities expected in a serum 
sample (1.00–1.20g/mL), as well as the serum sample.  During the process of 
ultracentrifugation, the solute forms a concentration gradient with a slope depending on 
the relative strengths of opposing diffusion and sedimentation forces.
151
  As the gradient 
forms, individual serum sample components sediment or float to the position in the 
ultracentrifugation tube, where their hydrated density matches that of the density 
gradient.  This particular position is known as the isopycnic point and is a fixed property 
of a particular molecule.  By modifying the density gradient solution, however, the 
relative position of a particle’s isopycnic point in a tube can be altered.  When the 
homogenous solution of the density gradient forming solute is spun; the density of the 
solution increases exponentially as the solution depth proceeds away from the meniscus.  
This results in the meniscus of the solution having a lower tube coordinate and density, 
while the bottom of the UC tube has a higher tube coordinate and density.  This density 
versus tube coordinate relationship can be fitted to an exponential curve function.  The 
slope of the density curve can be obtained by spinning a solution of the desired density 
gradient forming solute and measuring the refractive index as a function of tube depth.  
The resulting density curve is essential in equilibrium isopycnic DGU experiments 
because it enables the determination of the density of the components of a sample based 
on their position in the ultracentrifugation tube.  Lipoprotein molecules in serum samples 
are fluorescently labeled by NBD (C6-ceramide), a lipophilic fluorophore, prior to 
density gradient ultracentrifugation. This fluorophore consists of a hydrophilic head and 
a hydrophobic tail and fluoresces when the polar head is embedded into a non-polar 
22 
 
 
 
environment such as the hydrophobic lipid core of a lipoprotein particle.  In such an 
environment, the NBD-lipoprotein complex will exhibit characteristic excitation and 
emission spectra with excitation at 450 nm and emission at 520 nm.  After incubation of 
serum samples with this molecule for thirty-five minutes, samples are subjected to DGU.  
Upon completion of the spin the fluorescence of the NBD-lipoprotein complex allows 
for the generation of a lipoprotein density profile that enables the distribution of 
lipoprotein particles to be visualized.  The lipoprotein density profile shows the 
distribution of triglyceride rich, VLDL, LDL, and HDL particles and their subclasses.  
For fingerprint lipoprotein profiling, NaBiEDTA is used, in total 11 subclasses are 
observed including: TRL, LDL1, LDL2, LDL3, LDL4, LDL5, HDL2b, HDL2a, HDL3a, 
HDL3b, and HDL3c.  For preparative HDL work, Cs2CdEDTA is used to separate HDL 
adequately for secondary analysis which is followed by excision of HDL serum 
subfractions.  Though the described use of metal EDTA complexes in DGU offers 
several advantages compared to other methods, one of the drawbacks includes the 
contamination of albumin in denser lipoprotein subclasses, which is a common 
disadvantage of gradient ultracentrifugation methods.
138
   
 
Mass Spectrometry of Apolipoproteins 
Mass spectrometry (MS) is an analytical tool which separates and identifies 
apolipoproteins according to mass to charge ratio.  Mass determination by MS requires 
the conversion of proteins or peptides into gas-phase ions with an ionization source.  The 
ions are separated based on their mass and charge using a mass analyzer with detection 
occurring via an electronic multiplier.
152
  The resulting spectra are represented as ion 
intensity versus the m/z value.  There are several different types of mass spectrometers, 
which are classified according to the ionization source and mass analyzer employed.
153
  
One of the most widely used ionization sources is matrix-assisted laser desorption 
ionization (MALDI).
154
   MALDI sources are most frequently coupled to time-of-flight 
(TOF) mass analyzers.
152  
In the MALDI technique, samples containing peptides and 
proteins are dried on a plate together with a light absorbing matrix molecule.  
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Vaporization of the mixture of protein and matrix by a laser releases ionized protein 
molecules, often with a single charge, which can be analyzed in a TOF mass 
spectrometer.  Intact molecular ions are formed from individual peptide chains, allowing 
accurate determination of polypeptide mass.
155
  Since the mass of an intact protein offers 
limited diagnostic information, this method is generally limited to identifying known 
proteins.
156
  Protein quantification by MALDI-TOF-MS can also be problematic, and 
suffers from a limited dynamic range.  Thus, this technique is typically limited to 
relatively abundant proteins associated with lipoproteins such as C, A, and E 
apolipoproteins, and their isoforms.  Several studies have identified new isoforms of 
many apolipoproteins.
157, 158, 159
  Mass spectrometry is also ideal for identifying post-
translational modifications, as these alterations involve a change in molecular mass, 
which is reflected in the mass of any peptide carrying the modified amino acid(s).  Post-
translational modifications refer to the chemical alteration of proteins following 
translation.  Post-translational modifications result in the attachment or addition of 
biochemical functional groups such as carbohydrates, lipids, phosphates, and acetates to 
amino acids, and may also result in structural changes.  These modifications are 
observed due to increased and or decreased molecular weight.  Some changes are easily 
identified such as +16 Da for the addition of oxygen, but it may be unclear whether this 
is the common formation of methionine sulfoxide or another scenario.  Other 
modifications are ambiguous such as +80 Da which could indicate phosphorylation or 
sulfation, though these may be elucidated through the detection of anions at m/z 70 
versus 80 respectively.
 160
  The oxidation of lipoproteins is implicated in atherogenesis.
 
161
  It has been observed, that HDL isolated from humans with CAD contains elevated 
levels of oxidized amino acids chlorotyrosine and nitrotyrosine when compared to 
healthy human HDL samples.
132
  Chlorotyrosine is a direct oxidation product of the 
heme protein myeloperoxidase
162
 and macrophages in atherosclerotic lesions express 
high levels of this enzyme.
163
  When specific apoA-I methionine and tyrosine residues 
are oxidized by myeloperoxidase, HDL loses its ability to remove cholesterol from cells 
by the ABCAI pathway.
164
  As the interaction between apoA-I and ABCA1 is imperative 
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in protecting macrophages from cholesterol accumulation and atherosclerosis, 
impairment of this pathway may generate dysfunctional HDL.  These findings suggest 
that inflamed atherosclerotic lesions may be where oxidative damage of proteins occurs.  
Shao and colleagues showed post-translational modifications of apoA-I due to reactive 
carbonyls which subsequently impaired cholesterol transport.
165
  This modification was 
seen through MALDI-TOF-MS spectral shifting of approximately 350 Da.  Isoforms of 
C apolipoproteins have been identified in biological samples as a result of glycosylation 
and deglycosylation and proteolytic activity at the post-translational levels.
166, 167, 168
    
The truncated apoC-I isoform apoC-I′ was first identified by Bondarenko and colleagues 
and lacks Thr-Pro residues from the N terminus.
169   
In 2006, Wroblewski and colleagues 
identified a functional polymorphism of apoC-I detected by mass spectrometry.
170
  This 
polymorphism was found only in individuals of American Indian or Mexican ancestry.  
Tandem mass spectrometry showed the alteration to consist of a T45S variation which 
forms part of the lipid interacting surface of apoC-I.  This study reported the first case of 
a structural variant of apoC-I as well as some protein properties that suggest the 
functional significance of this residue change.  The individuals in this study showing the 
polymorphism had apoC-I double peaks for each of the two forms.  More recently, 
Puppione and colleagues detected two distinct isoforms of apoC-I in great apes.
171
  They 
designated these forms as acidic (apoC-IA), and basic (apoC-IB) based upon their 
calculated pI values.  It is hypothesized that the anomaly observed in the discovery of 
the acidic form of this protein is due to oxidation with a methionine converted to 
methionine sulfoxide.
171
  Other post translational modifications such as phosphorylation 
are part of common mechanisms for controlling protein behavior such as enzyme 
activation and inhibition.  Thus phosphorylation is of interest in regards to apoC-I post-
translational modifications in that apoC-I has been shown to inhibit the enzyme 
cholesterol ester transfer protein (CETP).
102
  Inhibition of this enzyme by apoC-I may 
subsequently influence the ability of HDL to effectively remove cholesterol from the 
periphery resulting in the acceleration of atherosclerosis.  
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Capillary Electrophoresis of Lipoprotein Apolipoproteins 
Capillary electrophoresis (CE) is used to analyze intact and delipidated 
lipoproteins, and analyzes the differences in charge/mass ratio, molecular size, and shape 
properties of lipoproteins and apolipoproteins.  The application of a direct current causes 
ions to move within the electric field of a fine capillary at a rate dependent upon the 
force of the field, and impeding effects between the sample and the surrounding media.  
In the cardiovascular field, CE applications include analysis of apolipoproteins,
172
 
lipoproteins,
173
 and modified lipoproteins.
174
  Due to rapid separation, high resolution 
and high sensitivity, CE is an invaluable analytical tool.  Capillary electrophoresis also 
exhibits advantages over other techniques such as HPLC for protein analysis in areas 
such as speed and affordability. In the past two decades, substantial progress has been 
made in the separation of serum proteins by CE using fused silica capillaries.  In the 
analysis of intact lipoproteins, electrophoretic separations under nondenaturing 
conditions can be used to determine differences in LDL particle size.  High density 
lipoprotein particles, on the other hand, are more heterogeneous with varying 
apolipoprotein composition.  Attempts to directly analyze intact lipoproteins by CE have 
had minimal success, this is most likely attributed to interaction between lipoproteins 
and capillary walls.  This problem is prevented through the use of detergents and organic 
solvent buffer modifiers which disrupt lipoprotein particles.  In the application of CE for 
apolipoprotein characterization, Stocks and colleagues demonstrated the capability of 
CE to resolve apoA-I and A-II in human HDL following UC and delipidation.
175
  This 
technique provided quantitative values of apoA-I and A-II which were comparable to 
those obtained by immunoassay.  Tadey, Purdy and colleagues, also demonstrated the 
use of CE in uncoated capillaries to resolve apoA-I in human plasma or apoA-I and A-II 
in HDL.
176
  Their technique involves electrophoresis in sodium dodecyl sulfate (SDS) 
containing buffers to overcome protein-capillary wall interactions.  Separation depends 
on differences in the amount of SDS bound by hydrophobic interaction to individual 
proteins, resulting in differences in charge to mass ratio.   In the absence of the 
detergent, the apolipoproteins eluted as a single peak.  The effect of SDS was attributed 
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to the presence of discrete, non-interacting detergent binding sites on the 
apolipoproteins.  Capillary electrophoresis offers incentives over conventional 
electrophoresis including its speed and instrumental format which removes the need for 
labor-intensive steps such as gel preparation and staining. 
Overall, ultracentrifugation provides separation and isolation of lipoprotein 
subclasses while MALDI-MS and CE provide subsequent characterization of the 
apolipoprotein content of these subclasses.  Through the development, modification, and 
implementation of these novel techniques, more information regarding how and why 
coronary artery disease develops will be obtained. 
 
 
Research  Aims 
Ultimately, the aim of this research was to utilize several analytical methods for 
analyzing human serum HDL subfractions.  In doing so, the information obtained 
assisted in the assessment of CAD risk.  Through applying the methodologies to human 
serum samples from individuals with and without CAD, a better understanding between 
the two patient cohorts was enabled, along with the identification of potential 
biomarkers.  With HDL being such an important factor in the quest for knowledge 
regarding the development and acceleration of CAD, its composition and 
subcomponents were the focus of this work.  The methodologies reported here, sought to 
look closely at the apolipoprotein content of the HDL subfractions from two cohorts of 
patients to identify striking differences.  It is possible that the effects and functions of 
HDL are highly controlled by these surface proteins.  Combining DGU both as a primary 
analysis method and a preparative tool for secondary analysis, with techniques capable 
of secondary analysis separation such as MALDI-MS, enabled a multi-dimensional 
examination of the various subfractions of serum HDL.  In addition, this combination of 
methods yielded important information regarding the character and distribution of 
apolipoproteins. Collectively, this information contributed to the ongoing effort to 
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identify features of HDL and HDL associated apolipoproteins that contribute to CAD 
risk, and to understand the chemistry of atherogenic HDL. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
 
 Materials 
 NBD (C6-ceramide) was purchased from Molecular Probes (Eugene, OR).  
Sodium bismuth ethylenediaminetetraacetic acid (NaBiY) was purchased from TCI 
America (Portland,OR).  Cesium hydroxide, cesium carbonate, cadmium carbonate, 
ethylenediaminetetraacetic acid (H4EDTA), sodium carbonate, bovine serum albumin, 
tricholoracetic acid, trifluoroacetic acid (TFA), ferulic acid, sinapinic acid, sodium 
borate, sodium dodecyl sulfate (SDS), Dextralip® 50, and magnesium chloride 
hexahydrate were purchased from Sigma Aldrich (St. Louis, MO).  Acetonitrile (ACN), 
dimethyl sulfoxide (DMSO), glycerol, phosphoric acid, and methanol were purchased 
from EM Science (Gibbstown, NJ).  Strata C18-E solid phase extraction cartridges and 
syringe adapter caps were purchased from Phenomenex (Torrance, CA). Cyanogen 
bromide (CNBr) activated Sepharose 4B was purchased from Amersham Biosciences.  
Anti-apoC-I IgY microbeads were purchased from GenWay Biotech, Inc. (San Diego, 
CA).  ApoA-I and apoC-I standards, and anti apoC-I were purchased from Academy 
Biomedical (Houston, TX). 
 
 
Analytical Methods 
Serum Collection 
 Serum samples were obtained from human subjects by blood draw following a 
12 hour fast into 9.5 mL Vacutainer™ tubes treated with a polymer gel and silica 
activator from Beckton Dickinson Systems (Franklin Lakes, NJ).  The serum was 
subsequently separated from erythrocytes by centrifugation at 3200 rpm for 20 minutes 
at 5°C, followed by aspiration of the supernatant into 500µL Eppendorf tubes for storage 
at -80°C prior to analysis.   
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Patient Selection 
Serum samples were selected from the laboratory serum library and consisted of 
CAD patients and non-CAD control patients.  The serum library consists of donated 
serum from Scott & White Hospital (Temple, TX) patients.  Informed consent was 
obtained from all donors.   
  The serum collected from the 8 control subjects without CAD included a 48 
year old Caucasian female (patient 1), 77 year old Caucasian female (patient 3), 44 year 
old Caucasian female (patient 7), 66 year old Hispanic female (patient 13), 75 year old 
Caucasian female (patient 14), 73 year old Caucasian female (patient 16), 68 year old 
Caucasian female (patient 24), and a 50 year old African-American male (patient 25).   
The serum collected from the 7 CAD patients included a 75 year old Caucasian 
female (patient 10), 72 year old Caucasian male (patient 41), 37 year old Caucasian 
female (patient 84), a 54 year old Caucasian male (patient 143), a 77 year old Caucasian 
female (patient 146), a 75 year old Caucasian male (patient 170), and a 72 year old 
Caucasian female who was also a low birth weight infant (patient 195). 
One patient, a 56 year old Caucasian female with normal to high HDL (patient 
49), was also used in this study.  This individual did not have diagnosed CAD, however, 
did have a family history of premature CAD and also displayed marked apoptosis of 
aortic smooth muscle cells in addition to an enrichment of apoC-I.   
 
Ultracentrifugation of Serum Samples 
Density gradient ultracentrifugation of serum samples incorporated the use of 
heavy metal density gradient forming solutes, NaBiY and Cs2CdY.  The term “Y” 
symbolizes an “EDTA” molecule when complexed with a metal ion.  NaBiY and 
Cs2CdY complexes were synthesized by stoichiometric combination of H4EDTA, the 
appropriate alkali carbonate or alkali hydroxide, and the appropriate heavy metal 
carbonate in 100mL of deionized water, followed by a two hour reflux yielding a clear 
density gradient solution.
79
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Serum density profiling was performed to obtain a fingerprint of the lipoprotein 
distribution of a serum sample.   Six microliters of serum and 184µL of 0.18M NaBiY 
were added to an 1100µL solution of the NaBiY density gradient forming solute, 
followed by the addition of 10µL of a 1.000 mg/mL solution of NBD (C6-ceramide) 
dissolved in DMSO.  An 1150µL aliquot of this solution was then added to a UC tube 
and spun in an Optima TLX UC with a TLA 120.2 fixed angle rotor and in 1.5mL thick-
walled polycarbonate UC tube from Beckman-Coulter (Palo Alto, CA) at a rotor speed 
of 120,000 rpm for 6 hours at 5°C.  (Figure 3)   
     
 
 
Figure 3.  Density gradient ultracentrifugation schematic. 
 
 
Preparative UC utilized larger serum volumes and preceded serum lipoprotein  
fraction studies.  This work focused on HDL subclasses and to eliminate interferences 
from apoB containing lipoproteins, serum was first treated with dextran sulfate (DS) and 
magnesium chloride hexahydrate in 100mL of deionized water.  The final solution had a 
concentration of 10.0g/L of DS and 0.500M magnesium chloride.  This working solution 
was added to a sample of serum at a volume of 10% of the serum volume.  This solution 
was mixed briefly by vortexing and left to stand at room temperature for 10 minutes.  A 
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tabletop centrifuge spun at 12,000g for 5 minutes was used to sediment out the apoB 
containing lipoprotein particles.  The supernatant was prepared for UC as a normal 
serum sample.  Sixty to two hundred microliters of serum after dextran sulfate treatment, 
was added to an 1100µL solution of a 0.300M solution of Cs2CdY, followed by the 
addition of 10µL of a 1.000 mg/mL solution of NBD (C6-ceramide) dissolved in DMSO.  
From this mixture, a 1000µL aliquot was added to a UC tube and spun according to the 
conditions previously described.   
 
Fluorescent Imaging Analysis 
 A digital color microscope camera, Microfire S99808, purchased from Optronics 
(Goleta, CA) with Fiber-Lite MH100A Illuminator from Edmund Industrial Optics  
(Barrington, NJ) was used to image each UC tube following DGU.  The light source 
consists of a metal halide continuous light source.  The camera and light source were 
positioned orthogonally to each other on an optical bench to illuminate the sample.  
Filters matching the excitation and emission properties of the fluorophore, NBD (C6-
ceramide), were purchased from Schott Glass (Elmsford, NY).  The respective filters for 
excitation and emission were a blue-violet filter (BG-12) with a bandwidth centered 
about 407nm and a yellow filter (OG-515) with a bandwidth centered about 570nm.  
Specific settings for the Microfire camera software included an exposure time of 53.3mS 
for serum density profiling and 41mS for preparative UC.  A gain of 1.000 and a target 
intensity of 30% were also applied. 
 Following fluorescence imaging, a density profile was generated from the image 
capture of each UC tube.  Using Origin 7.0 software, the image was first converted into 
grayscale intensity values as a function of pixels in two dimensions, subsequently, the 
grayscale intensity from a small strip of 10 pixels oriented in the center of the UC tube 
was averaged.  This averaged grayscale intensity was plotted as a function of tube 
coordinate (0-34mm) to give the final lipoprotein density profile.   
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Lipoprotein Fraction Collection  
 An in-laboratory developed freeze/slice method was used to collect serum 
lipoprotein fractions following preparative UC and fluorescence imaging.  
Ultracentrifugation tubes were slowly frozen in liquid nitrogen by placement into a 
custom 10-slot holder and lowering the holder into a Dewar of liquid nitrogen, causing 
the liquid in the tubes to freeze from the bottom to the top.  In this manner, the 
expansion of water to ice could be accounted for by the following : (Eq. 1) 
 
mms = ρl/ρs x mmL – 10.405        Eq. 1 
 
 
The tube coordinate in the solid state is represented by mms, while mmL corresponds to 
the tube coordinate in the liquid state, the state in which the image of the UC tube was 
captured.  The term ρl/ρs corresponds to the ratio of the density of water in its liquid state 
ρl to its density in its solid state ρs.  Since water is denser in its liquid state, this ratio 
gives a correction factor greater than unity and the equation can be simplified to: (Eq. 2) 
 
mms = 1.058 x mmL – 10.405       
 Eq. 2 
 
10.405mm was also subtracted from the solid state tube coordinate to correct for the 
calibration of the micrometer/tube holder assembly that was used to dial in the correct 
cut points.  This micrometer/tube holder assembly contained a micrometer head, which 
functioned to advance the position of the UC tube relative to the location of the notch for 
the saw blade.  A Dremel® scroll saw (Racine, WI) was fitted with 0.25mm blades for 
the cutting of the tubes.  The volumes of non HDL, HDL2, HDL3, and protein fractions 
were 212 ± 8 µL, 329 ± 8 µL, 249 ± 13 µL, and 60 ± 5 µL, respectively.  The 
freeze/slice method is depicted in Figure 4. 
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Figure 4.  Freeze/slice method for excising lipoprotein fractions. 
 
 
Gravimetric Density Determination 
 After sample excision and thawing, the density of each fraction was determined 
gravimetrically.  A 100µL aliquot of each non HDL, HDL2, and HDL3 fraction and a 
50µL aliquot of each protein fraction was added to a zeroed 1.5mL Eppendorf.  An 
analytical balance was used to obtain the mass of each aliquot.  The ratio of mass to 
volume was used to determine the density of each fraction.   
 
C18 Solid Phase Extraction, Desalting, and Delipidation 
 After gravimetric density determination, delipidation and desalting was 
accomplished by means of a solid phase extraction (SPE) cartridge from Phenomenex, 
Strata C18-E (Torrance, CA).  Delipidation of samples was based on a published 
method.
177
   
 The cartridge was conditioned drop wise with three 1mL rinses of 0.1% (v/v) 
TFA in acetonitrile (ACN), allowing no air to enter the cartridge.  The cartridge was then 
conditioned drop wise with three 1mL rinses of 0.1% (v/v) TFA in deionized water, 
allowing no air to enter the cartridge.  The sample to be delipidated was first acidified 
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with a sample volume of 0.1% (v/v) TFA in deionized water, then slowly added to the 
cartridge, allowing no air to enter the cartridge.  The cartridge was washed with three 
1mL rinses of 0.1% (v/v) TFA in deionized water to remove the density gradient solute, 
non-specifically bound apolipoproteins, and water soluble components of the serum 
sample.  One milliliter of air was then pushed through the cartridge to remove any 
remaining liquid.  Isocratic elution was performed with four 100µL aliquots of 0.1% 
(v/v) TFA in acetonitrile, purging with 1mL of air in between each aliquot and allowing 
at least one minute for the sorbent to soak prior to purging with air.  The first aliquot 
contained all serum proteins (verified by MALDI-MS) and was the only aliquot retained.  
The C18 cartridge additionally served as a filter for any residual polycarbonate 
particulates remaining following tube cutting. 
 Following solid phase extraction, the samples were evaporated to dryness 
through the use of a SVC-100H Speed-Vac concentrator with a refrigerated 
condensation trap from Savant Instruments (Farmingdale, NY) which was connected to a 
5KC36PN435AX vacuum pump from General Electric (Fort Wayne, IN).  Dried 
apolipoprotein fractions were then reconstituted in suitable solvents for the method of 
investigation which included 0.1% (v/v) TFA in deionized water for MS experiments. 
 
MALDI-MS Analysis of Apolipoproteins 
The matrix assisted laser desorption ionization mass spectrometry (MALDI-MS) 
analysis was used to analyze serum HDL subfractions for qualitative analysis and 
standard solutions to assess purity.  A commercial Voyager-DE STR, MALDI-TOF 
mass spectrometer equipped with a 2m flight tube from Applied Biosystems (Foster 
City, CA, USA) and a mass range of 500 – 300,000 Da was used for the analyses (Figure 
5).  The MALDI matrix consisted of a 10mg/dL solution of sinapinic acid in a 1:1 
mixture of acetonitrile and 0.1% TFA in water.  Serum samples underwent a thin-layer 
sample preparation method in which a MALDI plate was first spotted with the desired 
MALDI matrix and allowed to dry, and then a mixture of the sample and matrix (1:1 
ratio) was deposited atop the original spot.  Calibration was performed with bovine 
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insulin, bovine serum albumin, and Escherichia coli thioredoxin, 1µL of the standard 
was added to 24µL of the matrix.  For the lower mass range, the acceleration potential 
was held at 25kV, the grid potential was at 93% and delay time was 575ns.  
Approximately 100 shots per spectrum were collected. 
 
Capillary Electrophoresis Analysis of Apolipoproteins 
 Preparation of the Capillary 
The capillaries were prepared using the Beckman capillary cartridge assembly 
(Beckman Instruments, Fullerton, CA, USA) and untreated fused silica capillaries 
(Polymicro Technologies, Phoenix, AZ, USA) preceding the capillary electrophoresis 
(CE) experiments.  The capillaries had an inner diameter (i.d.) of 75µm and an outer 
diameter (o.d.) of 365µm.  Briefly, approximately 80cm in length of capillary, was cut 
from the spool of capillary tubing by scoring with a cleaving stone (Beckman) and 
gently pulling in opposite directions on both sides of the score.  Care was taken not to 
bend the capillary to avoid uneven breakage on the ends of the capillary.  The total 
length of the cut capillary was measured with a precision of ± 1mm.  Using a fine tipped 
pen, a mark was placed 12cm away from one end of the capillary.  To prepare the 
capillary window, the capillary tubing was then inserted into a small metal coil attached 
to a power supply so the mark was within the coil.  The power supply was turned on for 
approximately 10 seconds to heat the coil while the capillary was rotated to burn off the 
polyimide coating from the outside of the capillary tubing.  The capillary was then 
removed from the coil and the burnt polyimide coating was gently removed by wiping 
the capillary with a Kim Wipe™ and methanol.  The window was examined using a 
tabletop microscope to ensure that all of the coating was removed from the capillary 
window.  The capillary window was no longer than 3mm in length.  From this point on, 
extreme care was used when handling the capillary as the window region was fragile and 
finger oils can reduce detection sensitivity.  The distance from the detector end of the 
capillary to the middle of the capillary window was measured to the nearest mm. 
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The capillary was then inserted into the cartridge according to the Beckman 
cartridge assembly guide and was assembled as follows.  The capillary end farthest from 
the capillary window was inserted into the outlet side of the cartridge.  The capillary was 
carefully pushed and twisted through the cartridge until it appeared at the cartridge inlet.  
The capillary was then pulled through the cartridge until the capillary window appeared 
centered in the cartridge window.  From the back side of the cartridge, the center groove 
of the aperture clip was carefully aligned with the capillary window and pressed in place.  
From the front side of the cartridge, the retainer O-ring was placed in the aperture clip 
hole.  Using the O-ring insertion tool, the tool was pressed carefully until the O-ring was 
seated in the aperture clip.  The capillary seal retainer clips were then inserted over the 
capillary at each end and pressed to snap in place, being sure to clip both front and back 
edges into place for each clip.  Once snapped, the capillary ends were inspected visually 
to verify that they were straight.  The cartridge was then positioned against the capillary 
length template.  Holding the capillary against the template, each end was scored at the 
cross mark on the capillary-length template with the cleaving stone.  Each cut piece of 
capillary was measured to the nearest ± 0.5 mm.  The pieces removed from both ends 
were subtracted from the total length of capillary initially cut to determine the corrected 
length of the capillary or Lc.  In addition, the piece removed from the detector or outlet 
end of the capillary was subtracted from the distance from the detector end of the 
capillary to the window and was then subtracted from the initially measured length of 
the capillary to determine the length of the capillary to the detector or Ld.   
The total length Lc of the capillaries were approximately 60cm with an effective 
length Ld of approximately 50cm.  Precise measurements (±1mm) of the individual 
capillary distance parameters used in each experiment were used for calculating effective 
electrophoretic mobilities.  
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Capillary Electrophoresis Analysis of Samples 
Following solid phase extraction and evaporation to dryness, as stated 
previously, dried protein samples were reconstituted in 100µL of the background 
electrolyte (BGE), which was a buffer solution consisting of 12.5mM sodium borate, 
3.5mM SDS (70%) and 20% (v/v) acetonitrile prior to CE analysis.  On initial use, the 
newly prepared capillary was rinsed with 1M NaOH for ten minutes, 0.1M NaOH for ten 
minutes and buffer for ten minutes, to condition the column.  The neutral marker 
consisted of a 0.5% (v/v) solution of DMSO in deionized water.  Capillary 
electrophoresis analyses were performed on a Beckman P/ACE™ MDQ system 
(Fullerton,CA) that was equipped with a diode array detector.  Run parameters for a 
separation consisted of a rinse with buffer for two minutes, the injection of the neutral 
marker at 0.5psi for five seconds, injection of the sample at 0.5psi for five seconds and 
the application of 17.5kV for thirty-five minutes.  Before each use, the BGE was 
degassed by vacuum sonication until bubbles were no longer observed within the 
solution.  All solutions were filtered with a 0.22µm cellulose acetate membrane sterile 
syringe filter by Millipore (Billerica, MA) to remove microbes and blanketed with 
mineral oil (Amersham Biosciences) to eliminate sample evaporation.   
Analysis was performed at a wavelength of 214nm.  The capillary and sample 
tray of the instrument were thermostated at 25°C.  Migration times and corrected peak 
areas were automatically obtained using the data analysis feature of the Beckman P/ACE 
Station Migration software.  Identification of other apolipoprotein peaks was 
accomplished by comparison to previously published results.
178, 179
  The resulting 
electropherograms were analyzed by 24 Karat software from Beckman (Fullerton, CA).   
 
ApoA-I, ApoC-I and BSA Calibration Curves by Capillary Electrophoresis 
Prior to CE analysis of samples, calibration curves for major serum proteins were 
constructed to enable identification of serum subfraction components. An apoA-I 
solution (100.0mg/dL; Academy Biomedical) was used in the preparation of a 
calibration curve.  The apoA-I standard was diluted with BGE  through serial dilutions in 
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a 1:1 ratio to yield concentrations of 80.0mg/dL, 40.0mg/dL, 20.0mg/dL, 10.0mg/dL, 
and 5.0mg/dL apoA-I.  An apoC-I solution (80.0mg/dL; Academy Biomedical) was used 
in the preparation of a calibration curve.  The apoC-I standard was diluted with BGE 
through serial dilutions in a 1:1 ratio to yield concentrations of 40.0mg/dL, 20.0mg/dL, 
10.0mg/dL, and 5.0mg/dL apoC-I.  A 200.0mg/dL solution of bovine serum albumin 
(BSA) (Sigma) was prepared by dissolving 2.000g in 1L of 0.1% TFA in deionized 
water and was used in the preparation of a calibration curve.  The BSA stock solution 
was diluted with BGE to yield concentrations of 80.0mg/dL, 40.0 mg/dL, 20.0mg/dL, 
10.0mg/dL, and 5.0mg/dL BSA.  Each solution was analyzed by CE in triplicate and 
data analysis was carried out at 214nm to create calibration curves.  The standard 
corrected peak areas (CPA) were plotted as a function of the concentration of each 
solution injected into the CE.   
 
 
Collaborative Studies 
The collaborative studies provided the opportunity to obtain additional 
information from samples by shipping them to other laboratories for further analysis.  
These studies enabled the ability to assess apoptosis levels from fractionated serum and 
apoC-I immunodepleted and apoC-I immunorecovered samples through cell culture 
studies with the Chatterjee Laboratory at Johns Hopkins University (Baltimore, MD).  
The studies additionally enabled the analysis of the transfer protein rates of whole 
serum through CETP and PLTP assays performed by Roar Biomedical (New York, 
NY). 
 
ApoC-I Isolation by Immunoprecipitation 
Immunoprecipitation was performed in order to obtain apoC-I depleted and 
apoC-I recovered serum which was subsequently analyzed using DGU and fluorescence 
imaging as described previously. ApoC-I enriched and apoC-I depleted HDL fractions, 
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as well as whole serum HDL fractions, were prepared and sent to collaborating 
laboratories for analysis. 
Throughout the course of this study, two different methods were utilized in order 
to accomplish this goal.  The first of which incorporated commercial beads with the 
antibody conjugated to a Sepharose resin and the second consisted of an in-laboratory 
procedure to make the beads.   
 
Immunoprecipitation Using GenWay Anti ApoC-I IgY Beads 
Using the commercial beads, 60µL of serum was added to 500µL of anti-apoC-I 
IgY microbeads (GenWay Biotech, Inc. San Diego, CA).  Upon serum addition the 
mixture was incubated for 30 minutes at room temperature with shaking to suspend the 
microbeads.  Following incubation, the beads were spun down by centrifugation.  The 
supernatant which consisted of the apoC-I depleted serum was then carefully transferred 
into a new Eppendorf and stored at -85C until needed for secondary analysis.  The 
microbeads were then washed three times with 500µL of dilution buffer (10mM Tris-
HCl, 0.15M NaCl, pH = 7.4).  A volume of 250µL of stripping buffer (0.1M Glycine-
HCl, pH = 2.5) was then added to the microbeads and incubated for 4 minutes at room 
temperature with shaking to suspend the microbeads.  Following incubation, the beads 
were spun down.  The supernatant which consisted of recovered apoC-I serum was then 
removed and transferred into a new Eppendorf for secondary analysis; this process was 
repeated two additional times for a total recovered volume of 750µL.  Upon completion 
of immunorecovery, the recovered apoC-I sample was neutralized with 70µL of 
neutralization buffer (1M Tris-HCl, pH=8) and stored at -85°C freezer until analyzed. 
 
Immunoprecipitation Using “In-house” Anti ApoC-I Beads 
The in-laboratory method involved swelling the Sepharose beads and conjugating 
the antibody to the swollen beads.  In this procedure, the following solutions were 
prepared and used during the binding of antibody to the Sepharose beads and the binding 
of serum to the antibody-Sepharose gel: coupling buffer, which consisted of 0.1M 
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NaHCO3 and 0.5M NaCl, pH 9.0; 1mM HCl;  blocking buffer, which consisted of 1M 
Tris-Base, pH 9.0 in coupling buffer; a low pH wash buffer, which consisted of 0.1M 
HCl, 0.5M NaCl; and  0.05M Tris-HCl. 
An optical density reading at 280nm (OD280) of the antibody solution was taken 
to determine the protein concentration in the antibody solution.  A volume of 62.5µL of  
coupling buffer (0.1M NaHCO3 and 0.5M NaCl, pH 9.0) was then added to the 125µL 
antibody solution. The Sepharose beads were mixed and allowed to swell in 1mM HCl 
for approximately 15 minutes at room temperature.  The supernatant was then removed, 
and the Sepharose beads were washed with 1mM HCl solution for 1 minute, with the 
washing step repeated twice.  
The next two steps were done without pausing in between.  Washing with 5mL 
coupling buffer, the gel was prepped for the addition of the antibody-coupling buffer 
solution, and after the addition, the tube was rotated gently at room temperature for 4 
hours.  After the beads settled, the supernatant was removed, and the OD280 was taken. If 
the OD280 was at least 10-fold lower than before coupling, coupling was successful. If 
OD280 was not at least 10-fold lower than in step 1, coupling did not proceed as expected, 
mainly caused by not transferring gel to antibody solution quickly enough and had to be 
repeated. 
Following successful coupling, the resin was washed twice with 1mL coupling 
buffer. One milliliter of blocking buffer (1M Tris-Base, pH 9.0 in coupling buffer) was 
added and allowed to stand for 2 hours at room temperature.  The supernatant was then 
removed, and the gel was washed four times, alternating between low pH wash buffer 
(0.1M HCl, 0.5M NaCl) and high pH wash buffer (coupling buffer). The first and fourth 
washes were saved, and the OD280 of each was checked to verify that the antibody was 
no longer present in solution, which was demonstrated in an OD280 reading below ~0.01. 
The AB-Sepharose gel, that was freshly made and washed with coupling buffer, 
was mixed with 50µL serum and 600µL 0.05M Tris-HCl in a 1.5mL Eppendorf tube. 
The tube was gently rotated for 4 hours at 1400rpm at room temperature.  After rotation, 
the Sepharose gel was allowed to settle and the depleted serum, approximately 600µL, 
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was removed.  Using a 3,000 MWCO filter the supernatant, containing everything that 
did not bind to the AB, was concentrated for UC use.   
After removing the depleted serum from the AB-Sepharose gel, the beads were 
washed twice with coupling buffer to ensure that there was no residual serum left in the 
Eppendorf tube.  Afterwards, 600µL of 1mM HCl was added to the beads. The tube was 
gently rotated at 1400rpm for 5 hours at 37°C.  After rotation, the Sepharose gel was 
allowed to settle and the recovered serum, approximately 600µL, was removed.   
The Sepharose-AB gel was washed with coupling buffer twice and then stored in 
20% ethanol to prevent microbial growth at 4°C. 
 
Desalting and Purification of Intact Lipoproteins 
 For the analysis of intact lipoproteins, samples must be desalted while retaining 
the lipid components.  This procedure utilizes micro-concentration of the sample in place 
of solid phase extraction.  Micro-concentration results in the replacement of the EDTA 
solute with deionized water.  Micro-concentration decreased sample volume from 500µL 
to 50µL and then reconstituted the sample volume to 500µL for each cycle.  Following 
micro-concentration, samples were sterilized using a 0.22µm syringe filter from 
Millipore (Billerica, MA) to remove microbes.   
  
Smooth Muscle Cell Apoptosis 
Selected samples of intact HDL2 and HDL3 were isolated using the freeze/slice 
method following preparative UC and immunospecific DGU.  Samples were subjected 
to micro-concentration using filter units from Millipore (Billerica, MA) with a 30,000 
molecular weight cutoff in order to remove the EDTA solute which would otherwise 
interfere with the apoptosis assay.  Samples were then sterilized by a means of a 0.22µm 
sterile filter unit from Millipore (Billerica, MA).  Following purification, samples were 
submitted to the Chatterjee Laboratory at Johns Hopkins University for apoptosis cell 
culture studies.  Submitted HDL fractions were analyzed for apoptotic effects on cells in 
order to gain understanding of the functionality of HDL subfractions from patients.  
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Human aortic smooth muscle cells (ASMC) (Cambrex, Walkersville, MD) were grown 
on sterilized glass cover slips in 6-well trays and treated with the various lipoprotein 
fractions isolated from human subjects, pure apoC-I (2.5µg/µL medium). 
 
Transfer Protein Assays 
The effect of serum apolipoproteins on cholesteryl ester transfer protein rates and 
phospholipids transfer protein rates were determined through collaboration with Roar 
Biomedical.    
                
Cholesteryl Ester Transfer Protein 
Cholesteryl ester transfer protein, CETP, is a member of the lipid 
transfer/lipopolysaccharide binding protein gene family.  This protein transfers neutral 
lipids from HDL to VLDL and is present in normal human plasma and serum.  Playing 
an important role in lipoprotein metabolism, CETP influences the reverse cholesterol 
transport pathway.  The Roar CETP Activity Assay is useful for measuring the CETP 
activity in human plasma and serum in other species that express CETP.   The Roar 
CETP Activity Assay Kit uses a proprietary substrate that enables the detection of 
CETP-mediated transfer of neutral lipid from the substrate to a physiological acceptor.  
The transfer activity results in an increase in fluorescence intensity.  In a total volume of 
200µL, the assay is linear from 0.200 to 0.800µL of normal human plasma with a 3 hour 
incubation at 37°C.  Advantages of the assay include: results that are not affected by 
endogenous plasma HDL, LDL, or VLDL concentration; the Roar donor particle is the 
preferred substrate by CETP over HDL, thus eliminating competition from endogenous 
HDL present in the plasma sample; and the addition of excess exogenous acceptor 
normalizes endogenous acceptor lipoprotein concentration present in the sample, 
whereas other methods including radioisotopic methods are affected by endogenous 
HDL concentration.  Additionally, an increasing plasma HDL concentration in the 
sample decreases the specific activity of the labeled HDL substrate due to the equal 
preference by CETP for either labeled or unlabeled HDL; intra and inter assay 
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coefficients of variation are less than 3%; and assay components are stable for up to one 
year and assay substrates are stable at high DMSO concentrations greater than 10% v/v.  
The CETP Activity Assay Kit uses a donor molecule containing a fluorescent self-
quenched neutral lipid that is transferred to an acceptor molecule in the presence of 
CETP.  The CETP-mediated transfer of the fluorescent neutral lipid to the acceptor 
molecule results in an increase in fluorescence.  (Excitation 465nm; Emission 535nm).  
For the CETP assay, a standard curve was prepared by making serial dilutions of the 
donor molecule in isopropanol and subsequently recording the fluorescence intensity of 
each dilution, using isopropanol alone as a blank.  The fluorescence intensity values of 
the standard curve were applied directly to the results to express activity of the plasma 
sample.  For each reaction in the assay procedure, the following components were 
added: 10µL of the donor molecule, 10µL of the acceptor molecule, 20µL of the 10X 
CETP Assay Buffer, 1-3µL of serum sample and deionized water to a total of 200µL.  
These materials were incubated for 30 - 60 minutes at 37°C.  The fluorescence intensity 
of the blank, samples, and positive control were then measured and the fluorescence 
intensity from each sample was corrected by subtracting the blank fluorescence 
intensity.  The following equation was used to calculate the activity of the plasma 
sample (Eqn. 3): 
 
y = mx + b         Eqn. 3 
 
 
Where y corresponds to the fluorescence intensity of the sample subtracted from 
the fluorescence intensity of the blank, m corresponds to the slope of the standard curve, 
x corresponds to the concentration of the serum sample, and b corresponds to the 
intercept.   
The Roar Ex Vivo CETP Activity Assay is useful for evaluating the non-
reversible or reversible inhibitors on plasma CETP activity.  The assay is not affected by 
changes in HDL concentration or other endogenous lipoproteins.  The procedure follows 
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that described for the CETP assay, however, in the EVAK assay, the concentration of 
serum is 200µL with 5µL substrate compared to 0.5µL serum in 200µL substrate in the 
CETP assay.   
 
Phospholipid Transfer Protein 
Plasma phospholipid transfer protein (PLTP) is thought to play a major role in 
the facilitated transfer of phospholipids between lipoproteins and in the modulation HDL 
particle size and composition.  PLTP-facilitated lipid transfer activity is related to HDL 
and LDL metabolism, as well as lipoprotein lipase activity, adiposity, and insulin 
resistance.   The Roar PLTP Activity Assay Kit includes proprietary substrates to detect 
PLTP mediated transfer of the fluorescent substrate.  Transfer activity results in 
increased fluorescent emission intensity from the assay.  The PLTP Activity Assay Kit 
uses a donor molecule containing a fluorescent self-quenched phospholipid that is 
transferred to an acceptor molecule in the presence of PLTP.  Phospholipid transfer 
protein-mediated transfer of the fluorescent phospholipid to the acceptor molecule 
results in an increase in fluorescence (Excitation: 465nm; Emission: 535nm).  For the 
PLTP assay, a standard curve was prepared by making serial dilutions of the donor 
molecule in isopropanol and subsequently recording the fluorescence intensity of each 
dilution, using isopropanol alone as a blank.  The fluorescence intensity values of the 
standard curve were applied directly to the results to express activity of the plasma 
sample.  For each reaction in the assay procedure, the following components were 
added: 10µL of the donor molecule, 10µL of the acceptor molecule, 20µL of the 10X 
PLTP Assay Buffer, 1-3µL of serum sample, and deionized water to a total of 200µL.  
These materials were incubated for 30 - 60 minutes at 37°C.  The fluorescence intensity 
of the blank, samples, and positive control were then measured and the fluorescence 
intensity from each sample was corrected by subtracting the blank fluorescence 
intensity.  Equation 3 was used to calculate the activity of the plasma sample. 
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CHAPTER III 
 
RESULTS AND DISCUSSION 
 
 
Overview 
Ultimately, the aim of this research was to utilize novel analytical methods for 
analyzing human serum HDL subfractions.  Various method development studies were 
conducted to establish a reliable protocol, which would provide a comprehensive 
understanding of serum HDL subfractions.  The serum volumes reported here, were 
200µL, to adequately visualize all relevant apolipoprotein peaks via secondary analysis 
methods.  Serum was also treated with dextran sulfate, which eliminated all apoB 
containing lipoproteins, removing the possible influence from these lipoproteins in the 
analysis and interpretation of HDL subfraction results.  In the developmental stages of 
this method, samples were excised following DGU and re-spun to visualize the location 
of the excised fractions in the lipoprotein profiles.  Upon re-spinning, lipoprotein 
subfractions were within their defined density ranges demonstrating the accuracy and 
precision of the method.  Capillary electrophoresis analysis of these subfractions also  
resulted in accurate apolipoprotein distributions. 
Mass spectrometry was utilized for the analysis of commercial standards and 
human serum subfractions.  This method validated the serum subfraction elution patterns 
following solid phase extraction as well as HDL fraction composition. For serum 
fractions, MALDI-MS provided the molecular weights of the major proteins present in 
patient HDL fractions.  This technique also enabled the visualization of isoforms of 
apolipoproteins as well as post-translational modifications in the two patient cohorts. 
Capillary electrophoresis was also used to analyze commercial standards and 
human subfraction composition.  This method provided electrophoretic mobilities of the 
standards and also showed reproducible subfraction composition between cohorts. 
 Collaborative studies providing lipid levels, aortic smooth muscle cell apoptosis 
levels, and transfer protein activity rates provided further information regarding HDL 
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subfractions.  Apoptosis studies indicated that there was a distinct difference in apoptosis 
levels between the two cohorts.  Transfer protein rates provided additional information 
regarding the possible influence of cholesteryl ester transfer protein (CETP) and 
phospholipid transfer protein (PLTP) activity rates on CAD risk. 
 Overall, an array of analytical methods was used to successfully isolate, purify, 
and analyze HDL subfractions from two cohorts of patients.  In doing so, distinct 
differences in apolipoproteins were observed and provided strong evidence of possible 
biomarkers for CAD. 
 
 
Method Accuracy and Precision Studies 
Ultracentrifugation Studies 
Preparative UC was used as a primary analysis technique to separate the HDL 
region of the lipoprotein profile and facilitate excision for secondary analysis.  At a 
concentration of 0.300M the solute dicesium cadmium ethylenediaminetetraacetic acid 
(Cs2CdY), effectively broadens HDL particle distribution, allowing for excision of HDL 
subfractions while also providing ideal resolution of the HDL region from neighboring 
regions.  It was beneficial to remove all apoB containing lipoproteins such as VLDL, 
LDL, IDL, Lp(a) and chylomicrons.  The removal of apoB containing lipoproteins prior 
to ultracentrifugation minimized interferences particularly from LDL and Lp(a).  This 
process involved precipitation of apoB containing lipoproteins by the addition of a 
dextran sulfate reagent to whole serum prior to UC as described in the methods 
chapter.
180
  A superimposed comparison between lipoprotein density profiles using 
human serum spun in a 0.18M NaBiY density gradient solution with and without dextran 
sulfate treatment verified that the procedure cleanly removed all apoB-containing 
lipoproteins from the serum profile prior to sample analysis (Figure 5).  By merging 
treatment of serum with dextran sulfate with a UC spin using 0.300M Cs2CdY, it was 
possible to freeze serum samples following DGU, maintain their spatial arrangement, 
and subsequently excise them for secondary analyses. 
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Figure 5.  Superimposed lipoprotein density profiles corresponding to 6µL of whole 
serum (blue) and 6µL of serum following treatment with dextran sulfate (black) in a 
0.18M solution of NaBiY, spun for 6 hours at 120,000rpm at 5°C. 
 
 
Analysis of Re-Spun Fraction Lipoprotein Profiles _________________________________________  
 For preparative ultracentrifugation, it was determined that previously used 
density ranges were not ideal for the conditions used during DGU to obtain lipoprotein 
profiles and accurately excised serum subfractions.  The formerly used ranges were 
obtained from literature sources which utilized an alternative method known as rate 
zonal ultracentrifugation.  Upon re-spinning fractions using the former density ranges, 
the HDL3 fractions consistently appeared in the HDL2 region of the lipoprotein density 
profile.  Upon review of the literature, more accurate definitions for the density ranges 
including 1.063 – 1.125g/mL for HDL2 and 1.125 – 1.210g/mL for HDL3 were used.
181
  
All particles in the aggregated distribution in the density range below 1.063g/mL were 
designated as the top or non-HDL fraction, while those in the density range above 
1.210g/mL were designated as the bottom or protein fraction.  To investigate the 
redefined density boundaries, serum was spun in replicate to obtain DGU lipoprotein 
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profiles, subfractions were excised, the average densities were determined, and these 
subfractions were re-spun.   Figure 6 shows a lipoprotein profile from a 200µL serum 
sample following treatment with dextran sulfate.  The cut points for the HDL fractions 
were based upon the defined boundaries of the density regions for HDL2 and HDL3, and 
are represented by the blue vertical lines in the lipoprotein profile.  The first peak in the 
profile, is an imaging artifact that corresponds to the reflection of fluorescence radiation 
emanating from the lipoprotein layers to the meniscus in the UC tube.  As the density 
increased leading into the HDL2 region, there appeared to be overlap of the HDL2 peak 
into the non HDL fraction, spanning the density range of approximately 1.050 – 
1.063g/mL.  This observation is likely due to the use of the 200µL serum volume which 
was used in order to effectively analyze fractions by secondary methods.  Two hundred 
microliters of serum, is beyond the volume required for saturation.  Saturation is 
achieved using 10µL of the fluorophore NBD and 6µL of serum; thus the relatively large 
volume of serum used, is likely responsible for the appearance of the HDL2 peak outside 
of its defined boundary.  This result in turn indicated that minimal amounts of HDL 
would be present in the neighboring non HDL fraction.  Likewise, beyond the upper 
boundary of the HDL2 region proceeding into the HDL3 region, there was overlap of 
HDL2 into the HDL3 region spanning the density range of approximately 1.125 – 
1.175g/mL.  This result is also likely due the large serum volume used and indicated that 
HDL2 would be present in the HDL3 fraction following excision. The degree of overlap 
between the HDL3 and protein fraction was inconclusive prior to re-spinning.  The 
profile intensity suggested that there would be overlap between these fractions.  Overlap 
between the HDL3 and protein subfractions could be due to aggregation of HDL3 with 
protein fraction components, which may have caused the majority of the HDL3 peak to 
shift to the denser protein fraction though a shoulder remained in the HDL3 density 
region.  It is also important to note that the seam of the UC tube coincides with the 
density range between the HDL3 and protein fractions.  As this is the bottom of the UC 
tube, it is also possible that separation was limited in this region due to UC tube length.  
This seam or reference line in the wall of the UC tube, appears consistently between 28 – 
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29mm and is also a measurement of the reproducibility of the method.  The distribution 
above 1.210g/mL consists of free proteins which sediment to the bottom of the UC tube.  
The intensity of this region however indicated that there may also be a substantial 
amount of lipid in this region, since the fluorophore utilized in DGU is lipophilic and 
fluoresces in a hydrophobic environment.  Such fluorescence supports the hypothesis 
that there may be overlap of HDL3 in this region and may also be due to aggregation of 
HDL3 with protein, in addition to separation limitations due to the UC tube length. 
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Figure 6.  DGU lipoprotein profile of a 200µL serum sample after treatment with 
dextran sulfate using 0.300M Cs2CdY density gradient. 
 
 
Following the acquisition of the total lipoprotein profile, each non HDL, HDL2, 
HDL3, and protein fraction was excised and re-spun.  Figure 7 shows the resulting 
lipoprotein density profile following re-spinning the excised non HDL fraction.  This 
result supported the hypothesis that there would be overlap between the non HDL and 
HDL2 regions; and that the non HDL region would as a result, contain minimal amounts 
of HDL2.  The peak present in the re-spun non HDL fraction spanned a density range of 
1.050 – 1.063g/mL which is slightly greater than the range of overlap approximated 
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from the total lipoprotein profile shown in Figure 6.  The non HDL fraction contained an 
average density of 1.034 ± 0.004 g/mL which was within the defined density range of 
this fraction, however, as Figure 7 shows, this fraction contained a particle which 
appeared in the density range corresponding to HDL2.   Further analysis by secondary 
methods would elucidate the composition of this peak.   
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Figure 7. DGU lipoprotein profile of the re-spun non HDL fraction from a previously 
spun 200µL serum sample after treatment with dextran sulfate using 0.300M Cs2CdY 
density gradient. 
 
 
Figure 8 shows the resulting lipoprotein density profile following re-spinning the 
excised HDL2 fraction.  The resulting profile closely resembled the serum profile shown 
in Figure 6 prior to subfraction excision.  Figure 8 shows overlap into the neighboring 
non HDL and HDL3 density regions, with a total HDL2 re-spun fraction spanning the 
density range of 1.050 – 1.160g/mL.  The HDL2 fraction contained an average density of 
1.070 ± 0.004 g/mL.  As there is an enrichment of HDL2 in the total lipoprotein profile 
from this sample, it was observed that this fraction overlapped into neighboring density 
regions. Additionally, the aggregation of HDL2 with HDL3 or perhaps other serum 
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proteins may contribute to the HDL2  having higher density which spans beyond the 
defined HDL2  density range into the defined HDL3 density range. 
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Figure 8. DGU lipoprotein profile of the re-spun HDL2 fraction from a previously spun 
sample of 200µL serum after treatment with dextran sulfate using 0.300M Cs2CdY 
density gradient. 
 
 
Figure 9 shows the lipoprotein density profile following re-spinning the excised 
HDL3 fraction.  The resulting profile provided a much clearer understanding of the 
composition of this serum subfraction. As hypothesized from the visual distribution of 
HDL2 in Figure 6, the re-spun HDL3 contained a peak in the density range between 
1.063 – 1.150g/mL which may correspond to HDL2 and be due to overflow of HDL2 into 
the HDL3 region due to the large serum volume used.  It is also possible that this peak is 
an artifact or possibly a fragment which dissociated from the HDL3 particle during 
ultracentrifugation and possesses a density within the HDL2 density range.  It is also 
possible that there may be aggregation of HDL2 with HDL3, and that re-spinning cut 
fractions provided the force to separate joined lipoprotein particles.  Most importantly, 
the HDL3 peak was visualized within its defined boundary at a high intensity.  There was 
overlap between the HDL3 and bottom or protein regions, with a peak appearing in the 
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density range between 1.150 – 1.126g/mL which was also hypothesized from Figure 6.  
This overlap may be due to the HDL3/protein fraction boundary being in such close 
proximity to the bottom of the UC tube.  The HDL3 fraction contained an average 
density of 1.128 ± 0.016g/mL.   
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Figure 9. DGU lipoprotein profile of the re-spun HDL3 fraction from a previously spun 
200µL serum sample after treatment with dextran sulfate using 0.300M Cs2CdY density 
gradient. 
 
 
Figure 10 shows the resulting lipoprotein density profile following re-spinning 
the protein fraction.  As hypothesized from the serum profile shown in Figure 6, this 
fraction contained overlap with the HDL3 region.  The HDL3/protein fraction boundary 
appears near the bottom of the UC tube, limiting further separation of HDL3 from 
protein beyond this point.  The peak visualized in the re-spun protein fraction spanned a 
density range between 1.150 – 1.126g/mL which is the same as the re-spun HDL3 
fraction profile.  This result supported the hypothesis that the protein fraction fluoresces 
due to HDL3 contamination or overlap. The protein fraction contained an average 
density of 1.245 ± 0.016 g/mL which is within the defined range for the protein fraction, 
however, near the lower limits of the range influenced most likely by the HDL3 content 
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of this fraction.  Table 3 provides the average densities of each cut fraction from the 
replicate samples. 
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Figure 10.  DGU lipoprotein profile of the re-spun protein fraction from a previously 
spun 200µL serum sample after treatment with dextran sulfate using 0.300M Cs2CdY 
density gradient. 
 
 
Table 3.  Average density data corresponding to the cut fractions from the 200µL DS 
serum sample shown in Figures 6 through 9. 
Fraction 
Average 
Weight 
(g) 
Average 
Volume 
(µL) 
Average Density 
(g/mL) 
Literature 
Values 
(g/mL) 
Non 
HDL 0.1030 ± 0.0004 100 ± 0.1 1.034 ± 0.004 
<1.063 
HDL2 0.1070 ± 0.0004 100 ± 0.1 1.070 ± 0.004 1.063 – 1.125 
HDL3 0.1130 ± 0.0016 100 ± 0.1 1.128 ± 0.016 1.125 – 1.210 
Protein 0.0620 ± 0.0019 50 ± 0.1 1.245 ± 0.038 1.210< 
 
 
Overall, re-spinning excised serum subfractions provided a closer look into the 
actual composition and densities of the subfractions.  The redefined boundaries did result 
in an improvement in the accuracy of obtaining the desired subfractions.  All 
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subfractions with the exception of HDL2 showed the presence of additional peaks 
outside of the fraction’s defined density range.  It is possible that these fractions were 
contaminated by neighboring density region subfractions, which can be expected in a 
liquid state sample system with closely defined boundaries.  Such overlap may be 
attributed to the limitations of the current laboratory fractionation technology and 
equipment as well.  The cryogenic procedure used to freeze serum samples, saw used to 
excise fractions, and the fact that the HDL3/protein fraction boundary is near the bottom 
of the UC tube, may introduce further error into the fractionation process. The major 
contributing factor to any possible overlapping of fractions however, is hypothesized to 
be due to the fact that the 200µL serum volume is over 30 times greater than the serum 
volume needed for saturation.  The densities of each excised fraction were obtained in 
triplicate and the average densities of each were within their defined ranges despite the 
possible mixing that occurred between the subfractions.  Most importantly, the results 
demonstrate the capability of the methodology to excise serum fractions accurately and 
precisely within the defined density ranges.  As our current procedure incorporates a 
novel solute system unlike those predominantly reported in the literature, it has been 
shown that the heavy metal density gradient system does not substantially compromise 
the integrity or density of lipoproteins.  Due to the fact that the subfractions possibly 
contained neighboring serum subfractions particularly the non HDL and protein 
fractions, all four fractions were excised, retained and analyzed in subsequent 
experiments to obtain a comprehensive analysis of the each serum sample. 
 
 C18 Solid Phase Extraction Delipidation Studies 
 Purified apolipoproteins were prepared from lipoprotein fractions obtained from 
preparative UC using a delipidation procedure described in the methods chapter which 
incorporated a reversed phase SPE cartridge.  This purification facilitated the preparation 
of apolipoproteins for high resolution MALDI-MS and capillary electrophoresis.  Serum 
HDL subfractions must be subjected to delipidation prior to secondary analysis to both 
remove lipids and de-salt the sample following UC.  Solid phase extraction served to 
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retain the most nonpolar lipid components and elute the polar components of each 
sample. Using capillary electrophoresis, all four 100µL elutions were retained separately 
and analyzed following solid phase extraction to investigate the composition of each 
elution.  
 Figure 11 shows the resulting electropherograms following the analysis of the 
first 100µL elution after solid phase extraction.  The major apolipoproteins and serum 
proteins were observed in the first elution.  
 
Figure 11.   Electropherogram corresponding to the first elution following solid phase 
extraction of an HDL2 fraction from a 200µL serum sample.  
 
 
Figure 12 shows the resulting electropherograms following the analysis of the 
second, third, and fourth 100µL elutions following solid phase extraction.  There were 
no analyte peaks in the second, third, or fourth elutions.  This experiment was repeated 
in replicate, with reproducible results and that were observed in patient sample elutions 
as well.   
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Figure 12.   Electropherograms corresponding to the second, third, and fourth elutions 
following solid phase extraction of an HDL2 fraction from a 200µL serum sample.  
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This result was quite different from previous elution pattern experiments which 
reported analytes in all four 100µL eluents.
79
  This difference is most likely due to the 
modifications to the solid phase extraction procedure which included increasing the 
amount of time that the eluent interacted with the sorbent bed prior to elution, and 
decreasing flow rates to the rate of gravity.   Mass spectrometry  was also used to 
investigate and confirm the elution profile from the solid phase extraction cartridge.  
Four aliquots of 100µL eluents were individually obtained and prepared for MALDI-MS 
as described in the methods chapter.  Figure 13 corresponds to the first through fourth 
elutions following solid phase extraction of an excised HDL2 fraction.  This sample 
contained several apolipoprotein peaks including apoA-I, C-I, C-II/C-III isoforms, and 
albumin.  The second through fourth 100µL elutions of the excised HDL2 fraction 
following solid phase extraction, showed no detectable analyte peaks.     
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Figure 13.  MALDI-MS spectra corresponding to the first (large) through fourth elutions 
of an HDL2 serum subfraction following solid phase extraction. 
 
 
The results obtained from MALDI-MS analysis supported the results obtained by 
capillary electrophoresis and indicated that the elution of analyte peaks was completed in 
the first 100µL elution.  In Figure 11 the peaks are identified as human serum albumin, 
apoA-I, and apoC-I, with effective mobilities which all correspond with the mobility 
determination experimental results which will be presented in the following section.  
Overall, the C18-SPE desalting/delipidating method provided purified apolipoproteins 
from the HDL fractions in an analyte matrix amenable to a variety of analytical methods.   
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Serum Subfraction Composition Studies 
 High density lipoprotein as a whole contains a higher protein content and lower 
lipid content than less buoyant fractions such as LDL, VLDL, and chylomicrons.  This 
fraction likewise contains many apolipoproteins and varying ratios of these surface 
proteins between HDL subfractions.  Several studies were conducted to investigate the 
composition of HDL subfractions to identify differences between the two cohorts.  Prior 
to analyzing serum subfractions, several studies were conducted using commercial 
protein standards.   
 
Commercial Protein Standards: Electrophoretic Mobility and Purity Determination 
Protein mobility experiments were conducted to determine the effective 
mobilities of commercial standards.  These commercial standards were used in order to 
identify apolipoprotein serum fraction composition and elution patterns based on 
electrophoretic mobilities and molecular weight.  Each commercial standard solution 
was analyzed in triplicate by CE and the effective mobility of each was calculated.  For 
the CE electropherograms, the absorbance at 214nm was plotted as a function of the 
effective mobility (μeff x 10
-5
 cm
2
/V*s).  In the electropherograms, the mobilities were in 
the opposite direction of the electroosmotic flow, giving the effective mobilities a 
negative charge.  Calibration curves were prepared at a wavelength of 214nm as 
described in the methods section to enable quantitation by CE.  Briefly, a series of 
solutions including apoA-I, apoC-I, and bovine serum albumin, containing varying 
standard solution concentrations was analyzed in triplicate by CE. Linear regression was 
done for each of the calibration curves and the resulting equations were used for 
subsequent concentration calculations.   The MALDI-MS analysis assessed the purity of 
the commercial standards.  The MALDI-MS spectra are presented as the relative ion 
intensity plotted as a function of the mass to charge (m/z) ratio.  The commercial 
specifications for purity of the apolipoproteins were ≥ 99% by SDS-PAGE. 
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 The electropherogram of the 80.0mg/dL bovine serum albumin (BSA) solution in 
the presence of 0.1% aqueous TFA is shown in Figure 14.  Only one peak was observed 
in addition to the EOF marker in the electropherogram.  This indicated that the      
solution was relatively pure for BSA.  The mobility of the bovine serum albumin peak 
was -20.869 ± 0.069  x 10
-5 
cm
2
/V*s and the corrected peak area (CPA) was 78463 ± 
3317.   The corrected peak area was calculated using an algorithm in the Beckman 
P/ACE Station Migration software and accounted for the band broadening due to the 
duration of time required for the peak to pass by the detector.   
 
 
Figure 14.  Electropherogram corresponding to 80.0mg/dL bovine serum albumin. 
  
 
Figure 15 is the MALDI mass spectrum of the bovine serum albumin solution.  
One major peak was observed in the spectrum corresponding to bovine serum albumin. 
An additional peak was observed corresponding to doubly protonated bovine serum 
albumin.  In all MALDI spectra, the protonated molecule was designated by the 
apolipoprotein and the doubly protonated molecule was identified by a superscript 
charge.  To assess the effect of solid phase extraction on samples, the bovine serum 
albumin standard was subjected to solid phase extraction and analyzed by MALDI-MS.  
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Figure 15 corresponds to the resulting MALDI spectrum obtained following solid phase 
extraction.  There was no fragmentation observed in the bovine serum albumin standard.   
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Figure 15.   MALDI-MS spectrum corresponding to 80.0mg/dL bovine serum albumin 
in 0.1% (v/v) TFA. 
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Figure 16.   MALDI-MS spectrum corresponding to 80.0mg/dL bovine serum albumin 
in 0.1% (v/v) TFA after solid phase extraction. 
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Overall, the MALDI-MS and CE data indicated that the standard bovine serum 
albumin  solution was of high purity, and was not compromised following solid phase 
extraction.  Figure 17 corresponds to the bovine serum albumin calibration curve.  From 
the derived linear regression of the CPA in Figure 17, bovine serum albumin 
concentration from CPA values could be calculated according as follows: (Eq. 4) 
 
Calculated bovine serum albumin  concentration = CPA/993.13.    Eq. 4 
 
 The average electrophoretic mobility corresponding to bovine serum albumin was   
-20.914 ± 0.0961 x 10
-5 
cm
2
/V*s and the average elution time of bovine serum albumin 
was 10.139 ± 0.0789 min. Table 4 provides the average effective mobilities, corrected 
peak areas (CPA) and elution times for each of the standard dilutions. 
 
 
Figure 17.  Calibration curve generated from the corrected peak area (CPA) of bovine 
serum albumin standard dilutions versus the concentration of the bovine serum albumin 
standard dilutions by capillary electrophoresis at 214nm. 
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Table 4.  BSA data corresponding to each dilution of the bovine serum albumin 
standard. 
BSA 
Concentration 
(mg/dL) Area 
Calculated 
Concentration 
(mg/dL) 
Mobility 
(x10
-5
cm
2
/Vs ) 
Elution 
Time  
(min) 
80.0 78463 ± 3317 78.98 ± 0.005 -20.869 ± 0.149 10.061 ± 0.062 
40.0 39570 ± 3747 38.31 ± 0.185 -20.852 ± 0.136 10.121 ± 0.030 
20.0 22080 ± 1433 21.86 ± 0.004 -20.906 ± 0.065 10.131 ± 0.068 
10.0 12794 ± 1272 12.34 ± 0.007 -20.917 ± 0.033 10.159 ± 0.083 
5.0 7406 ± 1726 6.42 ± 0.014 -21.029 ± 0.037 10.225 ± 0.106 
 
 
The electropherogram of the 80.0mg/dL apoA-I solution in the presence of 0.1% 
aqueous TFA is shown in Figure 18.  Two additional peaks were observed in the 
electropherogram besides the EOF marker and the apoA-I peak indicating possible 
impurities in the standard.  The mobility of the apoA-I peak was -24.758 ± 0.295 x 10
-5 
cm
2
/V*s and the corrected peak area (CPA) was 28110 ± 2252.   
 
 
Figure 18.   Electropherogram corresponding to 80.0mg/dL apo A-I. 
 
 
Figure 19 is the MALDI mass spectrum corresponding to apoA-I.  Two major 
peaks were observed in the spectrum corresponding to singly and doubly protonated 
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apoA-I.  A third peak was observed on the shoulder of the protonated molecule 
designated A-Iadd +98.  This peak was likely attributed to the addition of phosphoric acid 
and or sulfuric acid molecules originating from the commercial sample purification 
procedure, as also observed in previous studies.
182
  Figure 20 corresponds to the 
resulting MALDI-MS spectrum following solid phase extraction.  There was no 
fragmentation of the commercial apoA-I standard following solid phase extraction.  The 
results obtained from the commercial apoA-I standard solutions by MALDI-MS and CE 
indicated that the standard was of high purity.  The MALDI-MS findings also verified 
that the predominant peak in the electropherogram corresponded to apoA-I.   
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Figure 19.   MALDI-MS spectrum corresponding to 80.0mg/dL apoA-I in 0.1%(v/v) 
TFA. 
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Figure 20.   MALDI-MS spectrum corresponding to 80.0mg/dL apoA-I in 0.1%(v/v) 
TFA after solid phase extraction. 
  
 
 Figure 21 corresponds to the apoA-I calibration curve.  From the derived linear 
regression of the CPA in Figure 21, apoA-I concentration from CPA values could be 
calculated according as follows: (Eq. 5)  
 
Calculated apoA-I concentration = CPA/360.40.       Eq. 5 
 
The average electrophoretic mobility corresponding to apoA-I was -24.776 ± 
0.2649 x 10
-5 
cm
2
/V*s and the average elution time of apoA-I was 13.610 ± 0.5612 min. 
Table 5 provides the average effective mobilities, corrected peak areas (CPA) and 
elution times for each of the standard dilutions.  
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Figure 21.   Calibration curve generated from the corrected peak area (CPA) of apoA-I 
standard dilutions versus the concentration of the apoA-I standard dilutions by capillary 
electrophoresis at 214nm. 
 
 
 
Table 5.  ApoA-I data corresponding to each dilution of the apoA-I standard. 
ApoA-I 
Concentration 
(mg/dL) Area 
Calculated 
Concentration 
(mg/dL) 
Mobility  
(x10
-5
cm
2
/Vs ) 
Elution  
Time  
(min) 
80.0 
28110 ± 
2252 77.32 ± 0.013 -24.758 ± 0.295 13.325 ± 0.778 
40.0 15788 ± 372 48.71 ± 0.035 -24.740 ± 0.313 13.429 ± 0.890 
20.0 7596 ± 90 22.36 ± 0.004 -24.752 ± 0.733 13.362 ± 0.926 
10.0 3245 ± 303 10.62 ± 0.009 -24.445 ± 0.586 14. 611 ± 2.808 
5.0 1704 ± 59 5.64 ± 0.012 -25.187 ± 1.661 13.321 ± 0.884 
  
 
The electropherogram of apoC-I is observed in Figure 22.  The major peak observed at a 
mobility of -31.325 ± 0.279 x 10
-5 
cm
2
/V*s with a CPA of 32017 ± 2988 was identified 
as apoC-I.  Additional peaks were observed, eluting before and after apoC-I which were 
likely impurities in the standard. 
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Figure 22.  Electropherogram corresponding to 80.0mg/dL apoC-I. 
  
 
The MALDI spectrum of the apoC-I solution is seen in Figure 23. The primary 
peak observed was due to the protonated molecule of apoC-I.  The shorter peak in front 
of the primary peak was identified as apoC-I' and corresponds to the truncated protein 
missing the last two N-terminal amino acids, threonine and proline.  As observed in the 
MALDI spectrum for apoA-I these two peaks were detected along with the addition of a 
+98 adduct which is likely attributed to the addition of phosphoric acid or sulfuric acid 
molecules originating from the commercial sample purification procedure.
182
  Figure 24 
shows the MALDI-MS spectrum corresponding to the apoC-I standard following solid 
phase extraction, and shows no fragmentation.  
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Figure 23.  MALDI-MS spectra corresponding to 80.0mg/dL apoC-I in 0.1% (v/v) TFA. 
 
 
6000 9000
0
10000
20000
30000
40000
50000
60000
70000
R
e
la
ti
v
e
 I
o
n
 I
n
te
n
s
it
y
m/z
Apo C-Iadd
Apo C-I
Apo C-I'
 
Figure 24.  MALDI-MS spectra corresponding to 80.0mg/dL apoC-I in 0.1% (v/v) TFA 
after solid phase extraction. 
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Figure 25 corresponds to the apoC-I calibration curve. From the derived linear 
regression of the CPA in Figure 25, apoC-I concentration from CPA values could be 
calculated as follows: (Eq. 6) 
 
Calculated apoC-I concentration = CPA/423.26.       Eq. 6 
 
The average electrophoretic mobility corresponding to apoC-I was -31.929 ± 0.4782 x 
10
-5 
cm
2
/V*s and the average elution time of apoC-I was 17.038 ± 0.7272 min.  Table 6 
provides the average effective mobilities, corrected peak areas (CPA) and elution times 
for each of the standard dilutions. 
 
 
 
Figure 25.  Calibration curve generated from the corrected peak area (CPA) of apoC-I 
standard dilutions versus the concentration of the apoC-I standard dilutions by capillary 
electrophoresis at 214nm. 
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Table 6.  ApoC-I data corresponding to each dilution of the apoC-I standard. 
ApoC-I  
Concentration 
(mg/dL) Area 
Calculated  
Concentration 
(mg/dL) 
Mobility 
(x10
-5
cm
2
/Vs ) 
Elution 
Time (min) 
0.800 
32017 ± 
2988 78.84 ± 0.0340 -31.325 ± 0.279 15.996 ± 0.117 
0.400 
19313 ± 
1052 47.61 ± 0.042 -31.891 ± 0.354 16.611 ± 0.004 
0.200 9812 ± 1249 24.06 ± 0.004 -32.328 ± 0.337 17.240 ± 0.021 
0.100 1003 ± 5593 13.67 ± 0.005 -31.573 ± 0.292 17.631 ± 0.003 
0.050 3560 ± 173 8.78 ± 0.008 -32.440 ± 0.708 17.713 ± 0.312 
 
 
The calibration curves showed a strong linear relationship between concentration 
and UV absorbance over the selected concentration range for both apolipoproteins.  The 
corrected area of peaks that migrated past the detector was calculated as a function of the 
integrated area and velocity of the peaks, length to the detector, and the migration time 
of the peaks as they eluted through the capillary.   
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MALDI-MS Accuracy and Precision  
Replicate commercial bovine insulin samples were used to assess the accuracy 
and precision of the MALDI-MS instrumentation.  This would in turn provide further 
confidence in the mass measurements that were detected in the actual serum samples.  
Ten 100.0mg/dL bovine serum insulin samples were ran and analyzed by MALDI-MS.   
The results of this experiment further demonstrated the accuracy and precision of 
the MALDI-MS procedure and instrumentation.  The known mass of bovine insulin is 
5734.59 Da as verified by the LBMS instrument database.  The results of this 
experiment showed the exceptional precision and accuracy of the MALDI-MS 
instrumentation from the closeness of each measured insulin standard mass to the known 
mass, as well as to the other standard sample masses.  Figures 26 and 27 show the 
MALDI-MS spectra corresponding to each of the ten samples.  The intensities of the 
samples were comparable with the exception of two samples with relatively lower 
intensities.  The fluctuation in intensities is due to the fact that the MALDI-MS analysis 
is qualitative as opposed to quantitative.  Fluctuations in intensity also may be attributed 
to the heterogeneity of the electromagnetic fields on the MALDI plate.   
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Figure 26. MALDI-MS spectra corresponding to the first through fifth 100.0mg/dL 
bovine insulin standard samples. 
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Figure 27.  MALDI-MS spectra corresponding to the sixth through tenth 100.0mg/dL 
bovine insulin standard samples. 
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From the calculation shown in Equation 7, it could be assumed that 95 times out 
of 100, the true mean, μ, would be within ± 0.192 Da for bovine insulin.  Overall, as 
hypothesized, the results of this experiment demonstrated the repeatability and accuracy 
of the MALDI instrumentation.  Table 7 shows the average mass of all ten insulin 
standards as well as the standard deviation. 
 
 
Table 7. Comparison of bovine insulin known and experimental masses. 
Bovine Insulin (known mass) 5734.59 Da 
Bovine Insulin (average experimental mass) 5734.54 Da 
Bovine Insulin (standard deviation) 0.269Da 
 
 
 
Student’s T Equation (at the 95% confidence level) t = 2.26 
 
 
μ =  x ±  ts 
 √N         Eq. 7 
 
μ = 5734.54 ± 0.192 Da    
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
 
 
Clinical Studies 
 
Overview 
To further investigate apolipoprotein composition of HDL subfractions and to 
correlate with and verify the apolipoprotein peaks observed and identified by CE, 
MALDI-MS was used as a qualitative method.  Although quantitation was not sought 
from MALDI-MS analysis, the relative intensities of the apo peaks following MALDI-
MS analysis was of interest.  The MALDI-MS spectra from all patients were obtained 
for the non HDL, HDL2, HDL3, and protein fractions.   
 Capillary electrophoresis (CE) was also used for secondary analysis following 
preparative UC to investigate potential differences in electrophoretic properties in non-
CAD control and CAD cohort subfractions.   The C18 solid phase extraction method of 
delipidation with subsequent CE was implemented as part of a comprehensive 
apolipoprotein analysis using both cohorts of patient samples.  Data obtained was also 
compared to MALDI-MS data to verify the identities of analyte peaks and to determine 
whether post-translational modifications could be detected by changes in the inherent 
mobility of the HDL apolipoproteins in these samples.  Following solid phase extraction 
and evaporation to dryness the subfractions were reconstituted in 100µL of the capillary 
electrophoresis buffer consisting of 12.5mM sodium borate, 3.5mM SDS, and 20% (v/v) 
acetonitrile.  This buffer system was chosen in order to provide a strong electroosmotic 
force due to the high pH of the buffer which was approximately 9.00, and to ensure 
significant negative charge on the apolipoproteins due their interaction with the anionic 
surfactant.  These conditions served to minimize apolipoprotein-apolipoprotein 
interactions and apolipoprotein-wall interactions.  The electrophoresis experiment was 
performed in normal polarity, such that the electroosmotic flow moved from the anode 
to the cathode.  Integration of peak areas was performed manually.   
Following the MALDI-MS analysis of both patient cohorts, a distinct difference 
was observed in the apoC-I peaks.  The apoC-I peaks were observed in detail in the mass 
range spanning 6300 – 6800m/z where these protein peaks were expected to be found.   
The HDL2 spectra from the control cohort are shown in Figures 28 and 29. 
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Figure 28.  MALDI-MS HDL2 apoC-I spectra from control cohort patients 1, 3, 7, and 
13. 
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Figure 29.  MALDI-MS HDL2 apoC-I spectra from control cohort patients 14, 16, 24 
and 25. 
 
 
The HDL3 subfraction apoC-I peaks are shown for the control cohort in Figures 
30 and 31.  In the control cohort, apoC-I' and apoC-I were both observed and identified 
based upon their molecular weights which are 6432.50 Da and 6630.60 Da respectively.  
Due to the consistent detection of apoC-I peaks in all patient HDL fractions, the mass 
accuracy of the apoC-I peaks was determined by averaging the masses of each peak 
from the control cohort, and calculating the standard deviation at the 95% confidence 
level.   
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Figure 30.  MALDI-MS HDL3 apoC-I spectra from control cohort patients 1, 3, 7, and 
13. 
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Figure 31.  MALDI-MS HDL3 apoC-I spectra from control cohort patients 14, 16, 24, 
and 25. 
 
 
Table 8 reports the average mass values of the apoC-I' and apoC-I peaks in the 
control cohort, as well as their differences from the known mass values of these peaks.  
Tables 9 – 10 report the average masses of the apoC-I peaks in the HDL serum 
subfractions.  Due to the accuracy and precision of the apoC-I values in the control 
cohort to the known masses of these proteins, apoC-I served also as an internal standard 
of the method. 
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Table 8.  Total control cohort average apoC-I masses by MALDI. 
 Control Cohort ApoC-I' Control Cohort ApoC-I 
Average Mass 6434.40 ± 0.93 6633.05 ± 1.08 
Known Mass 6432.50 6630.60 
Difference 1.90 ± 0.93 2.45 ± 1.08 
 
 
Table 9.  Control cohort HDL2 fraction average apoC-I masses by MALDI. 
 Control Cohort ApoC-I' Control Cohort ApoC-I 
Average Mass 6434.73 ± 1.36 6632.96 ± 1.61 
Known Mass 6432.50 6630.60 
Difference 2.23 ± 1.36 2.36 ± 1.61 
 
Table 10.  Control cohort HDL3 fraction average apoC-I masses by MALDI. 
 Control Cohort ApoC-I' Control Cohort ApoC-I 
Average Mass 6434.22 ± 2.04 6632.43 ± 1.92 
Known Mass 6432.50 6630.60 
Difference 1.72 ± 2.04 1.83 ± 1.92 
 
 
In the CAD cohort, it was observed that the peaks which were assumed to be 
apoC-I and apoC-I' upon initial visual inspection, possessed a molecular weight greater 
than the known calculated mass of these proteins.  Due to this significant shift in 
molecular weight, the peaks were designated apoC-I'1 and apoC-I1.  Figures 32 and 32  
show the HDL2 and HDL3 apoC-I spectra respectively, for the CAD cohort patients 
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Figure 32.  CAD cohort HDL2 apoC-I MALDI-MS spectra. 
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Figure 33.  CAD cohort HDL3 apoC-I MALDI-MS spectra. 
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In all samples of the CAD cohort it was observed that apoC-I contained peaks with 
greater masses than the known literature masses.  Due to this significant shift in 
molecular weight, the peaks were designated apoC-I′1 and apoC-I1.  Such a finding 
indicated post-translational modifications occurring in the CAD cohort which may be 
linked to CAD, as this diagnosis was the distinguishing difference between the two 
cohorts.  This analysis of HDL serum fractions in the CAD cohort, also demonstrated 
further variability in the isoform pattern in some subjects within the CAD cohort.  Figure 
34 shows the doublets observed in the HDL subfractions from CAD patient 143.  These 
further modified isoforms have been designated apoC-I2' and apoC-I2.   
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Figure 34.  CAD cohort HDL subfractions from patient 143 showing further variability 
in apoC-I. 
 
 
  Due to this variability, it is apparent that there are factors controlling the post-
translational modifications of apoC-I in the lipoprotein particles.  In certain patient 
samples it was observed that the apoC-I1 peak appeared to be nearly depleted.  It is 
hypothesized that some mechanism or process is resulting in the depletion of native 
apoC-I.  Perhaps the acceleration of CAD is resulting in the rapid transformation of 
apoC-I to apoC-I1, decreased or even inhibited apoC-I synthesis, or rapid removal of the 
derivative apoC-I1 from the body as a counter measure.   
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The differences between known apoC-I and apoC-I' masses and the observed 
apoC-I'1 and apoC-I1 masses were assessed to identify the variation between 
measurements.  The CAD cohort apoC-I peaks were averaged, and the standard 
deviation was calculated at the 95% confidence level.  Table 11 shows the average 
masses of the apoC-I'1 and apoC-I1 peaks in the CAD cohort.  Tables 12 – 13 show the 
average masses of the apoC-I'1 and apoC-I1 peaks in each serum subfraction.   
 
 
Table 11. Total CAD cohort average apoC-I masses by MALDI. 
 CAD Cohort ApoC-I'1 CAD Cohort ApoC-I1 
Average Mass 6522.47 ± 2.78 6720.47 ± 2.09 
Known Mass 6432.50 6630.60 
Difference 89.97 ± 2.78 89.87 ± 2.09 
 
 
Table 12. Total CAD cohort HDL2 fraction average apoC-I masses by MALDI. 
 CAD Cohort ApoC-I'1 CAD Cohort ApoC-I1 
Average Mass 6523.73 ± 4.54 6721.34 ± 4.08 
Known Mass 6432.50 6630.60 
Difference 91.23 ± 4.54 90.74 ± 4.08 
 
Table 13. Total CAD cohort HDL3 fraction average apoC-I masses by MALDI. 
 CAD Cohort ApoC-I'1 CAD Cohort ApoC-I1 
Average Mass 6520.79 ± 6.28 6719.79 ± 2.49 
Known Mass 6432.50 6630.60 
Difference 88.29 ± 6.28 89.19 ± 2.49 
 
 
 
Additionally, one patient, patient 49, displayed MALDI-MS results in accordance 
with the CAD cohort despite not having a CAD diagnosis.  Figure 35 shows the HDL 
spectra corresponding to apoC-I for this patient.  This result suggests that this analysis 
may be an initial screening that could indicate the future development of CAD and serve 
as a biomarker for CAD in this individual, as its MALDI spectra showed characteristics 
as seen in the CAD cohort.   
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Figure 35.  MALDI-MS apoC-I spectra from patient 49. 
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Patient history and lipoprotein density profiles are presented in this section for 
each of the 16 patients analyzed to correlate with each patient’s full MALDI-MS spectra 
and CE results. 
 
 
Control Cohort Analysis 
 
 
Table 14.  Control patient 1 medical information 
Control Patient 1  
Age 48 years old 
Height 66 inches 
Weight 136 lbs. 
Gender Female 
Race Caucasian 
Major Risk Factors None 
Current Medications Beta Blocker 
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Figure 36.  Lipoprotein density profile from control patient 1 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
 
 
Control Patient 1 Discussion 
Control patient 1, whose medical history is presented in Table 14, is a 48 year old 
Caucasian female who does not have CAD and does not possess major risk factors.  The 
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Cs2CdY lipoprotein profile which expands the HDL region is shown in Figure 36 and 
shows a broad peak spanning both HDL subfractions, but primarily in the HDL2 subclass. 
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Figure 37.  MALDI-MS non HDL spectra from control patient 1. 
 
Table 15. Identification of apolipoproteins in the non HDL fraction from control patient 
1. 
Identification Mass (Da) 
ApoC-I' 6432.16 
ApoC-I 6629.37 
ApoA-I1 28444.99 
88 
 
 
 
Figure 38.  Electropherogram of the non HDL fraction from control patient 1. 
 
 
Table 16.  CE data for the non HDL fraction from a 200µL serum sample from control 
patient 1. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.7 -21.109 360 0.36 
ApoA-I 11.8 -26.443 480 1.33 
ApoC-I 14.9 -31.773 364 0.86 
 
 
 
           Figure 37 shows the MALDI spectra for the non HDL subfraction which contained 
apos C-I', C-I, A-I, and HSA. Table 15 shows the peak masses for this fraction.  All 
proteins present in this most buoyant fraction were relatively low in intensity which 
suggests minimal concentration of these proteins in this fraction.  The presence of proteins 
in this fraction indicated mixing with the neighboring HDL2 fraction following excision.  
The proteins were identified through comparison with their known masses which are based 
on amino acid sequences in well validated databases such as the Swiss-Prot database 
(www.ebi.ac.uk/swissprot). Apolipoprotein A-I, however, was higher in mass than the 
C-I 
  A-I 
  HSA 
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known value of this protein, further analysis of the remaining patients in the cohort would 
identify if this mass shifting would be unanimous or restricted to this particular patient.  
Due to this shifting, however, the protein was designated as A-I1.  Figure 38 shows the 
electropherogram from the CE analysis of the non HDL fraction.  Low intensity peaks 
with mobilities matching albumin, apoA-I, and apoC-I were detected, which further 
indicated mixing from the neighboring HDL2 fraction.  Compared to the MALDI-MS 
results, all proteins were detected with the exception of albumin.    
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Figure 39.  MALDI-MS HDL2 spectra from control patient 1. 
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Table 17. Identification of apolipoproteins in the HDL2 fraction from control patient 1. 
Identification Mass (Da) 
ApoC-I' 6434.93 
ApoC-I 6631.52 
ApoA-II'm 8692.76 
ApoC-III0 8768.46 
ApoA-IIm 8809.81 
Pro ApoC-II 8914.36 
ApoC-III0,glyc 9130.18 
ApoC-III1 9418.77 
ApoA-I
2+ 
14037.06 
ApoA-I
2+
add 14149.75 
ApoA-II'' 17146.11 
ApoA-II' 17260.55 
ApoA-II 17391.00 
ApoA-IIadd 17591.94 
ApoA-I1 28447.82 
 
Figure 40.  Electropherogram of the HDL2 fraction from control patient 1. 
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Table 18. CE data for the HDL2 fraction from a 200µL serum sample from control 
patient 1. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.7 -20.414 905 0.91 
ApoC-II 10.1 -21.653 90 ------- 
ApoC-III 10.2 -22.182 729 ------- 
ApoA-I 11.5 -25.355 6582 18.26 
ApoC-I 14.9 -31.213 366 0.86 
 
 
The HDL2 subfraction MALDI-MS spectra, shown in Figure 39, contained 
several proteins including apos C-I', C-I, A-IImonomer, C-III0, Pro C-II, C-III0,glyc, C-III1, A-
I
2+
, A-II, and A-I1.  Table 17 shows the peak masses for this fraction The intensity and 
high resolution suggested an enrichment of these apolipoproteins in this buoyant HDL 
subfraction.  This subfraction showed sharp peaks corresponding to apoC-I along with its 
truncated form apoC-I' which appeared at an intensity slightly lower than half of that seen 
by apoC-I.  The mass region between m/z 8000 – 10000, showed many peaks 
corresponding to apos C-II and C-III with pro apoC-II having the highest peak intensity.  
Figure 40 shows the electropherogram following the CE analysis of the HDL2 fraction.  
Albumin and apos C-II, C-III, A-I, and C-I were detected and identified based upon their 
electrophoretic mobilities.  Though apoC-II, and apoC-III calibration curves were not 
constructed in this work, these apolipoproteins were identified by the mobilities presented 
in previous work
.79
 ApoA-I was the strongest peak observed in this fraction, indicating that 
this protein had the highest concentration, followed by apoC-III, and apoC-I.  Compared to 
the MALDI-MS results, albumin was detected by CE only, while apoA-II was detected by 
MALDI-MS only.   
 
 
92 
 
 
 
10000 20000 30000 40000 50000 60000 70000
0
1000
2000
3000
4000
5000
6000
13500 13750 14000 14250 14500
0
200
400
600
800
Prealbumin
 A-I'''
2+
A-I
2+
11000 11500 12000
0
200
400
600
800
SAA'
1
SAA''
1
SAA
1 add
8000 8500 9000 9500 10000
0
250
500
750
1000
1250
1500
C-III
1
'
Pro C-II
C-III
0,Glyc C-III
1
m/z
6300 6400 6500 6600 6700 6800
0
1000
2000
3000
4000
5000
6000 C-I
C-I'
m/z
R
e
la
ti
v
e
 I
o
n
 I
n
te
n
s
it
y
m/z
A-I
1
HSA
E
 
Figure 41.  MALDI-MS HDL3 spectra from control patient 1 
 
.Table 19.  Identification of apolipoproteins in the HDL3 fraction from control patient 1. 
Identification Mass (Da) 
ApoC-I' 6436.81 
ApoC-I 6632.77 
Pro ApoC-II 8915.57 
ApoC-III0,glyc 9129.22 
ApoC-III1' 9294.38 
ApoC-III1 9422.96 
SAA1'' 11440.92 
SAA1' 11536.19 
SAA1add 11730.31 
Prealbumin
 
13767.87 
ApoA-I'''
2+ 
13885.53 
ApoA-I
2+ 
14046.65 
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Table 19. (Continued) 
Identification Mass (Da) 
ApoA-I1 28444.81 
ApoE 33738.66 
HSA 67476.65 
 
Figure 42. Electropherogram of the HDL3 fraction from control patient 1. 
 
 
Table 20. CE data for the HDL3 fraction from a 200µL serum sample from control 
patient 1. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.8 -20.967 26687 26.87 
ApoA-I 11.9 -26.241 778 2.16 
ApoC-I 15.6 -32.025 555 1.31 
 
 
 
 
94 
 
 
 
Figure 41 shows the HDL3 subfraction MALDI-MS spectra which contained 
apos C-I', C-I, Pro C-II, C-III0glyc, C-III1, SAA1, SAA4, A-I+, A-I1, E, and HSA.  Table 19 
shows the peak masses for this fraction.  The apoC-I peaks were sharp with apoC-I 
appearing at approximately 3 times higher relative ion intensity.  The region spanning m/z 
8000 – 10000 in this subfraction, did not show the abundance of proteins nor the 
resolution that were observed in the HDL2 subfraction. Likewise, the apoA-II peaks were 
not present in this fraction.  Interestingly, serum amyloid a (SAA) peaks were observed in 
the region between m/z 11000 – 12000.  Serum amyloid a isoforms are expressed 
constitutively or in response to inflammatory stimuli.  Patient 1 contained both SAA1 and 
SAA4, SAA4 is a constitutive isoform of SAA, and, SAA1 is an acute phase SAA protein 
(A-SAA).  Although this patient was confirmed to not possess CAD, A-SAA proteins have 
been implicated in several chronic inflammatory diseases such as atherosclerosis.  Figure 
42 shows the electropherogram from the CE analysis of the HDL3 fraction.  A large and 
sharp peak corresponding to albumin was detected in addition to apoA-I and apoC-I.  
ApoA-I was detected in a much lower abundance than the HDL3 fraction, while apoC-I 
was detected in a greater abundance.  Compared to the MALDI-MS results from this 
subfraction, all protein peaks detected by CE were also detected by MALDI-MS.  
MALDI-MS also detected SAA peaks as well as apoE, apoC-II, and apoC-III peaks, all of 
which were low in relative ion intensity . 
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Figure 43.  MALDI-MS protein spectra from control patient 1. 
 
Table 21.  Identification of apolipoproteins in the protein fraction from control patient 1. 
Identification Mass (Da) 
ApoE 33782.86 
HSA 67396.19 
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Figure 44.  Electropherogram of the protein fraction from control patient 1. 
 
 
Table 22.  CE data for the protein fraction from a 200µL serum sample from control 
patient 1. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.7 -21.363 9640 9.71 
ApoC-I 15.3 -32.392 471 1.11 
 
 
     The protein subfraction for patient 1 contained only apoE and human serum albumin 
as shown in the MALDI-MS spectrum in Figure 43.  Table 21 shows the peak masses for 
this fraction.  Albumin was present at approximately three times the intensity of apoE.  
The CE results following the analysis of this fraction are shown in Figure 44 and shows 
peaks corresponding to the mobility of albumin and apoC-I.  The albumin peak contained 
a shoulder which may be due to its co-elution with another serum component.  Compared 
to the MALDI-MS results from this subfraction, both methods detected albumin, while CE 
detected apoC-I and MALDI-MS detected apoE.  It is possible that apoE has an 
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electrophoretic mobility which matches that of apoC-I, and that the apoC-I identified by 
CE is actually apoE. 
 
 
Table 23.  Control patient 3 medical information 
Control Patient 3  
Age 77 years old 
Height 61 inches 
Weight 130 lbs. 
Gender Female 
Race Caucasian 
Major Risk Factors Family history of CAD 
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Figure 45.  Lipoprotein density profile using a 200µL serum sample from control patient 
3 in a 0.300M solution of Cs2CdY, spun for 6 hours at 120,000rpm at 5°C after 
treatment with dextran sulfate. 
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Control Patient 3 Discussion 
Control patient 3, whose medical history is presented in Table 23, is a 77 year old 
Caucasian female who does not have CAD however, does have a family history of the 
disease.  Figure 51 shows the Cs2CdY profile showing the expanded HDL region for this 
patient which contains one sharp peak with a small shoulder on its buoyant side.   
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Figure 46.  MALDI-MS non HDL spectra from control patient 3. 
 
Table 24.   Identification of apolipoproteins in the non HDL fraction from control 
patient 3. 
Identification Mass (Da) 
ApoC-I' 6432.09 
ApoC-I 6633.61 
ApoA-I1 28656.42 
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Figure 47.  Electropherogram of the non HDL fraction from control patient 3. 
 
 
 
Table 25.  CE data for the non HDL fraction from a 200µL serum sample from control 
patient 3. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.7 -20.205 224 0.23 
ApoA-I 13.7 -29.067 93 0.26 
ApoC-I 15.1 -31.150 77 0.18 
 
 
 
Figure 46 shows the MALDI spectra for the non HDL subfraction for this patient 
which contained apos C-I', C-I, and A-I1.  Table 24 shows the peak masses for this 
fraction.  The apoC-I peaks were poorly resolved and were low in relative ion intensity.  
The CE results for this fraction are shown in Figure 47.  Very low intensity peaks were 
observed with mobilities corresponding to albumin, apoA-I, and apoC-I demonstrating 
minimal mixing of HDL2 with non HDL.  In comparison to MALDI-MS analysis, apos 
A-I and C-I were detected by both methods.  The CE results also detected a peak whose 
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mobility matched that of albumin, however, no albumin was detected in this fraction by 
MALDI-MS.  
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Figure 48. MALDI-MS HDL2 spectra from control patient 3. 
 
Table 26. Identification of apolipoproteins in the HDL2 fraction from control patient 3. 
Identification Mass (Da) 
ApoC-I' 6436.23 
ApoC-I 6632.92 
ApoC-II 8206.61 
ApoA-II'm 8683.24 
ApoA-IIm 8812.34 
Pro ApoC-II 8916.87 
ApoC-III0,glyc 9134.99 
ApoC-III1 9423.04 
A-I'
2+ 
13980.43 
ApoA-I
2+ 
14036.87 
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Table 26.   (Continued) 
Identification Mass (Da) 
ApoA-I
2+
add 14147.70 
ApoA-II''' 17085.46 
ApoA-II'' 17135.98 
ApoA-II' 17262.97 
ApoA-II 17382.68 
ApoA-I1 28453.53 
 
 
 
 
Figure 49.  Electropherogram of the HDL2 fraction from control patient 3. 
 
 
 
 
Table 27.  CE data for the HDL2 fraction from a 200µL serum sample from control 
patient 3. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.6 -20.657 734 0.74 
ApoA-II 11.2 -24.915 2076 ------- 
ApoA-I 12.5 -27.734 6110 16.95 
ApoC-I 14.9 -31.151 214 0.51 
Unidentified 16.2 -33.098 221 ------- 
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Figure 48 shows the MALDI-MS spectra for the HDL2 subfraction which 
detected peaks for apos C-I', C-I, Pro C-II, A-IImonomer, C-III0,glyc, C-III0, C-III1, A-I
2+
, A-
II, and A-I1.  Table 26 shows the peak masses for this fraction.  ApoC-I peaks were 
sharp and high in relative ion intensity.  The region between m/z 8000 – 10000 was also 
abundant in proteins which appeared as sharp,  highly resolved peaks.  The strongest 
peak in this mass range was apoC-III1.  Two peaks were shown corresponding to the 
doubly protonated form of apoA-I as well as several peaks corresponding to apoA-II.  
Following apoC-I, the next strongest peak in intensity corresponded to apoA-I.  No 
human serum albumin was present in this fraction.  Figure 49, shows the CE results for 
this fraction which detected albumin, apoA-II, apoA-I, apoC-I, and an unidentified peak 
eluting after apoC-I.  The largest peak detected corresponded to apoA-I, followed by 
apoA-II.  ApoA-II also appeared with a small shoulder.  Both methods detected apos A-
I, C-I, and A-II.  It is interesting to note that the apoA-II peak contained a shoulder in CE 
which may correspond to the isoforms observed in the MALDI spectra.   
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Figure 50. MALDI-MS HDL3 spectra from control patient 3. 
 
Table 28. Identification of apolipoproteins in the HDL3 fraction from control patient 3. 
Identification Mass (Da) 
ApoC-I' 6431.27 
ApoC-I 6628.75 
Pro ApoC-II 8912.14 
ApoC-III0, glyc 9133.93 
ApoC-III1'' 9289.26 
ApoC-III1 9419.06 
Prealbumin 13759.67 
ApoA-I''
2+ 
13879.38 
ApoA-I1 28435.98 
ApoE 33653.85 
HSA 67421.95 
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\Figure 51.  Electropherogram of the HDL3 fraction from control patient 3. 
 
 
Table 29. CE data for the HDL3 fraction from a 200µL serum sample from control 
patient 3. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration  
(mg/dL) 
HSA 9.9 -20.206 20,288 20.43 
ApoA-I 12.4 -26.219 964 2.67 
ApoC-I 15.6 -31.107 438 1.03 
 
 
The HDL3 subfraction MALDI-MS spectra is shown in Figure 50 and contained 
apos C-I', C-I, Pro C-II, C-III0,glyc, C-III1, A-I
2+
, A-I1, E, and HSA.   Table 28 shows the 
peak masses for this fraction.  As seen in the HDL2 fraction, apoC-I was present along 
with its truncated form.  The intensity of these two peaks however was lower in the 
HDL3 subfraction than the HDL2 fraction despite the lysine content of apoC-I which 
results in its strong basicity. The C-I' peak was also substantially lower in intensity in 
this fraction, the apoC-I peak was observed to be over 3 times as intense as C-I'.  As also 
observed in the subfractions of patient 1, there were not as many apoC peaks in this 
fraction compared to the more buoyant HDL2 fraction for patient 3.  The relative 
intensity and resolution of these peaks were also lower than the more buoyant fraction.  
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The doubly charged ion of apoA-I was detected however, without any related isoforms 
and with a lower relative ion intensity than that  the HDL2 fraction.  Figure 51 shows the 
CE results for this subfraction which detected albumin, apoA-I and apoC-I.  The apoA-I 
and apoC-I peaks were substantially lower than the albumin peak, and the apoA-I peak 
also contained a small shoulder.  All peaks detected by CE were also identified by 
MALDI-MS; MALDI-MS further identified apoE and apoC-III isoforms.   
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Figure 52. MALDI-MS protein spectra from control patient 3. 
 
Table 30. Identification of apolipoproteins in the protein fraction from control patient 3. 
Identification Mass (Da) 
Prealbumin 13765.90 
Prealbuminadd 13885.77 
ApoE 35934.86 
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Table 30.  (Continued) 
Identification Mass (Da) 
HSA 67687.42 
 
 
Figure 53.  Electropherogram of the protein fraction from control patient 3. 
 
 
Table 31.  CE data for the protein fraction from a 200µL serum sample from control 
patient 3. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.9 -20.289 12198 12.28 
ApoC-I 15.6 -31.154 197 0.47 
 
 
In the protein subfraction, shown in Figure 52, there were peaks corresponding to 
human serum albumin, and low relative ion intensity peaks corresponding to prealbumin 
and apoE.  Table 30 shows the peak masses for this fraction.  The CE results for this 
fraction, shown in Figure 53, detected albumin and apoC-I.  The albumin peak was large 
indicating an enrichment  of the protein in this fraction.  In comparison to the MALDI-
MS spectra for this fraction, human serum and albumin were detected by both methods, 
neither of which detected apoA-I.   
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Table 32.  Control patient 7 medical information 
Control Patient 7  
Age 44 years old 
Height 66.5 inches 
Weight 185 lbs. 
Gender Female 
Race Caucasian 
Major Risk Factors Family history of CAD 
 
 
4 6 8 10 12 14 16 18 20 22 24 26 28 30 32
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
2800
3000
1.000
1.025
1.050
1.075
1.100
1.125
1.150
1.175
1.200
1.225
1.250
1.275
1.300
1.325
1.350
1.375
1.400
1.425
1.450
In
te
n
s
it
y
Tube Coordinate (mm)
Protein
Non HDL
 
 D
e
n
s
it
y
 (
g
/m
L
)
HDL
2
HDL
3
 
Figure 54.  Lipoprotein density profile from control patient 7 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
 
 
Control Patient 7 Discussion 
Control patient 7, whose medical history is presented in Table 32, is a 44 year old 
Caucasian female who does not have CAD, however, does have a family history of the 
disease.  Figure 54 shows the Cs2CdY lipoprotein profile for this patient which contains a 
split peak with high intensity.   
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Figure 55.  MALDI-MS non HDL spectra from control patient 7. 
 
Table 33.  Identification of apolipoproteins in the non HDL fraction from control patient 
7. 
Identification Mass (Da) 
ApoC-I' 6399.72 
ApoC-I 6630.61 
ApoA-I1 28297.62 
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Figure 56.  Electropherogram of the non HDL fraction from control patient 7. 
 
 
Table 34. CE data for the non HDL fraction from a 200µL serum sample from control 
patient 7. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoA-I 12.5 -27.628 437 1.21 
ApoC-I 14.9 -31.455 168 0.40 
 
 
Figures 55 shows the MALDI-MS spectra for the non HDL subfraction which 
contained low intensity and low resolution peaks corresponding to apoC-I and  C-I', and a  
low intensity peak corresponding to apoA-I1.  Table 33 shows the peak masses for this 
fraction.  The C-I' peak was hardly visible and the C-I peak was only slightly higher in 
relative ion intensity.  The CE analysis of this fraction detected only apoA-I and apoC-I as 
shown in Figure 56.  Both methods detected apoA-I and apoC-I at very low intensities, 
indicating minimal contamination of HDL2. 
 A-I 
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Figure 57.  MALDI-MS HDL2 spectra from control patient 7. 
 
Table 35. Identification of apolipoproteins in the HDL2 fraction from control patient 7. 
Identification Mass (Da) 
ApoC-I' 6435.40 
ApoC-I 6633.97 
ApoC-II 8210.33 
ApoA-II'm 8684.24 
ApoC-III0 8767.09 
ApoA-IIm 8812.73 
Pro ApoC-II 8917.12 
ApoC-III0,glyc 9133.92 
ApoC-III'1 9361.55 
ApoC-III1 9424.38 
ApoC-III2' 9647.17 
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Table 35.  (Continued) 
Identification Mass (Da) 
ApoC-III2 9717.28 
ApoA-I'
2+ 
13980.76 
ApoA-I
2+ 
14044.54 
ApoA-I
2+
add 14152.17 
ApoA-II'' 17132.03 
ApoA-II' 17261.50 
ApoA-II 17388.00 
ApoA-I1 28456.30 
 
 
Figure 58.  Electropherogram of the HDL2 fraction from control patient 7. 
 
 
Table 36.  CE data for the HDL2 fraction from a 200µL serum sample from control 
patient 7. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoA-II 11.3 -25.540 438 ------- 
ApoA-I 12.5 -27.994 2232 6.19 
ApoC-I 14.9 -31.750 169 0.40 
 
           A-II 
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Figure 57 shows the MALDI-MS spectra corresponding to the  HDL2 subfraction 
which contained apos C-I', C-I, C-II, A-IImonomer, C-III0, Pro C-II, C-III0,glyc, C-III1, A-I
2+
, 
A-II, and A-I1.  Table 35 shows the peak masses for this fraction.  The apoC-I peaks were 
sharp with C-I having a relative ion intensity greater than twice the intensity of C-I'.  As 
observed in the HDL2 subfractions of other patients, there was an abundance of proteins in 
the region between m/z 8000 – 10000 with the highest peak detected from ApoC-III1.  
With the exception of the apoA-II peaks, the peaks in this subfraction were highly 
resolved.   Figure 58 shows the CE results following the analysis of this subfraction and 
detected apoA-II, apoA-I, and apoC-I.  Both MALDI-MS and CE detected the same apos 
with MALDI-MS additionally detecting apoA-II, and apoC-III isoforms, neither method 
detected albumin in this fraction.  
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Figure 59.  MALDI-MS HDL3 spectra from control patient 7. 
 
Table 37.  Identification of apolipoproteins in the HDL3 fraction from control patient 7. 
Identification Mass (Da) 
ApoC-I' 6435.43 
ApoC-I 6633.90 
ApoA-II'm 8685.18 
ApoC-III0 8763.49 
ApoA-IIm 8813.11 
Pro ApoC-II 8914.86 
ApoC-III0,glyc 9130.89 
ApoC-III'1 9291.11 
ApoC-III1 9419.99 
ApoC-III2'' 9564.72 
ApoC-III2' 9681.73 
Prealbumin 13877.65 
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Table 37.  (Continued) 
Identification Mass (Da) 
ApoA-I
2+ 
14047.01 
ApoA-I
2+
add 14150.13 
ApoA-I1 28444.91 
ApoE 33761.59 
HSA 67496.18 
 
Figure 60.  Electropherogram of the HDL3 fraction from control patient 7. 
 
 
Table 38.  CE data for the HDL3 fraction from a 200µL serum sample from control 
patient 7. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.9 -20.578 26598 26.78 
ApoA-II 12.1 -25.954 114 ------- 
ApoA-I 12.9 -27.559 877 2.43 
ApoC-I 15.6 -31.519 439 1.04 
 
 
A-II 
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The HDL3 subfraction contained apos C-I', C-I, C-II, C-III, A-II, A-I
2+
, A-I1, E, 
and HSA as shown in Figure 59.  Table 37 shows the peak masses for this fraction.  
Overall, the HDL3 peaks were less intense than those observed in the HDL2 subfraction for 
patient 7.  The apoC-I' peak was barely visible with less than three times the relative ion 
intensity of apoC-I.  The albumin peak was also as intense as the apoA-I1 peak in this 
region.  The CE results for this fraction, shown in Figure 60 detected albumin, apoA-II, 
apoA-I, and apoC-I.  
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Figure 61.  MALDI-MS protein spectra from control patient 7. 
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Table 39.  Identification of apolipoproteins in the protein fraction from control patient 7. 
Identification Mass (Da) 
ApoE 33644.00 
HSA 67087.75 
 
 
Figure 62. Electropherogram of the protein fraction from control patient 7. 
 
 
Table 40.  CE data for the protein fraction from a 200µL serum sample from control 
patient73. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.8 -20.521 12083 12.17 
ApoC-I 15.3 -31.370 351 0.83 
 
 
The MALDI-MS spectrum for the protein subfraction, shown in Figure 61, 
contained apoE, and HSA at low relative ion intensities.  Table 39 shows the peak masses 
for this fraction.  The CE results for this subfraction, shown in Figure 62, detected albumin 
and apoC-I.  As also observed in previously reported protein subfractions, albumin 
contained a shoulder which may be due to its co-migration with another analyte.  As also 
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previously observed, the MALDI-MS spectrum detected apoE along with albumin while 
the CE results detected apoC-I along with albumin. 
 
Table 41.  Control patient 13 medical information 
Control Patient 13  
Age 66 years old 
Height 60 inches 
Weight 98 lbs. 
Gender Female 
Race Hispanic 
Major Risk Factors Hypertension 
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Figure 63.  Lipoprotein density profile from control patient 13 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
 
 
 
Control Patient 13 Discussion 
Control patient 13, whose medical history is presented in Table 41, is a 66 year 
old Hispanic female who does not have CAD, but suffers from hypertension.  Figure 63 
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shows the Cs2CdY profile for this subject which contains a sharp peak with high 
intensity that is shifted toward the non HDL region and has a shoulder on its denser side.   
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Figure 64.  MALDI-MS non HDL spectra from control patient 13. 
 
Table 42.  Identification of apolipoproteins in the non HDL fraction from control patient 
13. 
Identification Mass (Da) 
ApoC-I' 6436.18 
ApoC-I 6633.76 
ApoA-II'm 8689.28 
Pro ApoC-II 8921.29 
ApoC-III0,glyc 9151.57 
ApoC-III1' 9366.26 
ApoC-III1 9419.98 
ApoC-III2'' 9589.35 
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Table 42.  (Continued) 
Identification Mass (Da) 
A-I'
2+ 
13968.47 
A-I
2+ 
14041.73 
A-I
2+
add 14104.83 
ApoA-I1 28409.59 
 
 
Figure 65. Electropherogram of the non HDL fraction from control patient 13. 
 
 
Table 43.  CE data for the non HDL fraction from a 200µL serum sample from control 
patient 13. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.9 -21.171 276 0.28 
ApoC-II 11.0 -24.045 59 ------- 
ApoC-III 12.6 -25.395 30 ------- 
ApoA-II 13.6 -27.562 427 ------- 
ApoA-I 14.8 -29.289 396 1.10 
ApoC-I 14.8 -31.011 170 0.40 
 
HSA 
C-II C-III 
A-II 
A-I C-I 
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Figure 64 show the MALDI spectra for the non HDL subfraction which 
contained apos C-'I, C-I, A-IImonomer, Pro C-II, C-III0,glyc, C-III1, C-III2, A-I
2+
, and A-I1.  
Table 42 shows the peak masses for this fraction.  It appears as though this individual 
has more buoyant HDL2 compared to other patients due to the greater quantity of 
proteins in the non HDL subfraction, though the intensity of these proteins was low.  The 
CE results from the analysis of this fraction are shown in Figure 65, and also showed an 
abundance of very small protein peaks corresponding to apos C-II, C-III, A-II, A-I, and 
C-I.  Both methods detected similar apos all of which were low in intensity suggesting 
very minimal mixing of the HDL2 subfraction. 
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Figure 66.  MALDI-MS HDL2 spectra from control patient 13. 
 
121 
 
 
 
Table 44. Identification of apolipoproteins in the HDL2 fraction from control patient 13. 
Identification Mass (Da) 
ApoC-I' 6435.10 
ApoC-I 6632.82 
ApoC-II 8207.62 
Amyloid 8563.95 
ApoA-IIm 8685.18 
ApoA-IIm 8811.14 
Pro ApoC-II 8916.41 
ApoC-III0,glyc 9133.77 
ApoC-III1' 9353.21 
ApoC-III1 9422.45 
ApoC-III2 9707.24 
ApoA-I'
2+ 
13974.62 
ApoA-I
2+ 
14046.19 
ApoA-I
2+
add 14133.74 
ApoA-IIt'' 17061.80 
ApoA-II'' 17123.09 
ApoA-II' 17259.05 
ApoA-II 17375.71 
ApoA-I1 28451.60 
 
     
Figure 67.  Electropherogram of the HDL2 fraction from control patient 13. 
   A-II 
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Table 45. CE data for the HDL2 fraction from a 200µL serum sample from control 
patient 13. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.7 -20.198 543 0.55 
ApoA-II 11.2 -24.387 2028 ------- 
ApoA-I 12.4 -26.896 8902 24.70 
ApoC-I 14.9 -30.927 369 0.87 
 
 
The MALDI-MS spectra from the HDL2 subfraction, shown in Figure 66,  
contained apos C-I', C-I, C-II, amyloid, A-IImonomer, Pro C-II, C-III0,glyc, C-III1, C-III2, A-
I
2+
, A-II, and A-I1.  Table 44 shows the peak masses for this fraction.  These protein 
peaks were highly resolved and higher in intensity than any other subfraction for this 
patient.  This subfraction contained amyloid, a protein involved in many diseases 
including atherosclerosis. The CE analysis shown in Figure 67, contained peaks 
corresponding to albumin, apoA-II, apoA-I, and apoC-I.  ApoA-I was the greatest peak 
in this subfraction.  Both methods reported comparable results with MALDI-MS 
detecting the presence of apoC-III isoforms that were not detected by CE.  
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Figure 68.  MALDI-MS HDL3 spectra from control patient 13. 
 
 
 
Table 46.  Identification of apolipoproteins in the HDL3 fraction from control patient 13. 
Identification Mass (Da) 
ApoC-I' 6434.93 
ApoC-I 6633.72 
Pro ApoC-II 8917.01 
ApoC-III0,glyc 9134.99 
ApoC-III1 9428.18 
ApoC-III1' 9316.64 
ApoC-III2 9729.57 
ApoA-I1 28306.78 
ApoE 33858.07 
HSA 67576.77 
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Figure 69.  Electropherogram of the HDL3 fraction from control patient 13. 
 
 
 
Table 47.  CE data for the HDL3 fraction from a 200µL serum sample from control 
patient 13. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.9 -20.381 21940 22.09 
ApoA-II 12.9 -27.461 381 ------- 
ApoA-I 14.2 -29.536 2535 7.03 
ApoC-I 15.4 -31.115 499 1.18 
 
 
Figure 68 shows the HDL3 subfraction MALDI-MS spectra, which contained 
apos C-I', C-I, C-II, C-III0,glyc, C-III1, A-I1, E, and HSA.  Table 46 shows the peak 
masses for this fraction.  The relative ion intensity of the peaks in the region spanning 
m/z 8000 – 10000 were overall low and the HSA peak had higher relative ion intensity 
than the apoA-I peak, indicating a predominance of HSA.  Figure 69 shows the CE 
results for this subfraction which detected albumin, apoA-II, apoA-I and apoC-I.  The 
   A-II 
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largest peak detected was from albumin followed by apoA-I, which corresponded to the 
albumin enrichment observed by MALDI-MS. 
10000 20000 30000 40000 50000 60000 70000
0
500
1000
1500
2000
2500
13000 13200 13400 13600 13800 14000 14200 14400
0
200
400
600
800
1000
Prealbumin
Prealbumin
add
R
e
la
ti
v
e
 I
o
n
 I
n
te
n
s
it
y
m/z
HSA
Figure 70.  MALDI-MS protein spectra from control patient 13. 
 
 
Table 48.  Identification of apolipoproteins in the protein fraction from control patient 
13. 
Identification Mass (Da) 
Prealbumin 13756.91 
Prealbuminadd 13883.16 
HSA 67671.83 
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Figure 71.  Electropherogram of the protein fraction from control patient 13. 
 
 
 
Table 49.  CE data for the protein fraction from a 200µL serum sample from control 
patient 13. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.9 -20.497 25763 25.95 
ApoA-I 14.4 -29.696 6009 16.67 
ApoC-I 15.7 -31.367 356 0.84 
Unidentified 21.9 -36.771 186 ------- 
 
 
The MALDI-MS protein subfraction spectra contained prealbumin and HSA as 
shown in Figure 70.  Table 48 shows the peak masses for this fraction.  The CE results in 
Figure 71 detected an enrichment of albumin, in addition to apoA-I, apoC-I, and an 
unidentified peak.  The albumin peak also contained a large shoulder.  It is possible that 
prealbumin and apoA-I have comparable electrophoretic mobilities since apoA-I was not 
detected by MALDI-MS. 
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Table 50.  Control patient 14 medical information 
Control Patient 14  
Age 75 years old 
Height 64 inches 
Weight 145 lbs. 
Gender Female 
Race Caucasian 
Major Risk Factors Family history of CAD 
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Figure 72.  Lipoprotein density profile from control patient 14 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
 
 
Control Patient 14 Discussion 
Control patient 14, whose medical history is presented in Table 50, is a 76 year 
old Caucasian female who does not have CAD, however, does have a family history of 
the disease.  Figure 72 shows the Cs2CdY profile for this subject which contains a broad 
peak with a shoulder on the buoyant side of the peak.  
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Figure 73.  MALDI-MS non HDL spectra from control patient 14. 
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Figure 74.  Electropherogram of the non HDL fraction from control patient 14. 
 
 
 
Table 51.  CE data for the non HDL fraction from a 200µL serum sample from control 
patient 14. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoA-I 11.5 -26.804 210 0.58 
ApoC-I 13.9 -31.225 141 0.33 
 
 
Figure 73 shows the MALDI spectrum for the non HDL subfraction for this 
patient which did not contain any apolipoproteins.  The CE analysis detected small peaks 
which corresponded to the electrophoretic mobilities of apoA-I and apoC-I, shown in 
Figure 74.  Due to the sensitivity of the MALDI-MS technique, it is possible that the 
peaks detected by CE were artifacts or impurities.     
 
   A-I  C-I 
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Figure 75.  MALDI-MS HDL2 spectra from control patient 14. 
 
 
 
Table 52.  Identification of apolipoproteins in the HDL2 fraction from control patient 14. 
Identification Mass (Da) 
ApoC-I' 6431.60 
ApoC-I 6629.29 
ApoA-II'm 8678.25 
ApoA-IIm 8809.01 
ApoC-III0 8763.49 
Pro ApoC-II 8912.07 
C-III0,glyc 9125.06 
C-III1'
 
9372.32 
C-III1 9421.80 
C-III2 9709.08 
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  Table 52.  (Continued) 
Identification Mass (Da) 
ApoA-I'
2+ 
13978.72 
ApoA-I
2+ 
14036.83 
ApoA-I1 28439.96 
 
 
Figure 76.  Electropherogram of the HDL2 fraction from control patient 14. 
 
 
  
Table 53.  CE data for the HDL2 fraction from a 200µL serum sample from control 
patient 14. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.3 -20.221 1050 1.06 
ApoC-II 9.8 -22.071 152 ------- 
ApoC-III 10.3 -23.521 717 ------- 
ApoA-II 10.7 -24.720 26 ------- 
ApoA-I 11.4 -26.246 3779 10.49 
ApoC-I 13.9 -30.888 241 0.57 
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Figure 75 shows the MALDI-MS spectra corresponding to the HDL2 subfraction 
which contained apos C-I', C-I, A-IImonomer, C-III0, Pro C-II, C-III0,glyc, C-III1, A-I
2+
, and 
A-I1.  Table 52 shows the peak masses for this fraction.  The apoC-I peaks were sharp 
with what appeared to be a shoulder.  The region spanning m/z 8000 – 10000 was 
abundant in proteins which were overall slightly less intense than apoC-I'.  Figure 76 
shows the CE results from this fraction which detected albumin, and apos C-II, C-III, A-
II, A-I, and C-I.  Apo A-I was the largest peak in this fraction.  Both methods reported 
comparable results. 
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Figure 77.  MALDI-MS HDL3 spectra from control patient 14. 
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Table 54.  Identification of apolipoproteins in the HDL3 fraction from control patient 14. 
Identification Mass (Da) 
ApoC-I' 6433.11 
ApoC-I 6631.62 
ApoC-III0 8767.58 
ApoA-IIm 8808.72 
Pro ApoC-II 8913.38 
ApoC-III0,glyc 9134.75 
ApoC-III1 9419.93 
Prealbumin 13883.19 
ApoA-I
2+ 
14038.58 
ApoA-I
2+
add 14141.93 
ApoA-I1 28443.19 
HSA 67674.20 
 
 
Figure 78.  Electropherogram of the HDL3 fraction from control patient 14. 
 
 
 
Table 55.  CE data for the HDL3 fraction from a 200µL serum sample from control 
patient 14. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.5 -20.323 14643 14.74 
  
 
 
 
 
      
   A-II 
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Table 55. (Continued) 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoA-II 11.5 -25.698 124 ------- 
ApoA-I 11.7 -26.303 361 1.00 
ApoC-I 14.6 -31.162 284 0.67 
 
The HDL3 subfraction MALDI-MS spectra contained apos C-I', C-I, C-III0, A-
IImonomer, Pro C-II, C-III0,glyc, C-III1, prealbumin, A-I
2+
, A-I1, and HSA as shown in 
Figure 77.  Table 54 shows the peak masses for this fraction.  The apoC-I peaks were 
approximately equal in relative ion intensity.  The relative ion intensities were lower in 
this fraction compared to HDL2 as was the abundance of proteins in the 8000 – 10000 
m/z region. The CE results, shown in Figure 78, were comparable to MALDI-MS and 
detected albumin, and apos A-II, A-I, and C-I.   
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Figure 79.  MALDI-MS protein spectra from control patient 14. 
 
Table 56.  Identification of apolipoproteins in the protein fraction from control patient 
14. 
Identification Mass (Da) 
HSA 67644.32 
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Figure 80.  Electropherogram of the protein fraction from control patient 14. 
 
 
Table 57.  CE data for the protein fraction from a 200µL serum sample from control 
patient 14. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.4 -20.411 8010 8.07 
ApoC-I 14.4 -31.279 587 1.39 
 
 
The protein subfraction contained only HSA in the MALDI-MS spectrum shown 
in Figure 79.  Table 56 shows the peak masses for this fraction.  The CE results detected 
peaks corresponding to albumin and apoC-I in Figure 80.   
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Table 58.  Control patient 16 medical information 
Control Patient 16  
Age 73 years old 
Height 58 inches 
Weight 92 lbs.  
Gender Female 
Race Caucasian 
Major Risk Factors None 
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Figure 81.  Lipoprotein density profile from control patient 16 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
 
 
Control Patient 16 Discussion 
Control patient 16, whose medical history is presented in Table 58, is a 73 year 
old Caucasian female who does not have CAD and does not possess any risk factors.    
Figure 81 shows the Cs2CdY profile for this subject which contains a sharp peak with a 
poorly resolved shoulder on its denser side.   
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Figure 82.  MALDI-MS non HDL spectra from control patient 16. 
 
 
 
Table 59. Identification of apolipoproteins in the non HDL fraction from control patient 
16. 
Identification Mass (Da) 
ApoC-I' 6436.00 
ApoC-I 6634.51 
ApoA-I
2+ 
14037.34 
ApoA-I
2+
add 14152.24 
ApoA-II'' 17122.55 
ApoA-II' 17250.57 
ApoA-II 17384.11 
ApoA-I1 28450.03 
HSA 67644.32 
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Figure 83.  Electropherogram of the non HDL fraction from control patient 16. 
 
 
Table 60.  CE data for the non HDL fraction from a 200µL serum sample from control 
patient 16. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoC-I 14.1 -31.033 105 0.25 
 
 
Figure 82 shows the MALDI spectra for the non HDL subfraction which 
contained several proteins including apos C-I', C-I, A-I
2+
, A-II and A-I1.  Table 59 shows 
the peak masses for this fraction.  The abundance of protein suggests an overlap of 
HDL2 into this neighboring region, although the overlap is assumed to be minimal due to 
the relative ion intensity of the peaks.  The CE results from this fraction, shown in 
Figure 83, detected a small peak corresponding to the mobility of apoC-I. 
 
   C-I 
140 
 
 
 
10000 20000 30000 40000 50000 60000 70000
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
13500 13750 14000 14250 14500
0
500
1000
1500
2000
2500
3000
A-I
2+
17000 17100 17200 17300 17400 17500
0
200
400
600
800
1000
1200
1400
1600
1800
2000
A-II
A-II'
8000 8500 9000 9500 10000 10500
0
1000
2000
3000
4000
5000
6000
7000
A-II
monomer
A-II'
monomer
C-III
0
C-III
1
m/z
C-III
0,glyc
6300 6400 6500 6600 6700 6800
0
2000
4000
6000
8000
10000
C-I'
C-I
m/z
R
e
la
ti
v
e
 I
o
n
 I
n
te
n
s
it
y
m/z
A-I
1
 
Figure 84.  MALDI-MS HDL2 spectra from control patient 16. 
 
 
 
Table 61. Identification of apolipoproteins in the HDL2 fraction from control patient 16. 
Identification Mass (Da) 
ApoC-I' 6436.33 
ApoC-I 6635.31 
ApoA-II'm 8693.06 
ApoA-IIm 8813.00 
Pro ApoC-II 8917.72 
 ApoC-III0,glyc 9145.57 
ApoC-III1 9428.98 
ApoA-I
2+
 14042.58 
ApoA-II' 17247.49 
ApoA-II 17374.24 
ApoA-I1 28453.02 
HSA 67644.32 
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Figure 85.  Electropherogram of the HDL2 fraction from control patient 16. 
 
 
Table 62.  CE data for the HDL2 fraction from a 200µL serum sample from control 
patient 16. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.5 -19.792 982 0.989 
ApoC-II 10.0 -21.646 219 ------- 
ApoC-III 10.5 -22.948 544 ------- 
ApoA-I 11.6 -25.504 4020 11.15 
ApoC-I 14.3 -30.402 200 0.47 
 
 
Figure 84 shows the MALDI-MS spectra corresponding to the HDL2 subfraction 
which contained apos C-I', C-I, A-IImonomer, C-III0, C-III0,glyc, C-III1, A-I
2+
, A-II and A-I1.  
Table 61 shows the peak masses for this fraction. The peaks in this subfraction were 
higher in intensity that those observed in the non HDL fraction.  The apoC-I peaks were 
sharp and nearly equal in intensity and apoC-I contained a small shoulder on the lower 
mass side of the peak.  ApoA-II peaks consisted of doublets which may indicate 
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oxidative processes.  The CE results for this fraction, shown in Figure 85, detected 
albumin, and apos C-II, C-III, A-II, A-I, and C-I.  The greatest peak corresponded to 
apoA-I followed by apoC-III.  Both MALDI-MS and CE detected the same 
apolipoproteins with MALDI-MS detecting further isoforms of these proteins. 
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Figure 86.  MALDI-MS HDL3 spectra from control patient 16. 
 
 
 
Table 63. Identification of apolipoproteins in the HDL3 fraction from control patient 16. 
Identification Mass (Da) 
ApoC-I' 6436.60 
ApoC-I 6634.99 
143 
 
 
 
Table 63.  (Continued) 
Identification Mass (Da) 
ApoA-IIm 8809.01 
Pro ApoC-II 9040.29 
ApoC-III1'' 9292.71 
ApoA-I1 28421.80 
HSA 67713.86 
 
 
Figure 87.  Electropherogram of the HDL3 fraction from control patient 16. 
 
 
 
Table 64.  CE data for the HDL3 fraction from a 200µL serum sample from control 
patient 16. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.7 -20.795 13916 14.01 
ApoA-I 11.8 -26.269 101 0.28 
ApoC-I 14.9 -31.578 180 0.43 
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Figure 86 shows the MALDI-MS spectra for the HDL3 subfraction which 
contained apos C-I', C-I, A-IImonomer, Pro C-II, C-III1, A-I1, and HSA.   Table 63 shows 
the peak masses for this fraction.  The apoC-I peaks were sharp with apoC-I being only 
slightly higher in relative ion intensity than apoC-I'.  Figure 87, shows the CE results 
which detected albumin, apoA-I and apoC-I.   
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Figure 88.  MALDI-MS protein spectra from control patient 16. 
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Table 65. Identification of apolipoproteins in the protein fraction from control patient 
16. 
Identification Mass (Da) 
Prealbumin 13788.75 
Prealbuminadd 13843.35 
ApoE 33869.45 
HSA 67382.43 
 
 
Figure 89.  Electropherogram of the protein fraction from control patient 16. 
 
 
Table 66.  CE data for the protein fraction from a 200µL serum sample from control 
patient 16. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.4 -20.213 4552 4.58 
ApoC-I 14.1 -30.898 87 0.21 
Unidentified 19.0 -36.177 53 ------- 
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Figure 88 shows the MALDI-MS spectra corresponding to the protein fraction 
which contained prealbumin, apoE, and HSA.  Table 65 shows the peak masses for this 
fraction.  The CE results shown in Figure 89, detected albumin and apoC-I.  Albumin 
contained a shoulder, however, both the shoulder and overall peak was smaller than 
those previously observed in other control patient protein subfractions. 
 
 
Table 67. Control patient 24 medical information 
Control Patient 24  
Age 68 years old 
Height 63 inches 
Weight 176 lbs. 
Gender Female 
Race Caucasian 
Major Risk Factors Family history of CAD 
Hypertension 
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Figure 90.  Lipoprotein density profile from control patient 24 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
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Control Patient 24 Discussion 
Control patient 24, whose medical history is presented in Table 67, is a 68 year 
old Caucasian female who does not have CAD, however, does have a family history of 
the disease and suffers from hypertension.  Figure 90 shows the Cs2CdY profile for this 
subject which contains a broad peak with a shoulder on its buoyant side.   
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Figure 91.  MALDI-MS non HDL spectra from control patient 24. 
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Figure 92.  Electropherogram of the non HDL fraction from control patient 24. 
 
 
Table 68.  CE data for the non HDL fraction from a 200µL serum sample from control 
patient 24. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoA-II 10.8 -23.933 118 ------- 
ApoC-I 14.7 -31.272 80 0.19 
 
 
Figure 91 shows the MALDI-MS spectra for the serum subfractions for this 
patient.  The non HDL subfraction did not contain any proteins as also observed in the 
non HDL fraction of patient 16.  The CE results for this fraction contained barely visible 
peaks with mobilities matching apoA-II and apoC-I as shown in Figure 92. 
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Figure 93.  MALDI-MS HDL2 spectra from control patient 24. 
 
 
 
Table 69. Identification of apolipoproteins in the HDL2 fraction from control patient 24. 
Identification Mass (Da) 
ApoC-I' 6434.50 
ApoC-I 6633.07 
ApoA-II'm 8681.69 
ApoC-III0 8771.05 
ApoA-IIm 8811.94 
Pro ApoC-II 8919.89 
ApoC-III0,glyc 9134.05 
ApoC-III1 9427.40 
ApoC-III2' 9646.34 
ApoA-I
2+ 
14040.37 
A-II'
 
17265.01 
A-II
 
17396.11 
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Table 69.  (Continued) 
Identification Mass (Da) 
ApoA-I1 28448.99 
 
 
Figure 94.  Electropherogram of the HDL2 fraction from control patient 24. 
 
 
 
Table 70.  CE data for the HDL2 fraction from a 200µL serum sample from control 
patient 24. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
  CPA Concentration 
(mg/dL) 
HSA 9.7 -20.398 842 0.85 
ApoC-II 10.4 -22.598 201 ------- 
ApoC-III 10.9 -23.848 536 ------- 
ApoA-II 11.4 -24.991 3044 ------- 
ApoA-I 12.6 -27.585 13967 38.75 
ApoC-I 14.8 -31.041 495 1.17 
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The HDL2 subfraction contained apos C-I', C-I, A-IImonomer, C-III0, Pro C-II, C-
III0,glyc, C-III1, C-III2, A-I
2+
, A-II, and A-I1 as shown in Figure 93.   Table 69 shows the 
peak masses for this fraction.  The apoC-I peaks were highly resolved with what 
appeared to be a small shoulder on apoC-I.  The doubly protonated apoA-I peak 
appeared as a single peak and apoA-II appeared as two poorly resolved peaks.  The CE 
results for this fraction, shown in Figure 94, detected albumin, and apos C-II, C-III, A-II, 
A-I, and C-I.  The predominant peak in this fraction was apoA-I.  Both methods had 
comparable results. 
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Figure 95.  MALDI-MS HDL3 spectra from control patient 24. 
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Table 71. Identification of apolipoproteins in the HDL3 fraction from control patient 24. 
Identification Mass (Da) 
ApoC-I' 6434.85 
ApoC-I 6633.70 
ApoA-II'm 8696.86 
ApoA-IIm 8812.47 
Pro ApoC-II 8923.99 
ApoC-III0,glyc 9134.27 
ApoC-III1'' 9279.01 
ApoC-III1 9431.49 
ApoA-I1 28455.00 
ApoE
 
33845.75 
HSA 67594.72 
 
 
Figure 96.  Electropherogram of the HDL3 fraction from control patient 24. 
 
 
 
Table 72.  CE data for the HDL3 fraction from a 200µL serum sample from control 
patient 24. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.8 -20.715 23356 23.52 
ApoA-I 12.8 -27.797 841 2.33 
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Table 72.  (Continued) 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoC-I 15.1 -31.338 332 0.78 
 
The HDL3 subfraction MALDI-MS spectra, shown in Figure 95, contained apos 
C-I', C-I, A-IImonomer, Pro C-II, C-III0,glyc, C-III1, A-I1, E, and HSA.  Table 71 shows the 
peak masses for this fraction.  The apoC-I peak was approximately three times higher in 
relative ion intensity than apoC-I' and apoC-III peaks were low in relative ion intensity.  
The CE results shown in Figure 96, detected albumin, and apos A-I and C-I. 
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Figure 97.  MALDI-MS protein spectra from control patient 24. 
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Table 73. Identification of apolipoproteins in the HDL2 fraction from control patient 24. 
Identification Mass (Da) 
ApoE
 
33685.00 
HSA 67414.29 
 
 
Figure 98.  Electropherogram of the protein fraction from control patient 24. 
 
 
 
Table 74.  CE data for the protein fraction from a 200µL serum sample from control 
patient 24. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.7 -20.459 11307 11.39 
ApoC-I 14.8 -31.000 208 0.49 
 
 
Figure 97 shows the MALDI-MS spectrum corresponding to the protein 
subfraction which contained apo E and HSA at relatively low intensity.  Table 73 shows 
the peak masses for this fraction.  The CE results detected albumin and apoC-I as shown 
in Figure 98.  The albumin peak contained a broad base in addition to shoulders.  
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Table 75. Control patient 25 medical information 
Control Patient 25  
Age 50 years old 
Height 71 inches 
Weight 181 lbs. 
Gender Male 
Race African-American 
Major Risk Factors Hypertension 
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Figure 99.  Lipoprotein density profile from control patient 25 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
 
 
Patient 25 Discussion 
Control patient 25, whose medical history is presented in Table 75, is a 50 year 
old African-American male who does not have CAD, however, does have a family 
history of the disease and suffers from hypertension.  Figure 99 shows the Cs2CdY 
profile for this subject which contains a sharp peak with a shoulder on its denser side.   
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Figure 100.  MALDI-MS non HDL spectra from control patient 25. 
 
 
 
Table 76. Identification of apolipoproteins in the non HDL fraction from control patient 
25. 
Identification Mass (Da) 
ApoA-I1 28450.76 
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Figure 101.  Electropherogram of the non HDL fraction from control patient 25 
 
. 
 
Table 77.  CE data for the non HDL fraction from a 200µL serum sample from control 
patient 25. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA 
Unidentified 12.4 -15.678 578 
Unidentified 14.5 -19.142 209 
 
 
Figure 100 shows the MALDI spectrum for the non HDL fraction which 
contained a poorly resolved A-I1 peak.  Table 76 shows the peak mass for this fraction.  
Figure 101 shows the CE results for this fraction,  low intensity unidentified peaks were 
detected with elution times similar to apoA-I and C-I though the mobilities did not 
match those of these two proteins. 
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Figure 102.  MALDI-MS HDL2 spectra from control patient 25. 
 
 
 
Table 78. Identification of apolipoproteins in the HDL2 fraction from control patient 25. 
Identification Mass (Da) 
ApoC-I' 6433.71 
ApoC-I 6633.80 
ApoA-II'm 8688.67 
ApoC-III0 8767.23 
ApoA-IIm 8813.17 
Pro ApoC-II 8918.80 
ApoC-III0,glyc 9143.45 
ApoC-III1 9424.67 
ApoC-III2 9720.53 
ApoA-I
2+ 
14044.78 
ApoA-I1 28457.12 
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Figure 103.  Electropherogram of the HDL2 fraction from control patient 25. 
 
 
 
Table 79.  CE data for the HDL2 fraction from a 200µL serum sample from control 
patient 25. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.6 -20.929 388 0.39 
ApoC-III 10.8 -24.589 306 ------- 
ApoA-II 11.3 -25.643 734 -------- 
ApoA-I 12.6 -28.449 6206 17.22 
ApoC-I 14.6 -31.575 365 0.80 
 
 
Figure 102 shows the HDL2 subfraction which contained apos C-I', C-I, A-
IImonomer, C-III0, Pro C-II, C-III0,glyc, C-III1, C-III2, A-I
2+
, and A-I1.  Table 78 shows the 
peak masses for this fraction.  The apoC-I peaks were poorly resolved and C-I' was very 
low in relative ion intensity.  One sharp peak corresponding to apoA-I
2+
 was detected 
and several peaks relating to apoC-III.  The CE results are shown in Figure 103 for this 
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subfraction and contained albumin, and apos C-II, C-III, A-II, A-I, and C-I.  The 
predominant peak was apoA-I.  Both methods showed comparable results.   
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Figure 104.  MALDI-MS HDL3 spectra from control patient 25. 
 
 
 
Table 80. Identification of apolipoproteins in the HDL3 fraction from control patient 25. 
Identification Mass (Da) 
ApoC-I' 6430.72 
ApoC-I 6629.96 
ApoC-III0 8762.86 
ApoA-IIm 8806.04 
ApoC-III0,glyc 9134.27 
ApoC-III1' 9361.40 
ApoC-III1 9416.74 
SAA1' 11433.75 
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 Table 80.  (Continued)  
Identification Mass (Da) 
SAA1 11679.68 
Prealbumin 13761.72 
Prealbuminadd 13881.43 
ApoA-I1 28430.86 
ApoE
 
33654.23 
HSA 67396.47 
 
 
Figure 105.  Electropherogram of the HDL3 fraction from control patient 25. 
 
 
Table 81.  CE data for the HDL3 fraction from a 200µL serum sample from control 
patient 25. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.7 -20.472 26225 26.41 
ApoC-III 11.4 -24.960 74 ------- 
ApoA-II 11.7 -25.728 98 ------- 
ApoA-I 12.6 -27.410 746 2.07 
ApoC-I 14.9 -31.146 725 1.71 
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The HDL3 subfraction MALDI-MS spectra contained apos C-I', C-I, C-III0, A-
IImonomer, C-III0,glyc, C-III1, SAA1, prealbumin, A-I1, E, and HSA as shown in Figure 104.  
Table 80 shows the peak masses for this fraction.    ApoC-I' was barely visible.  The 
acute inflammatory response protein SAA1 was also present in this fraction.  The CE 
results for this fraction, shown in Figure 105 detected albumin, which was the 
predominant peak, as well as apos A-I and C-I. 
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Figure 106.  MALDI-MS protein spectra from control patient 25. 
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Table 82. Identification of apolipoproteins in the protein fraction from control patient 
25. 
Identification Mass (Da) 
HSA 67541.51 
 
 
Figure 107.  Electropherogram of the protein fraction from control patient 25. 
 
 
Table 83.  CE data for the protein fraction from a 200µL serum sample from control 
patient 25. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.6 -20.764 3846 3.87 
ApoC-I 14.7 -31.584 448 1.06 
 
 
The protein subfraction contained HSA only as shown in the MALDI-MS 
spectrum in Figure 106.  Table 82 shows the peak masses for this fraction.  The CE 
results, shown in Figure 107, detected albumin and apoC-I.  Albumin contained a large 
shoulder. 
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Control Cohort MALDI-MS Overview Discussion  
In analyzing the control cohort MALDI-MS spectra, the major apolipoprotein 
peaks seen in the non HDL fraction were apos: C-I', C-I, C-II, C-III, A-II, A-I
2+
, A-I1 and 
HSA.  All patient non HDL fractions with the exception of patients 14 and 24 showed 
apolipoprotein peaks.  In patients 3 and 7, apoC-I was very poorly resolved while patient 
16 contained sharp apoC-I peaks.  Most patients containing apoC-I peaks had a ratio of 
relative ion intensity that was approximately 1:2 for apoC-I' and apoC-I.  The presence 
of these proteins in this fraction was due to minimal overlap from the HDL2 region.  
The HDL2 subfractions from the control cohort showed an abundance of 
apolipoproteins.  The major apolipoprotein peaks in the HDL2 subfractions of the control 
samples were apos:  C-I', C-I, C-II, C-III, A-II, SAA4, amyloid, A-I
2+
, A-I1 and D.  It was 
observed that none of the control patient HDL2 samples contained human serum 
albumin.  Across the cohort, the HDL2 fractions contained the highest abundance of 
proteins and highest relative ion intensities, indicating protein enrichment in this 
fraction.  Sharp apoC-I peaks were present in the HDL2 spectra for all patients; though 
all C-I peaks were more intense than C-I' peaks, the ratio varied.  Patient 7 however, had 
an apoC-I' peak that was substantially low in intensity.  Patient 1 also displayed slight 
splitting of the C-I' peak which may suggest early signs of oxidative processes.  The 
apoC-II/C-III region was highly populated in most patients with isoforms of apos C-II 
and C-III which possessed high mass accuracy.  ApoA-II appeared in all patients with 
the exception of patients 14 and 25 and was poorly resolved with splitting.  ApoA-I1 
intensity was overall consistent with slightly lower intensity in patients 3 and 24.   
 The HDL3 subfractions from the control cohort showed major apolipoprotein 
peaks for: C-I', C-I, C-II, C-III, A-I1, E, SAA1, SAA4, prealbumin, and human serum 
albumin.  ApoC-I peaks had overall lower relative ion intensity and poorer resolution in 
this fraction.  There was also greater variation in the intensity ratio between C-I' and C-I 
in this subfraction.  Patients 3, 7, 13, and 25 had hardly visible C-I' peaks.  The protein 
SAA1 was also present in patients 1 and 25 which indicates an acute inflammatory 
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response.  Human serum albumin was present in all patients which may be due to mixing 
between the protein and HDL3 fractions as shown in re-ultracentrifugation studies.   
The protein subfractions from the control cohort showed peaks corresponding to 
human serum albumin, prealbumin, SAA1, and apoE primarily.  None of the patients 
contained peaks corresponding to apoA-I in this fraction, which strongly demonstrated 
that there was minimal if any HDL contamination in this protein fraction.   The HSA 
peak intensity was relatively high with apo E intensities ranging from 40% to 75% of 
HSA peak intensity.  The acute inflammatory response protein SAA1 was also observed 
in this fraction for patient 7 which was likely due to its dissociation from an HDL 
particle. 
 
Control Cohort ApoA-I1 MALDI-MS Discussion 
The apoA-I peaks were observed in detail in the mass range spanning 27,000 – 
30,000m/z where this protein was expected to be found.  In the control cohort, upon 
closer inspection it was observed that the peak in this region was shifted.  Due to this 
shift, this apolipoprotein peak was designated as apoA-I1.  Such mass shifting may be 
due to biological processes.  To evaluate the differences between the known mass of 
apoA-I and the observed mass of apoA1 in the control cohort, the mathematical 
differences between these values were calculated for the cohort. The mass accuracy of 
the apoA-I1 peaks was determined by averaging the masses of each peak from the 
control cohort, and calculating the standard deviation at the 95% confidence level. The 
apoA-I1 peaks for the total cohort had an average mass of 28440.96 ± 29.36Da, which 
indicated a shifted mass of approximately 362Da.  The apoA-I1 peaks for the non HDL 
fractions had an average mass of 28451.57 ± 116.17 Da, which was 373Da higher than 
the known mass of this protein.   ApoA-I1 peaks in the HDL2 subfraction had an average 
mass of 28451.04 ± 4.92 Da with a mass difference of 372Da between this experimental 
value and the known mass value of the protein.  Likewise, the HDL3 subfraction had an 
average apoA-I1 mass of 28422.92 ± 42.89, which corresponded to a difference of 
approximately 344Da.  
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Apolipoprotein A-I is composed of 243 amino acids and has a calculated 
molecular weight of 28,079 Da.  ApoA-I post-translational modifications can have a 
large impact on its function and is a prominent factor that can lead to HDL dysfunction.  
Copper mediated oxidation of HDL results in altered HDL migration on an agarose gel, 
apoA-I proteolysis, and decreased ability of HDL to unload cholesteryl esters from 
cholesterol-loaded macrophages.
183
  HDL from diabetic subjects has evidence of 
glycated apoA-I, this glycated apoA-I has altered structure and lipid binding activity.
184
  
Myeloperoxidase (MPO) is an enzyme that uses hydrogen peroxide to generate 
chlorinating and nitrating oxidants.  These reactive species can also modify host proteins 
and lipids.  Myeloperoxidase is enriched in human atheroma and its presence may 
promote lesion progression, by increasing LDL oxidation, and block plaque regression 
by modifications of apoA-I/HDL that impair reverse cholesterol transport.
185
  ApoA-I 
has also been shown to exhibit increased molecular weight when modified by carbonyls.  
Intact protein analysis by MALDI demonstrated a steadily increased molecular weight of 
apoA-I after exposure to malondialdehyde (MDA) of approximately 350 Da.  This result 
indicates that MDA covalently modifies apoA-I and progressively increases the proteins 
molecular weight.
165
   
Overall, the apoA-I peaks were not as resolved as other spectral peaks such as 
apoC-I and showed the appearance of multiple adducts and truncations.  In the control 
cohort, it is highly probable that the post-translational modification resulting in this 
adduct, if atherogenic, are prevented from causing atherogenic effects due to other HDL 
atheroprotective functions and proteins.  Additionally, the sample preparation and 
purification techniques could account for the addition of mass of this protein as it was 
seen consistently in all samples from this cohort. 
 
Control Cohort CE Analysis Discussion 
In the control cohort, A-I was most abundant in the HDL2 subfraction, apoC-I 
was most abundant in the HDL3 subfraction and human serum albumin was most 
abundant in the HDL3 subfractions.  The ratio of apoA-I to apoC-I was observed to be 
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higher in the HDL2 subfraction and similarly, this subfraction had a larger quantity of 
serum proteins.  It is worth noting that the CPA values obtained by CE were relatively 
low compared to the known concentrations of these apolipoproteins in human serum.  
This decrease in calculated concentrations from these fractions may be attributed to 
sample loss from primary and secondary methods of analysis, sample preparation, and 
purification techniques including dextran sulfate precipitation, ultracentrifugation, 
fraction excision, solid phase extraction, and evaporation. 
In reference to the electrophoretic mobilities,  the apoA-I mobility was highest in 
the non HDL and HDL3 subfractions and lower in the HDL2 subfractions, though all 
average mobilities were higher than that observed from the commercial apoA-I standard.  
The apoC-I mobility was more constant and highest in the protein fraction while lowest 
in the HDL2 fraction, though all values were quite comparable to that observed from the 
commercial apoC-I standard.  The human serum albumin mobility was also fairly 
constant and was highest in the non HDL fraction and lowest in the HDL2 fraction 
though all values were also comparable to that observed from the commercial bovine 
serum albumin standard.  Throughout the cohort, mobility values were consistently 
lower in the HDL2 fraction.  This abundance of proteins in this fraction may have 
attributed to the rate at which each protein migrated through the capillary.  The average 
electrophoretic mobility values for each fraction are shown in Table 84 for the control 
cohort.   
 
Table 84.  Average electrophoretic mobilities for the non HDL, HDL2, HDL3, and 
protein fractions from 200µL serum samples from the control cohort. 
Serum  
Fraction 
Average ApoA-I 
Mobility 
( x 10
-5
cm
2
/Vs) 
Average ApoC-I 
Mobility 
( x 10
-5
cm
2
/Vs) 
Average HSA  
Mobility 
( x 10
-5
cm
2
/Vs) 
Non HDL -27.469 ± 1.163 -31.244 ± 0.278 -20.721 ± 0.491 
HDL2 -26.824 ± 1.175 -31.085 ± 0.409 -20.373 ± 0.404 
HDL3 -27.258 ± 1.192 -31.359 ± 0.337 -20.551 ± 0.279 
Protein ------------- -31.377 ± 0.498 -20.571 ± 0.406 
Overall Average -27.271 ± 1.254 -31.267 ± 0.389 -20.533 ± 0.366 
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In the control cohort, the non HDL fraction contained homogeneous 
electropherograms.  For this subfraction, there were very small peaks with mobilities 
corresponding to albumin, apoA-I, and apoC-I in most patients.  These results correlated 
well with MALDI-MS results from this subfraction.  In the HDL2 subfraction, there were 
peaks corresponding to apoA-II, apoC-II, apoC-III, apoA-I, apoC-I and albumin.  Patient 
7 did not show peaks corresponding to apoC-II and apoC-III in this fraction.  Patient 13 
contained a sharp apoA-I peak, and patient 14 contained an apoA-I peak with a shoulder.  
Patient 24 showed an apoA-II peak containing a shoulder as well as a split human serum 
albumin peak.  ApoA-I was the predominant peak in this fraction and these results 
correlated well with MALDI-MS results.  Although CE detected albumin in these 
subfractions, MALDI-MS did not detect this protein.  It is probable that albumin 
identified by CE was actually another serum protein with a comparable electrophoretic 
mobility.  In the HDL3 subfraction, across the cohort, there was an enrichment of 
albumin which was seen in the large albumin peaks in this fraction, which mostly 
contained very broad bases.  Patients 24 and 25 contained albumin peaks with shoulders.  
Patient 13 contained many unidentified peaks eluting before and after the albumin peak 
which may have been contaminants or serum proteins.  Patient 14 contained a very sharp 
apoA-I peak and also contained many small unidentified peaks eluting before the apoA-I 
peak.  The results from this fraction correlated well with MALDI-MS which also 
showed the albumin enrichment.  In the protein fraction, it was observed that none of the 
patients contained apoA-I.  This fraction was also enriched with human serum albumin, 
which appeared as a doublet.  ApoC-I was consistently observed in this fraction, though 
MALDI-MS did not detect apoC-I in most spectra, apoE was consistently observed.  It is 
possible that apoE has a mobility that is comparable to apoC-I, which may have resulted 
in its misidentification by CE. 
In several patients, a small peak was observed eluting after apoC-I.  This peak’s 
mobility and elution time indicated that it was smaller and more highly charged than 
apoC-I.  It was hypothesized that this small peak corresponded to the truncated form of 
apoC-I, apoC-I .   
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CAD Cohort Analysis 
 
Table 85. CAD patient 10 medical information 
CAD Patient 10  
Age 75 years old 
Height 65 inches 
Weight 163 lbs. 
Gender Female 
Race Caucasian 
Family History of Premature 
CAD/CAD/PVD 
First Degree – Yes 
Second Degree - No 
Major Risk Factors Family history of CAD 
Prior or Current History Of: Angina, MI, Angioplasty or Stent 
Current Medications Statin, Estrogen, Beta Blocker, Thiazide 
Highest LDL 130-160mg/dL 
Highest TG > 200mg/dL 
Any Prior HDL <35 No 
Any Prior Homocysteine >14 No 
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Figure 108.  Lipoprotein density profile using a 200µL serum sample from CAD patient 
10 in a 0.300M solution of Cs2CdY, spun for 6 hours at 120,000rpm at 5°C after 
treatment with dextran sulfate. 
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CAD Patient 10 Discussion 
CAD patient 10 whose medical history is presented in Table 85, is a 75 year old 
Caucasian female who has been diagnosed with CAD, and has a family history of 
premature first degree CAD.  Patient 10 has prior and/or current history of angina, 
myocardial infarction, angioplasty and/or stent, and is currently prescribed and taking a 
statin, beta blocker, thiazide, and estrogen therapy.  Their highest LDL level was 130 – 
160 mg/dL and their highest triglyceride level was greater than 200 mg/dL.  There are no 
prior levels of HDL below 35 mg/dL or homocysteine above 14 mg/dL.  Figure 108 
shows the Cs2CdY profile for this subject which contains a sharp peak overlapping into 
the non HDL fraction.   
 
10000 20000 30000 40000 50000 60000 70000
0
1000
2000
3000
4000
13500 13750 14000 14250 14500
0
200
400
600
800
1000
A-I
2+
6300 6400 6500 6600 6700 6800
0
500
1000
1500
2000
C-I
2
C-I
2
'
C-I
1
' C-I1
11000 11200 11400
0
100
200
300
400
500
SAA
1
'''
9000 9200 9400 9600 9800 10000
0
200
400
600
800
1000
C-III
1 C-III
2
'''
R
e
la
ti
v
e
 I
o
n
 I
n
te
n
s
it
y
m/z
A-I
1
 D
D'
 
Figure 109.  MALDI-MS non HDL spectra from CAD Patient 10 
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Table 86. Identification of apolipoproteins in the non HDL fraction from CAD patient 
10. 
Identification Mass (Da) 
ApoC-I1' 6528.95 
ApoC-I2' 6538.05 
ApoC-I1 6724.13 
ApoC-I2 6734.91 
ApoC-III1 9427.02 
ApoC-III2''' 9467.59 
SAA1''' 11234.79 
ApoA-I
2+ 
14016.95 
ApoD' 20778.80 
ApoD 21343.17 
ApoA-I1 28447.30 
 
 
 
Figure 110.  Electropherogram of the non HDL fraction from CAD patient 10. 
 
 
 
Table 87.  CE data for the non HDL fraction from a 200µL serum sample from CAD 
patient 10. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoA-I 13.4 -28.936 509 1.41 
ApoC-I 15.0 -31.273 198 0.47 
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Figure 109 shows the MALDI-MS spectra for the non HDL subfraction which 
contained apos C-I1', C-I2' C-I1, C-I2, C-III1, C-III2, SAA1, D', D, and A-I1.  Table 86 
shows the peak masses for this fraction.  ApoC-I peaks, were observed in this fraction at 
relatively equal intensities and at a higher mass than the known value of these proteins 
and as a result, were designated C-I1' and C-I1. In addition to the mass shift, apoC-I 
peaks also showed splitting, these additional peaks were designated C-I2' and C-I2.  The 
acute inflammatory response marker SAA1 was observed as well as two peaks which 
corresponded to the mass of apoD, one of which was a truncated form of this protein.  
Lastly, a high relative ion intensity peak corresponding to apoA-I1 was observed. The 
CE results for this fraction are shown in Figure 110.  Very small peaks corresponding to 
apos A-I and C-I were detected in this subfraction.  In comparison to the MALDI-MS 
results, apos A-I and C-I were detected by both methods, however the human serum 
albumin detected by CE was not observed in the MALDI spectrum.  
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Figure 111.  MALDI-MS HDL2 spectra from CAD Patient 10 
 
Table 88. Identification of apolipoproteins in the HDL2 fraction from CAD patient 10. 
Identification Mass (Da) 
ApoC-I1' 6522.06 
ApoC-I1 6717.45 
ApoC-III0' 8737.59 
ApoA-IIm 8817.07 
Apo Pro C-II add 8974.18 
ApoC-III0,glyc add 9181.99 
ApoC-III1 add 9459.69 
ApoC-III2 9694.74 
ApoA-I'
2+ 
13990.89 
ApoA-I1 28459.01 
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Figure 112.  Electropherogram of the HDL2 fraction from CAD patient 10. 
 
 
 
Table 89.  CE data for the HDL2 fraction from a 200µL serum sample from CAD patient 
10. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.8 -20.771 986 0.99 
ApoC-II 10.9 -23.738 113 ------- 
ApoC-III 11.8 -25.658 841 ------- 
ApoA-II 12.5 -27.047 372 ------- 
ApoA-I 13.2 -28.282 5706 15.83 
ApoC-I 15.0 -31.045 514 1.21 
 
 
The HDL2 subfraction contained apos C-I1', C-I1, C-III0, A-IImonomer, Pro C-II,  C-
III0,glyc, C-III1, C-III2, A-I
2+
, and A-I as shown in the MALDI-MS spectra shown in 
Figure 111.  Table 88 shows the peak masses for this fraction.  The shapes of the apoC-I 
peaks were not as sharp as those seen in the control patient samples.  It appeared that the 
two major apoC-I peaks contained shoulders as well.  This HDL2 subfraction also 
contained several peaks in the 8000 – 10000 m/z region as seen in the HDL2 subfractions 
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from control patients.  There was no human serum albumin detected in this fraction as 
also observed in the control cohort HDL2 subfractions.  The CE results from this 
subfraction, shown in Figure 112, detected albumin, and apos C-II, C-III, A-II, A-I, and 
C-I.  All CE peaks were also detected by MALDI-MS with the exception of albumin. 
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Figure 113.  MALDI-MS HDL3 spectra from CAD Patient 10 
 
 
 
Table 90. Identification of apolipoproteins in the HDL3 fraction from CAD patient 10. 
Identification Mass (Da) 
ApoC-I1' 6516.49 
ApoC-I1 6720.36 
Unidentified Peak 1 10299.49 
176 
 
 
 
Table 90.  (Continued) 
Identification Mass (Da) 
Unidentified Peak 2 10501.76 
Unidentified Peak 3 10665.79 
ApoA-I1 28513.88 
HSA 67550.63 
 
 
Figure 114.  Electropherogram of the HDL3 fraction from CAD patient 10. 
 
 
Table 91.  CE data for the HDL3 fraction from a 200µL serum sample from CAD patient 
10. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.8 -20.821 28140 28.33 
ApoC-II 11.7 -25.539 85 ------- 
ApoC-III 12.1 -26.391 30 ------- 
ApoA-II 12.6 -27.455 32 ------- 
ApoA-I 13.2 -28.478 816 2.26 
ApoC-I 15.0 -31.160 503 1.19 
 
 
Figure 113 shows the MALDI-MS spectra for the HDL3 subfraction which 
contained apos C-I1', C-I1, A-I1, and HSA in addition to several unidentified proteins. 
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Table 90 shows the peak masses for this fraction.   There was an aberration from the 
normal appearance of apoC-I in this sample in that there was only one high intensity 
peak with a subsequent low intensity peak corresponding to apoC-I1, instead of two high 
intensity peaks corresponding to the truncated and full form of the protein.  Another 
interesting finding in this sample was the observation of several unidentified peaks in the 
10kDa mass range.  It is hypothesized that these unidentified peaks correspond to an 
inflammatory marker such as a modified form of serum amyloid a.  It is also highly 
probable that these unidentified proteins are related to CAD since they were not detected 
in the control cohort.  There was a peak corresponding to HSA in this fraction as also 
observed in the control cohort HDL3 fractions.  The CE results for this subfraction are 
shown in Figure 114.  The CE analysis detected albumin, and apos C-II, C-III, A-II, A-I, 
and C-I.   
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Figure 115.  MALDI-MS protein spectra from CAD Patient 10. 
 
 
 
Table 92. Identification of apolipoproteins in the protein fraction from CAD patient 10. 
Identification Mass (Da) 
ApoC-I1' 6518.61 
ApoC-I1 6719.89 
Unidentified Peak 1 10305.46 
Unidentified Peak 2 10670.82 
HSA 67459.81 
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Figure 116.  Electropherogram of the protein fraction from CAD patient 10. 
 
 
 
Table 93.  CE data for the protein fraction from a 200µL serum sample from CAD 
patient 10. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.9 -20.922 13734 13.83 
ApoA-I 13.5 -28.730 54 0.15 
ApoC-I 15.2 -31.226 246 0.58 
 
 
The protein subfraction contained apos C-I1', C-I1, HSA and two unidentified 
peaks as shown in the MALDI-MS spectra in Figure 115.  Table 92 shows the peak 
masses for this fraction.  ApoC-I peaks were poorly resolved with C-I1' having 
substantial splitting and C-I1 being hardly visible.  The CE results are shown in Figure 
116 and contained a poorly resolved albumin peak and a peak corresponding to apoC-I.  
In comparison to the MALDI-MS results for the protein fraction both methods identified 
apoC-I and albumin in this fraction. 
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Table 94.  CAD patient 41 medical information 
CAD Patient 41  
Age 72 years old 
Height 66 inches 
Weight 163 lbs. 
Gender Female 
Race Caucasian 
Family History of Premature 
CAD/CAD/PVD 
First Degree – Yes 
Second Degree – Yes 
Major Risk Factors Family history of CAD 
Hypertension 
Prior or Current History Of: Angina, MI, Angioplasty or Stent, CABG, 
Tobacco use 
Current Medications Statin,  Beta Blocker 
Highest LDL >160mg/dL 
Highest TG  150 – 200mg/dL 
Any Prior HDL <35 No 
Any Prior Homocysteine >14 Yes 
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Figure 117.  Lipoprotein density profile from CAD patient 41 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
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CAD Patient 41 Discussion 
CAD patient 41 whose medical history is presented in Table 94, is a 72 year old 
Caucasian female who has been diagnosed with CAD, has a family history of premature 
first and second degree CAD, and suffers from hypertension.  Patient 41 has prior and/or 
current history of angina, myocardial infarction, angioplasty and/or stent, coronary artery 
bypass graft (CABG) surgery and tobacco use.  Patient 41 is currently prescribed and 
taking a statin and beta blocker.  Their highest LDL was above 160 mg/dL and their 
highest triglyceride level was between 150 - 200 mg/dL.  There are no prior levels of 
HDL below 35 mg/dL however there are prior homocysteine levels above 14 mg/dL.    
Figure 117 shows the Cs2CdY profile for this subject which contains a low intensity 
peak in the HDL2 region.  
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Figure 118.  MALDI-MS non HDL spectra from CAD patient 41. 
 
 
Table 95. Identification of apolipoproteins in the non HDL fraction from CAD patient 
41. 
Identification Mass (Da) 
ApoC-I1' 6528.28 
ApoC-I1'add 6576.29 
ApoC-I1 6721.97 
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Figure 119.  Electropherogram of the non HDL fraction from CAD patient 41. 
 
 
 
Table 96.  CE data for the non HDL fraction from a 200µL serum sample from CAD 
patient 41. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoA-I 13.5 -29.582 156 0.43 
ApoC-I 15.0 -31.792 147 0.35 
 
 
Figure 118 shows the MALDI-MS spectra for the non HDL subfraction which 
only contained apoC-I peaks.  Table 95 shows the peak masses for this fraction.  The 
truncated form of the protein had a higher relative ion intensity than the full protein and 
also contained a small adduct peak.  The CE analysis results are shown in Figure 119 
and contain barely visible peaks corresponding to apos A-I and C-I.   
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Figure 120.  MALDI-MS HDL2 spectra from CAD patient 41. 
 
 
 
Table 97. Identification of apolipoproteins in the  HDL2 fraction from CAD patient 41. 
Identification Mass (Da) 
ApoC-I1' 6528.09 
ApoC-I1 6723.18 
ApoC-III0' 8746.47 
ApoA-IIm add 8878.47 
Pro ApoC-II add 8969.05 
ApoC-III0,glyc add 9183.89 
ApoC-III1 9431.49 
ApoA-I
2+ 
13991.40 
ApoA-I
2+
add 14098.09 
ApoA-II''' 17143.26 
ApoA-II'' 17258.11 
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Table 97.  (Continued) 
Identification Mass (Da) 
ApoA-I1 28468.82 
 
 
Figure 121.  Electropherogram of the HDL2 fraction from CAD patient 41. 
 
 
Table 98.  CE data for the HDL2 fraction from a 200µL serum sample from CAD patient 
41. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.9 -21.545 2225 2.24 
ApoC-III 12.5 -27.405 614 ------- 
ApoA-II 13.1 -28.519 130 ------- 
ApoA-I 13.5 -29.166 2500 6.94 
ApoC-I 15.0 -31.364 520 1.23 
 
 
The HDL2 subfraction MALDI-MS spectra contained apos C-I1', C-I1, C-III0, A-
IImonomer, Pro C-II, C-III0,glyc, C-III1, A-I
2+
, A-II and A-I1 as shown in Figure 120.  Table 
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97 shows the peak masses for this fraction.  The apoC-I' peak had a slightly higher 
relative ion intensity in the truncated form and both peaks were highly resolved.  ApoA-
I
2+ 
was poorly resolved and apoA-II peaks had substantial splitting.  The CE results are 
shown in Figure 121 and contain peaks corresponding to albumin, and apos C-III, A-II, 
A-I, and C-I.   
10000 20000 30000 40000 50000 60000 70000
0
500
1000
1500
2000
2500
3000
8000 8500 9000 9500 10000
0
200
400
600
800
1000
C-III
1
'
Pro C-II
add
C-III
0,glyc add
C-III
1
m/z
6300 6400 6500 6600 6700 6800
0
500
1000
1500
2000
2500
3000
C-I
1
'
C-I
1
m/z
R
e
la
ti
v
e
 I
o
n
 I
n
te
n
s
it
y
m/z
A-I
1
Figure 122.  MALDI-MS HDL3 spectra from CAD patient 41. 
 
 
 
Table 99. Identification of apolipoproteins in the  HDL3 fraction from CAD patient 41. 
Identification Mass (Da) 
ApoC-I1' 6522.68 
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Table 99. (Continued) 
Identification Mass (Da) 
ApoC-I1 6717.95 
Pro ApoC-II add 8961.49 
ApoC-III0,glyc add 9175.15 
ApoC-III1' 9340.46 
ApoC-III1 9459.38 
ApoA-I1 28446.90 
 
 
Figure 123.  Electropherogram of the HDL3 fraction from CAD patient 41. 
 
 
 
Table 100.  CE data for the HDL3 fraction from a 200µL serum sample from CAD 
patient 41. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.1 -21.809 27847 28.04 
ApoA-I 13.7 -29.477 2778 7.71 
ApoC-I 15.3 -31.739 361 0.85 
Unidentified  20.2 -36.383 115 ------- 
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The HDL3 subfraction MALDI-MS spectra, shown in Figure 122 contained apos 
C-I1', C-I1, Pro C-II, C-III0,glyc, C-III1, and A-I1.  Table 99 shows the peak masses for this 
fraction.  In this fraction, the apoC-I peaks had high resolution, C-I1' was slightly higher 
in intensity than C-I1.  Additionally, the peaks in the 8000 – 10000 m/z region had lower 
relative ion intensity than those in the HDL3 fraction, which is indicative of much lower 
concentration in this fraction.  The CE results, shown in Figure 123, contained albumin, 
apoA-I, and apoC-I.  The albumin peak contained a small shoulder and was the 
predominant peak.   
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Figure 124.  MALDI-MS protein spectra from CAD patient 41. 
 
 
189 
 
 
 
Table 101. Identification of apolipoproteins in the  protein fraction from CAD patient 
41. 
Identification Mass (Da) 
ApoC-I1' 6515.64 
ApoC-I1 6733.33 
Unidentified Peak 10652.81 
SAA1add 11981.23 
ApoA-I1 28368.13 
HSA 67614.33 
 
 
Figure 125.  Electropherogram of the protein fraction from CAD patient 41. 
 
 
 
Table 102.  CE data for the protein fraction from a 200µL serum sample from CAD 
patient 41. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.6 -23.767 25463 25.64 
ApoA-I 13.5 -29.700 1848 5.13 
ApoC-I 15.0 -31.896 346 0.82 
Unidentified 19.0 -36.029 94 -------- 
 
C-I 
   A-I 
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Figure 124 shows the protein subfraction which contained apos C-I1', C-I1, SAA1, 
A-I1, HSA, and an unidentified peak.  Table 101 shows the peak masses for this fraction.  
The apoC-I peaks were hardly visible with low relative ion intensity and low resolution, 
and the C-I1' and C-I1 peaks were of equal intensity.  Figure 125 shows the CE results 
which detected albumin and apoC-I.  The albumin peak was poorly resolved, contained a 
shoulder, and was the predominant peak. 
 
 
Table 103.  Patient 49 medical information 
Patient 49  
Age 56 years old 
Height 64 inches 
Weight 162 lbs. 
Gender Female 
Race Caucasian 
Family History of Premature 
CAD/CAD/PVD 
First Degree – Yes 
Second Degree – Yes 
Major Risk Factors Family history of CAD 
Current Medications Estrogen 
Highest LDL 100 – 129mg/dL 
Highest TG  150 – 200mg/dL 
Any Prior HDL <35 No 
Any Prior Homocysteine >14 No 
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Figure 126.  Lipoprotein density profile from patient 49 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
 
 
Patient 49 Discussion 
Patient 49 whose medical history is presented in Table 103, is a 56 year old 
Caucasian female who has not had coronary angiography and has not been diagnosed 
with CAD.  This patient has a family history of premature first and second degree CAD 
and is currently taking estrogen therapy. Their highest LDL was between 100 – 129 
mg/dL and their highest triglyceride level was between 150 - 200 mg/dL.  There are no 
prior levels of HDL below 35 mg/dL or homocysteine levels above 14 mg/dL.  Figure 
126 shows the Cs2CdY profile for this subject which contains a broad split peak. 
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Figure 127.  MALDI-MS non HDL spectra from patient 49. 
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Figure 128.  Electropherogram of the non HDL fraction from patient 49. 
 
 
 
Table 104.  CE data for the non HDL fraction from a 200µL serum sample from patient 
49. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoA-I 10.9 -25.717 152 0.42 
ApoC-I 13.3 -30.482 254 0.60 
 
 
Figure 127 shows the MALDI-MS spectra for the non HDL subfraction which 
did not contain any proteins.  Figure 128 shows the CE results for this fraction which 
detected small peaks with mobilities matching apos A-I and C-I. 
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Figure 129.  MALDI-MS HDL2 spectra from patient 49. 
 
 
 
Table 105. Identification of apolipoproteins in the  HDL2 fraction from patient 49. 
Identification Mass (Da) 
ApoC-I1' 6522.74 
ApoC-I2' 6536.12 
ApoC-I1 6717.18 
ApoC-I2 6730.02 
ApoA-IIm 8814.18 
Pro ApoC-II add 8964.63 
ApoC-III0,glyc add 9178.25 
ApoC-III1 9459.38 
ApoA-I
2+ 
14025.85 
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 Table 105.  (Continued) 
Identification Mass (Da) 
ApoA-I
2+ 
add 14155.43 
ApoA-I1 28437.96 
 
 
Figure 130.  Electropherogram of the HDL2 fraction from patient 49. 
 
 
Table 106.  CE data for the HDL2 fraction from a 200µL serum sample from patient 49. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 13.6 -25.669 4122 4.15 
ApoA-II 14.5 -28.139 250 ------- 
ApoA-I 15.1 -30.556 207 0.57 
ApoC-I 17.4 -31.798 109 0.26 
Unidentified 18.9 -35.212 435 ------- 
 
 
The HDL2 subfraction contained apos C-I1', C-I2', C-I1, C-I2, A-IImonomer, Pro C-
II, C-III0,glyc ,C-III0, A-I
2+
, and A-I1, as shown in Figure 129.  Table 105 shows the peak 
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masses for this fraction.  The apoC-I peaks were poorly resolved and showed splitting in 
addition to the mass shifting.  Figure 130 shows the CE results for this fraction, which 
detected albumin and apos A-II, A-I, C-I and an unidentified peak.   
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Figure 131.  MALDI-MS HDL3 spectra from patient 49. 
 
 
Table 107. Identification of apolipoproteins in the  HDL3 fraction from patient 49. 
Identification Mass (Da) 
ApoC-I1' 6522.10 
ApoC-I1 6718.77 
ApoA-IIm 8817.46 
Pro ApoC-II add 8961.35 
ApoC-III0,glyc add 9176.12 
ApoC-III1 9402.48 
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 Table 107.  (Continued) 
Identification Mass (Da) 
ApoC-III2''' 9464.49 
SAA1add 12007.23 
ApoA-I''
2+
 13826.32 
ApoA-I'
2+ 
13978.30 
ApoA-I1 28523.29 
 
 
Figure 132.  Electropherogram of the HDL3 fraction from patient 49. 
 
 
Table 108.  CE data for the HDL3 fraction from a 200µL serum sample from patient 49. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.8 -25.537 13889 13.99 
ApoA-I 13.7 -30.802 422 1.17 
ApoC-I 14.3 -32.151 279 0.66 
Unidentified 17.4 -35.852 184 ------- 
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Figure 131 shows the HDL3 subfraction MALDI-MS spectra which contained 
apos C-I1', C-I1, A-IImonomer, Pro C-II, C-III0,glyc, C-III1, C-III2, SAA1, A-I
2+
, and A-I1.  
Table 107 shows the peak masses for this fraction.    The C-I1' peak was low in relative 
ion intensity, with the C-I1 peak having approximately three times the intensity of C-I1'.  
The inflammatory marker SAA1 was also present in this fraction.   The CE results, 
shown in Figure 132, detected albumin, apos A-I and C-I, and an unidentified peak.   
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Figure 133.  MALDI-MS protein spectra from patient 49. 
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Table 109. Identification of apolipoproteins in the protein fraction from patient 49. 
Identification Mass (Da) 
Unidentified Peak
 
10661.77 
HSA 67712.50 
 
 
Figure 134.  Electropherogram of the protein fraction from patient 49. 
 
 
Table 110.  CE data for the protein fraction from a 200µL serum sample from patient 
49. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 11.0 -25.567 11765 11.85 
ApoC-I 14.6 -32.064 261 0.62 
Unidentified 17.9 -35.835 167 ------- 
 
 
The protein fraction contained HSA and an unidentified peak as shown in the 
MALDI-MS spectra in Figure 133.  Table 109 shows the peak masses for this fraction.  
The CE results, shown in Figure 134, contained albumin and apoC-I.  The albumin peak 
co-eluted with an unidentified peak. 
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Table 111. CAD patient 84 medical information 
CAD Patient 84  
Age 37 years old 
Height 61 inches 
Weight 172 lbs. 
Gender Female 
Race Caucasian 
Family History of Premature 
CAD/CAD/PVD 
First Degree – Yes 
Second Degree – Yes 
Major Risk Factors Hypertension, DM, Tobacco use,  
Family history of CAD, HDL <35mg/dl 
Prior or Current History Of: Angina, Angioplasty or Stent,  
CHF (EF <50%), PVD, Tobacco use 
Current Medications Statin, Beta Blocker, Thiazide 
Highest LDL > 160mg/dL 
Highest TG  150 – 200mg/dL 
Any Prior HDL <35 Yes 
Any Prior Homocysteine >14 No 
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Figure 135.  Lipoprotein density profile from CAD patient 84 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
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CAD Patient 84 Discussion 
CAD patient 84 whose medical history is presented in Table 111, is a 75 year old 
Caucasian female who has been diagnosed with CAD, and has a family history of 
premature first and second degree CAD.  Patient 84 has major risk factors including 
hypertension, diabetes mellitus, tobacco use, and HDL levels below 35mg/dL.  Patient 
84 also has prior and/or current history of angina, angioplasty and/or stent, congestive 
heart failure, and peripheral vascular disease, and is currently prescribed and taking a 
statin, beta blocker, and thiazide.  Their highest LDL was above 160 mg/dL and their 
highest triglyceride level was between 150 - 200 mg/dL.  There are no prior levels of  
homocysteine above 14 mg/dL.  Figure 135 shows the Cs2CdY profile for this subject 
which contains a slightly split peak with high intensity.  
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Figure 136.  MALDI-MS non HDL spectra from CAD patient 84. 
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Figure 137.  Electropherogram of the non HDL fraction from CAD patient 84. 
 
 
 
Table 112.  CE data for the non HDL fraction from a 200µL serum sample from CAD 
patient 84. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 11.2 -25.990 437 0.44 
ApoA-I 13.7 -30.877 202 0.56 
ApoC-I 15.2 -32.309 179 0.42 
 
 
Figure 136 shows the MALDI-MS spectra for the non HDL subfraction and did 
not contain any proteins.  The CE results for this fraction, shown in Figure 137, detected 
small peaks with mobilities corresponding to albumin, and apos A-I and C-I.    
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Figure 138.  MALDI-MS HDL2 spectra from CAD patient 84. 
 
 
 
Table 113. Identification of apolipoproteins in the  HDL2 fraction from CAD patient 84. 
Identification Mass (Da) 
ApoC-I1' 6526.32 
ApoC-I1 6721.46 
ApoA-II'
2+ 
8626.16 
ApoC-III0' 8746.47 
ApoC-III0 8791.53 
ApoA-IIm 8820.66 
ApoA-IIm add 8866.18 
Pro ApoC-II add 8964.95 
ApoC-III0,glyc add 9183.88 
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Table 113.  (Continued) 
Identification Mass (Da) 
ApoC-III1 9402.82 
ApoC-III2''' 9472.92 
ApoC-III2 add 9753.76 
Unidentified Peak 1 10366.87 
Unidentified Peak 2 10864.3 
SAA4'' 12547.94 
SAA4 12839.65 
ApoA-I'
2+
 13986.13 
  ApoA-I
2+ 
14091.94 
ApoA-IIt''       17009.33 
ApoA-II''       17132.13 
ApoA-II' 17248.97 
ApoA-I1 28448.96 
 
 
Figure 139.  Electropherogram of the HDL2 fraction from CAD patient 84. 
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Table 114.  CE data for the HDL2 fraction from a 200µL serum sample from CAD 
patient 84. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.9 -25.044 1325 1.33 
ApoA-II 12.4 -28.330 1255 ------- 
ApoA-I 13.7 -30.486 6512 18.07 
ApoC-I 14.6 -31.880 382 0.90 
Unidentified 15.3 -32.877 109 ------- 
Unidentified 18.5 -36.178 179 ------- 
Unidentified 19.4 -36.878 91 ------- 
 
 
Figure 138 shows the HDL2 subfraction MALDI-MS spectra which contained 
apos C-I1', C-I1, A-II
2+
, C-III0, A-IImonomer, Pro C-II, C-III0.glyc, C-III1, C-III2, SAA4, A-
I
2+
, A-II, A-I1 and two unidentified proteins.  Table 113 shows the peak masses for this 
fraction.  The apoC-I peaks were highly resolved and there was an abundance of proteins 
in the range between 8000 – 10000 m/z.  Two peaks were observed corresponding to the 
constitutive isomer SAA4.  Figure 139 shows the CE results for this fraction which 
contained albumin, apoA-II, A-I, C-I, and several unidentified peaks eluting after apoC-
I. 
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Figure 140.  MALDI-MS HDL3 spectra from CAD patient 84. 
 
 
 
Table 115. Identification of apolipoproteins in the  HDL3 fraction from CAD patient 84. 
Identification Mass (Da) 
ApoC-I1' 6519.18 
ApoC-I1 6722.75 
ApoA-I1 28682.86 
HSA 67568.87 
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Figure 141.  Electropherogram of the HDL3 fraction from CAD patient 84. 
 
 
Table 116.  CE data for the HDL3 fraction from a 200µL serum sample from CAD 
patient 84. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.9 -25.241 16589 16.70 
ApoA-I 13.7 -30.571 985 2.73 
ApoC-I 14.6 -31.933 383 0.90 
Unidentified 18.7 -36.301 147 ------- 
Unidentified 19.7 -37.106 67 ------- 
 
 
 
The HDL3 subfraction contained apos C-I1', C-I1, A-I1 and HSA, shown in Figure 
140.  Table 115 shows the peak masses for this fraction.  The apoC-I peaks were poorly 
resolved and C-I1' had a higher relative ion intensity than C-I1.  The apoC-I peaks were 
overall lower in relative ion intensity in this fraction.  The apoA-I1 peak was also poorly 
resolved with low intensity. The CE results, shown in Figure 141 detected albumin, 
apoA-I, apoC-I, and unidentified peaks.  
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Figure 142.  MALDI-MS protein spectra from CAD patient 84. 
 
 
 
Table 117. Identification of apolipoproteins in the protein fraction from CAD patient 84. 
Identification Mass (Da) 
Pro ApoC-IIadd 8987.91 
Unidentified Peak 1 10667.70 
ApoE 33769.10 
HSA 67594.14 
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Figure 143.  Electropherogram of the protein fraction from CAD patient 84. 
 
 
 
Table 118.  CE data for the protein fraction from a 200µL serum sample from CAD 
patient 84. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 9.9 -22.723 3181 3.20 
ApoA-I 11.1 -25.619 3424 9.50 
ApoC-I 14.7 -32.210 671 1.59 
Unidentified 18.2 -36.131 135 ------- 
Unidentified 19.6 -37.286 104 ------- 
 
 
The protein subfraction contained apos Pro C-II, E, HSA and a sharp unidentified 
protein peak shown in the MALDI-MS spectra in Figure 142.  Table 117 shows the peak 
masses for this fraction.  Figure 143, shows the CE results for this fraction which 
detected albumin, apoA-I, apoC-I and two unidentified peaks. 
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Table 119. CAD patient 143 medical information 
CAD Patient 143  
Age 54 years old 
Height 68 inches 
Weight 168 lbs. 
Gender Male 
Race Caucasian 
Major Risk Factors Family history of CAD, Hypertension 
Prior or Current History Of: MI, Beta Blockers 
Current Medications Statin 
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Figure 144.  Lipoprotein density profile from CAD patient 143 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
 
 
 
 
CAD Patient 143 Discussion 
CAD patient 143 whose medical history is presented in Table 119, is a 54 year 
old Caucasian male who has been diagnosed with CAD, has a family history of 
premature CAD, and suffers from hypertension. Patient 143 also has prior history of 
myocardial infarction (MI) and is currently prescribed and taking a statin and beta 
blocker, though no LDL lowering has resulted from statin therapy.  Despite, having 
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elevated HDL levels this patient has CAD, having an HDL level of 67mg/dL at the time 
of MI.  Figure 144 shows the Cs2CdY profile for this subject which contains a broad 
peak spanning both HDL subclasses with a shoulder on its buoyant side.   
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Figure 145.  MALDI-MS non HDL spectra from CAD patient 143. 
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Figure 146.  Electropherogram of the non HDL fraction from CAD patient 143. 
 
 
Table 120.  CE data for the non HDL fraction from a 200µL serum sample from CAD 
patient 143. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoC-I 15.9 -30.973 101 0.24 
Unidentified 17.5 -32.667 195 ------- 
 
 
Figure 145 shows the MALDI-MS spectra for the non HDL subfraction which 
did not contain any proteins.  The CE results are shown in Figure 146, and contained 
barely visible peaks with mobilities corresponding to apoC-I and an unidentified peak. 
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Figure 147.  MALDI-MS HDL2 spectra from CAD patient 143. 
 
 
 
Table 121. Identification of apolipoproteins in the  HDL2 fraction from CAD patient 
143. 
Identification Mass (Da) 
ApoC-I1' 6512.33 
ApoC-I2' 6528.55 
ApoC-I1 6709.54 
ApoC-I2 6726.34 
ApoC-III0' 8754.67 
Pro ApoC-II add 8977.69 
ApoC-III0,glyc add 9187.98 
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 Table 121. (Continued) 
Identification Mass (Da) 
ApoC-III1 add 9456.53 
ApoA-I1 28523.70 
 
           
Figure 148.  Electropherogram of the HDL2 fraction from CAD patient 143. 
 
 
 
Table 122.  CE data for the HDL2 fraction from a 200µL serum sample from CAD 
patient 143. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.1 -19.998 742 0.75 
ApoA-II 11.4 -23.334 1252 ------- 
ApoA-I 12.8 -26.257 4599 12.76 
ApoC-I 16.0 -30.892 320 0.76 
Unidentified 17.7 -32.600 211 ------- 
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  The MALDI-MS spectra for the HDL2 subfraction are shown in Figure 147, and 
contained apos C-I1', C-I2' C-I2, C-III0, Pro C-II, C-III0,glyc, C-III1, A-I1, and an 
unidentified protein.  Table 121 shows the peak masses for this fraction.  The apoC-I 
peaks consisted of doublets, had low relative ion intensities and broad bases.  The CE 
results are shown in Figure 148 and contained peaks corresponding to albumin, apos A-
II, A-I, C-I and an unidentified peak. 
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Figure 149.  MALDI-MS HDL3 spectra from CAD patient 143. 
 
 
 
Table 123. Identification of apolipoproteins in the  HDL3 fraction from CAD patient 
143. 
Identification Mass (Da) 
ApoC-I1' 6525.27 
ApoC-I2' 6540.21 
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 Table 123. (Continued) 
Identification Mass (Da) 
ApoC-I1 6718.37 
ApoC-II' 8188.89 
ApoA-II'm 8659.53 
ApoC-III0 8758.76 
ApoA-IIm 8822.76 
Pro ApoC-II' 8878.47 
Pro ApoC-II add 8981.79 
ApoC-III0,glyc add 9213.01 
ApoC-III1' 9332.73 
ApoC-III1 add 9481.11 
Prealbumin
 
13790.62 
ApoA-I
2+
 14060.50 
ApoA-I1 28315.85 
ApoE 33731.90 
HSA 67559.85 
 
          
Figure 150.  Electropherogram of the HDL3 fraction from CAD patient 143. 
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Table 124.  CE data for the HDL3 fraction from a 200µL serum sample from CAD 
patient 143. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.1 -20.211 20696 20.84 
ApoA-I 12.4 -25.836 1226 3.40 
ApoC-I 16.1 -31.290 403 0.95 
Unidentified 17.9 -33.126 92 ------- 
 
 
The HDL3 subfraction MALDI-MS spectra contained apos C-I1', C-I2', C-I1, C-II, 
A-IImonomer, C-III0, Pro C-II, C-III0,glyc, C-III1, prealbumin, A-I1, E, and HSA, as shown in 
Figure 149.  Table 123 shows the peak masses for this fraction.  The apoC-I peaks were 
lower in intensity than the HDL2 fraction and the truncated form consisted of doublet 
peaks, while C-I1 appeared as a singlet.  The 8000 – 10000 m/z region consisted of an 
abundance of peaks with high resolution.  The CE results, shown in Figure 150, 
contained peaks corresponding to albumin, apos A-I and C-I, and an unidentified peak. 
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Figure 151.  MALDI-MS protein spectra from CAD patient 143. 
 
 
Table 125. Identification of apolipoproteins in the protein fraction from CAD patient 
143. 
Identification Mass (Da) 
ApoC-II' 8193.68 
ApoE 33528.40 
HSA 67423.67 
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Figure 152.  Electropherogram of the protein fraction from CAD patient 143. 
 
 
 
Table 126.  CE data for the protein fraction from a 200µL serum sample from CAD 
patient 143. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 11.2 -23.182 4181 4.21 
ApoC-I 15.9 -30.860 155 0.37 
 
 
The protein subfraction contained apos C-II, E, and HSA peaks as shown in the 
MALDI-MS spectra in Figure 151.  Table 125 shows the peak masses for this fraction.  
The CE results from this fraction contained peaks corresponding to albumin and apoC-I, 
as shown in Figure 152. 
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Table 127. CAD patient 146 medical information 
CAD Patient 146  
Age 77 years old 
Height 61 inches 
Weight 110 lbs. 
Gender Female 
Race Caucasian 
Family History of Premature 
CAD/CAD/PVD 
First Degree – No 
Second Degree – No 
Major Risk Factors Hypertension 
Prior or Current History Of: CABG – 3V 
Current Medications Statin, Beta Blockers, Estrogen 
Highest LDL 160mg/dL 
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Figure 153.  Lipoprotein density profile from CAD patient 146 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
 
 
 
CAD Patient 146 Discussion 
CAD patient 146 whose medical history is presented in Table 127, is a 77 year 
old Caucasian female who has been diagnosed with CAD, has a family history of 
premature first and second degree CAD, and suffers from hypertension.  Patient 146 also 
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has prior and/or current history of coronary artery bypass graft (CABG) surgery, and is 
currently prescribed and taking a statin, beta blocker, and estrogen therapy.  Their 
highest LDL was above 160 mg/dL however, this patient has responded well to statin 
therapy.  Patient 146 also has CAD despite elevated HDL levels.  Figure 153 shows the 
Cs2CdY profile for this subject which contains a slightly split peak with high intensity.   
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Figure 154.  MALDI-MS non HDL Spectra from CAD patient 146. 
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Table 128. Identification of apolipoproteins in the non HDL fraction from CAD patient 
146. 
Identification Mass (Da) 
ApoC-I1' 6524.31 
ApoC-I1 6718.87 
ApoA-I
2+ 
13988.54 
ApoA-I1 28430.44 
 
 
Figure 155.  Electropherogram of the non HDL fraction from CAD patient 146. 
 
 
 
Table 129.  CE data for the non HDL fraction from a 200µL serum sample from CAD 
patient 146. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.0 -20.517 409 0.41 
ApoA-I 13.5 -28.089 746 2.07 
ApoC-I 15.7 -31.251 204 0.48 
 
 
HSA 
   A-I 
  C-I 
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Figure 154 shows the MALDI-MS spectra for the non HDL subfraction which 
contained apos C-I1', C-I1, A-I
2+
, and A-I1.  Table 128 shows the peak masses for this 
fraction.  The apoC-I peaks were sharp with splitting near the base.  The apoA-I1 peak 
was sharp and had strong  relative ion intensity.  Figure 155 shows the CE results for this 
fraction which contained peaks corresponding to albumin, and apos A-I and C-I. 
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Figure 156.  MALDI-MS HDL2 spectra from CAD patient 146. 
 
 
 
Table 130. Identification of apolipoproteins in the HDL2 fraction from CAD patient 146. 
Identification Mass (Da) 
ApoC-I1' 6527.60 
ApoC-I1 6723.15 
ApoC-IIadd 8272.53 
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Table 130.  (Continued) 
Identification Mass (Da) 
ApoC-III0' 8741.92 
ApoA-IIm 8824.42 
ApoA-IIm add 8865.95 
Pro ApoC-II add 8968.93 
ApoC-III0, glyc add 9180.59 
ApoC-III1 add 9469.62 
ApoC-III2' 9679.53 
ApoA-I'
2+ 
13994.75 
ApoA-I
2+ 
14087.03 
ApoA-IIt'' 17013.47 
ApoA-II'' 17142.19 
ApoA-II' 17251.95 
ApoA-I1 28455.20 
 
 
Figure 157.  Electropherogram of the HDL2 fraction from CAD patient 146. 
 
 
 
 
225 
 
 
 
Table 131.  CE data for the HDL2 fraction from a 200µL serum sample from CAD 
patient 146. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
ApoA-II 12.3 -25.773 949 0.96 
ApoA-I 13.2 -27.535 3825 10.61 
ApoC-I 15.8 -31.149 374 0.88 
 
 
The HDL2 subfraction MALDI-MS spectra contained apos C-I1', C-I1, C-II, C-
III0, A-IIm, Pro C-II, C-III0,glyc, C-III1, A-I
2+
, A-II, and A-I1, as shown in Figure 156.  
Table 130 shows the peak masses for this fraction.    The apoC-I peaks were highly 
resolved and C-I1 had a relative ion intensity that was approximately twice the intensity 
of C-I1'.  The CE results in Figure 157 detected peaks corresponding to apoA-II, apoA-I, 
and apoC-I. 
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Figure 158.  MALDI-MS HDL3 spectra from CAD patient 146. 
 
 
 
Table 132. Identification of apolipoproteins in the HDL3 fraction from CAD patient 146. 
Identification Mass (Da) 
ApoC-I1' 6506.11 
ApoC-I1 6715.07 
ApoA-I1 28438.95 
ApoE 34010.38 
HSA 68033.10 
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Figure 159.  Electropherogram of the HDL3 fraction from CAD patient 146. 
 
 
 
Table 133.  CE data for the HDL3 fraction from a 200µL serum sample from CAD 
patient 146. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.1 -20.454 23333 23.49 
ApoA-I 13.6 -27.895 721 2.00 
ApoC-I 16.1 -31.248 605 1.43 
Unidentified 21.9 -36.070 91 ------- 
 
 
The HDL3 subfraction MALDI-MS spectra contained C-I1', C-I1, apoA-I1, E, and 
HSA which are shown in Figure 158. Table 132 shows the peak masses for this fraction.  
The C-I peaks were much lower in intensity than HDL2 and poorly resolved, C-I1 
appeared to have splitting to form the earliest appearance of a doublet and was less 
intense than C-I1'.  Figure 159 shows the CE results from this fraction which contained a 
sharp albumin peak and small peaks corresponding to apos A-I and C-I.   
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Figure 160.  MALDI-MS protein spectra from CAD patient 146. 
 
 
 
Table 134. Identification of apolipoproteins in the protein fraction from CAD patient 
146. 
Identification Mass (Da) 
ApoC-III1' 9354.02 
Unidentified Peak 1 9994.69 
Unidentified Peak 2 10300.16 
Unidentified Peak 3 10667.42 
ApoA-I1 28582.37 
HSA 67575.75 
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Figure 161.  Electropherogram of the protein fraction from control patient 146. 
 
 
 
Table 135.  CE data for the protein fraction from a 200µL serum sample from control 
patient 146. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.9 -20.171 6508 6.55 
ApoC-I 15.7 -31.056 187 0.44 
Unidentified 21.1 -35.818 43 ------- 
 
 
The protein subfraction MALDI-MS spectra, shown in Figure 160 contained A-
I1, HSA and three unidentified proteins.  Table 134 shows the peak masses for this 
fraction.  The three unidentified proteins were sharp with strong relative ion intensity, 
while A-I1 and HSA were poorly resolved and hardly visible.  The CE results shown in 
Figure 161 contained albumin, apoC-I, and an unidentified peak. 
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Table 136. CAD patient 170 medical information 
CAD Patient 170  
Age 75 years old 
Gender Male 
Race Caucasian 
Major Risk Factors Family history of CAD, Hypertension, 
Tobacco use 
Current Medications Statin, Niacin 
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Figure 162.  Lipoprotein density profile from CAD patient 170 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
 
 
CAD Patient 170 Discussion 
CAD patient 170 whose medical history is presented in Table 136, is a 75 year 
old Caucasian male who has been diagnosed with CAD, has a family history of CAD, 
uses tobacco products, and suffers from hypertension.  Patient 170 is currently 
prescribed and taking niacin and a statin.  Figure 162 shows the Cs2CdY profile for this 
patient which contains a sharp peak shifted towards the non HDL fraction.  
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Figure 163.  MALDI-MS non HDL spectra from CAD patient 170. 
 
 
Table 137. Identification of apolipoproteins in the non HDL fraction from CAD patient 
170. 
Identification Mass (Da) 
ApoA-I1 28479.85 
HSA 67487.64 
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Figure 164.  Electropherogram of the non HDL fraction from CAD patient 170. 
 
 
 
Table 138.  CE data for the non HDL fraction from a 200µL serum sample from CAD 
patient 170. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.1 -20.073 288 0.29 
ApoA-II 12.2 -25.194 25 ------- 
ApoA-I 13.6 -27.550 410 1.13 
ApoC-I 16.0 -30.834 189 0.45 
 
 
Figure 163 shows the MALDI-MS spectrum for the non HDL subfraction which 
contained apoA-I1 and HSA, both poorly resolved and low in relative ion intensity.  
Table 137 shows the peak masses for this fraction.  The CE results for this fraction, 
shown in Figure 164, detected small peaks corresponding to albumin, apoA-I, and apoC-
I.  
 
   
HSA    A-I 
 C-I 
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Figure 165.  MALDI-MS HDL2 spectra from CAD patient 170. 
 
 
 
Table 139. Identification of apolipoproteins in the HDL2 fraction from CAD patient 170. 
Identification Mass (Da) 
ApoC-I1' 6526.27 
ApoC-I1 6721.89 
ApoC-III0' 8738.28 
Pro ApoA-IIm add 8866.18 
Pro ApoC-II add 8973.60 
ApoC-III0,glyc add 9179.79 
ApoC-III1 add 9464.72 
ApoA-I
2+ 
13900.80 
ApoA-I1 28460.02 
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Figure 166.  Electropherogram of the HDL2 fraction from CAD patient 170. 
 
 
 
Table 140.  CE data for the HDL2 fraction from a 200µL serum sample from CAD 
patient 170. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.1 -20.098 988 0.99 
ApoA-II 11.8 -24.433 814 ------- 
ApoA-I 13.2 -27.089 5346 14.8 
ApoC-I 15.9 -30.836 450 1.06 
 
 
The HDL2 subfraction MALDI-MS spectra, shown in Figure 165, contained apos 
C-I1', C-I1, C-III0, A-IImonomer, Pro C-II, C-III0,glyc, C-III1, A-I
2+
, and A-I1.  Table 139 
shows the peak masses for this fraction.  The apoC-I peaks were strongly resolved and 
there appeared to be a shoulder on C-I1.  The 8000 – 10000 m/z region was also strongly 
resolved with high intensity.  ApoA-I
2+
 was sharp with splitting near the base.  The CE 
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results from this subfraction, shown in Figure 166 contained peaks corresponding to 
albumin, apoA-II, A-I, and C-I.   
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Figure 167.  MALDI-MS HDL3 spectra from CAD patient 170. 
 
Table 141. Identification of apolipoproteins in the HDL3 fraction from CAD patient 170. 
Identification Mass (Da) 
ApoC-I1' 6528.17 
ApoC-I1 6723.56 
ApoA-I'''
2+ 
1366.98 
ApoA-I1 28450.25 
HSA 67599.83 
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Figure 168.  Electropherogram of the HDL3 fraction from CAD patient 170. 
 
 
 
Table 142.  CE data for the HDL3 fraction from a 200µL serum sample from CAD 
patient 170. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.1 -20.069 18562 18.59 
ApoA-I 13.3 -26.896 1532 4.25 
ApoC-I 16.1 -30.895 253 0.60 
 
 
The HDL3 subfraction MALDI-MS spectra, shown in Figure 167, contained apos 
C-I1', C-I1, A-I
2+
, A-I1, and HSA.  Table 141 shows the peak masses for this fraction.  
The apoC-I peaks were sharp and C-I1 had a relative ion intensity that was 3 times 
higher than that of C-I1'.  The CE results, shown in Figure 168 contained albumin, apoA-
I, and apoC-I. 
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Figure 169.  MALDI-MS protein spectra from CAD patient 170. 
 
 
 
Table 143. Identification of apolipoproteins in the HDL2 fraction from CAD patient 146. 
Identification Mass (Da) 
Prealbumin 13747.16 
ApoA-I'''
2+ 
13862.13 
ApoA-I1 28385.77 
ApoE 33981.78 
HSA 67645.52 
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Figure 170.  Electropherogram of the protein fraction from CAD patient 170. 
 
 
Table 144.  CE data for the protein fraction from a 200µL serum sample from CAD 
patient 170. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.3 -20.205 15119 15.22 
ApoA-II 12.9 -25.950 287 ------- 
ApoA-I 15.0 -29.184 165 0.46 
ApoC-I 16.3 -30.770 383 0.90 
 
 
 
 
 
 
 
 
 
   A-II 
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Table 145. CAD patient 195 medical information 
CAD Patient 195  
Age 72 years old 
Height 64 inches 
Weight 132 lbs. 
Gender Female 
Race Caucasian 
Family History of Premature 
CAD/CAD/PVD 
First Degree – No 
Second Degree – No 
Major Risk Factors Hypertension 
Prior or Current History Of: Angina, CABG, PVD – mesenteric 
Current Medications Statin, Alpha Blocker 
Highest LDL 130 - 160mg/dL 
Highest TG  < 150mg/dL 
Any Prior HDL <35 No 
Any Prior Homocysteine >14 No 
 
4 6 8 10 12 14 16 18 20 22 24 26 28 30 32
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
2400
2600
2800
3000
1.000
1.025
1.050
1.075
1.100
1.125
1.150
1.175
1.200
1.225
1.250
1.275
1.300
1.325
1.350
1.375
1.400
1.425
1.450
In
te
n
s
it
y
Tube Coordinate (mm)
Non HDL Protein
 
 D
e
n
s
it
y
 (
g
/m
L
)
HDL
2
HDL
3
 
Figure 171.  Lipoprotein density profile from CAD patient 195 in a 0.300M solution of 
Cs2CdY, spun for 6 hours at 120,000RPM at 5°C after treatment with dextran sulfate. 
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The protein subfraction MALDI-MS spectra contained prealbumin, apos A-I1, E, 
and HSA, shown in Figure 169.  Table 143 shows the peak masses for this fraction.  
Figure 170 shows the CE results for this fraction which contain albumin, apoA-II, apoA-
I, and apoC-I. 
 
 
CAD Patient 195 Discussion 
CAD patient 195 whose medical history is presented in Table 145, is a 72 year 
old Caucasian female who has been diagnosed with CAD, has a family history of 
premature first and second degree CAD, and suffers from hypertension.  Patient 195 has 
prior and/or current history of angina, coronary artery bypass graft (CABG) surgery, and 
peripheral vascular disease, and is currently prescribed and taking a statin and alpha 
blocker.  Their highest LDL was between 130 - 160 mg/dL and their highest triglyceride 
level was below 150 mg/dL.  There are no prior levels of HDL below 35mg/dL or 
homocysteine levels above 14 mg/dL. Patient 195 was a low birth weight infant and has 
CAD despite elevated HDL levels.  Figure 171 shows the Cs2CdY profile for this subject 
which contains a broad peak with a shoulder on its denser side.   
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Figure 172.  MALDI-MS non HDL spectra from CAD patient 195. 
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Figure 173.  Electropherogram of the non HDL fraction from CAD patient 195. 
 
 
Figure 172 shows the MALDI-MS spectra for the non HDL subfraction which 
did not contain any proteins.  Comparably, the CE results of this subfraction, shown in 
Figure 173, did not contain any proteins.   
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Figure 174.  MALDI-MS HDL2 spectra from CAD patient 195. 
 
 
 
Table 146. Identification of apolipoproteins in the HDL2 fraction from CAD patient 195. 
Identification Mass (Da) 
ApoC-I1' 6524.48 
ApoC-I1 6720.08 
ApoC-IIadd 8271.73 
ApoA-II'
2+ 
8647.25 
ApoC-III0' 8738.28 
ApoA-IIm add 8866.18 
Pro ApoC-IIadd 8969.05 
ApoC-III0, glyc add 9179.79 
ApoC-III1 add 9460.63 
ApoA-I
2+ 
13981.27 
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Table 146.  (Continued) 
Identification Mass (Da) 
ApoA-IIt'' 17071.21 
ApoA-II'' 17116.89 
ApoA-II' 17256.85 
ApoA-I1 28439.29 
 
 
Figure 175.  Electropherogram of the HDL2 fraction from CAD patient 195. 
 
 
 
Table 147.  CE data for the HDL2 fraction from a 200µL serum sample from CAD 
patient 195. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.1 -20.259 384 0.39 
ApoC-III 12.1 -25.122 990 ------- 
ApoA-II 12.6 -26.125 453 ------- 
ApoA-I 13.4 -27.579 4566 12.67 
ApoC-I 15.9 -30.925 272 0.64 
Unidentified 17.5 -32.618 78 ------- 
 
245 
 
 
 
The HDL2 subfraction MALDI-MS spectra, shown in Figure 174, contained apos 
C-I1', C-I1, C-II, A-II
2+
, C-III0, C-III1, A-I
2+
, A-II, and A-I1.  Table 146  shows the peak 
masses for this fraction.  The apoC-I peaks were sharp and highly resolved as were all 
other proteins in this fraction.  The CE results from this fraction, shown in Figure 175, 
contained albumin apos C-III, A-II, A-I, C-I, and an unidentified peak. 
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Figure 176.  MALDI-MS HDL3 spectra from CAD patient 195. 
 
 
 
Table 148. Identification of apolipoproteins in the HDL3 fraction from CAD patient 195. 
Identification Mass (Da) 
ApoC-I1' 6526.32 
ApoC-I1 6721.46 
Pro ApoC-IIadd 8984.29 
ApoC-III0, glyc add 9175.47 
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Table 148.  (Continued) 
Identification Mass (Da) 
ApoC-III1' 9340.46 
ApoA-I'
2+ 
13986.13 
ApoA-I1 28445.32 
ApoE 33676.44 
HSA 67352.79 
 
 
Figure 177.  Electropherogram of the HDL3 fraction from CAD patient 195. 
 
 
 
Table 149.  CE data for the HDL3 fraction from a 200µL serum sample from CAD 
patient 195. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.2 -20.473 12125 12.21 
ApoA-I 13.7 -28.053 373 1.03 
ApoC-I 16.0 -31.175 193 0.46 
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The HDL3 subfraction MALDI-MS spectra, shown in Figure 176, contained apos 
C-I1', C-I1, Pro C-II, C-III0,glyc, C-III1, A-I
2+
, A-I1, E, and HSA.  Table 148 shows the 
peak masses for this fraction.  The C-I1 peak was comparable in intensity to the apoC-I 
peaks in HDL2, however, C-I1', was poorly resolved and very low in intensity.  The CE 
results from this fraction, shown in Figure 177, contained albumin, and apos A-I and C-
I. 
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Figure 178.  MALDI-MS protein spectra from CAD patient 195. 
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Table 150. Identification of apolipoproteins in the protein fraction from CAD patient 
195. 
Identification Mass (Da) 
Prealbumin 13710.35 
ApoA-I'''
2+ 
13836.88 
ApoA-I1 28513.88 
ApoE 33693.56 
HSA 67441.09 
 
 
Figure 179.  Electropherogram of the protein fraction from CAD patient 195. 
 
 
Table 151.  CE data for the protein fraction from a 200µL serum sample from CAD 
patient 195. 
Protein Elution Time 
(min) 
Mobility 
( x 10
-5
cm
2
/Vs) 
CPA Concentration 
(mg/dL) 
HSA 10.7 -28.639 2895 2.91 
ApoA-I 11.7 -31.209 8751 24.28 
ApoC-I 12.5 -32.890 208 0.49 
 
 
  A-I 
  HSA 
249 
 
 
 
The protein subfraction MALDI-MS spectra, contained apoA-I
2+
, A-I1, and HSA, 
as shown in Figure 178.  Table 150 shows the peak masses for this fraction.  The CE 
results, shown in Figure 179, contained albumin, apoA-I, and apoC-I. 
 
CAD Cohort MALDI-MS Overview Discussion 
In analyzing the CAD cohort samples, the major peaks in the non HDL fraction 
corresponded to: apos C-I1', C-I1, C-III, A-I1, D, and HSA.  Patients 49, 84, 143, and 195 
contained no detectable peaks in this fraction.  ApoA-I1 was observed in patients 10, 
146, and 170 only.  
The CAD HDL2 fractions contained peaks corresponding to C-I1', C-I1, C-II, C-III, 
A-II, SAA4, A-I1  and several unidentified peaks. As seen in the HDL2 fractions from the 
control cohort, there were no peaks corresponding to human serum albumin in this 
fraction.  Patient 84 contained several unknown peaks in the 10,000 Da mass region 
which were hypothesized to be related to SAA1 and or indicative of an acute 
inflammatory response. ApoA-I1 intensity was constant throughout all patients. Patients 
10, 84, 146, 170 showed an abundance of proteins in the 8000 – 1000 m/z  range.  ApoC-
I1' and apoC-I1 peaks were overall highly resolved and sharp with the exception of 
patients 49 and 143 which also contained doublets indicative of oxidative processes. 
The CAD HDL3 fractions contained apos C-I1', C-I1, C-II, C-III, A-II, unidentified 
peaks, prealbumin, SAA1, A-I1, E, and HSA.   A-I1 peaks were present in all patients and 
were primarily of high relative ion intensity with the exception of patients 10, 84, 41, 
and 146.  Differing from the enrichment of proteins observed in the HDL2 fraction for 
the 8000 – 10000 m/z range, the HDL3 fraction was not as populated in this region, as 
also observed in the control cohort.  The apoC-I1' and apoC-I1 peaks were also lower in 
intensity in this fraction with doublets observed in patients 146 and 143. 
The CAD cohort protein fraction showed peaks corresponding to apos C-I1', C-I1, 
SAA, C-II, A-I1, E, prealbumin, and human serum albumin.  The apoC-I peaks were 
poorly resolved with low relative ion intensity. There were also several sharp and highly 
resolved unidentified peaks which consistently appeared in this fraction. The apoA-I1 
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peaks were present in half of the patients with relatively low intensity.  The albumin 
peaks in this fraction were generally of high relative ion intensity.   
 
CAD Cohort ApoC-I MALDI-MS Discussion 
The most interesting finding following MALDI-MS analysis was the distinct 
difference in the apoC-I peaks from subfractions in this cohort.  This difference was 
observed in the apparent molecular weight shifting observed in all CAD subfractions as 
well as the further modifications observed in the splitting of apoC-I peaks in select 
patients.  Tables corresponding to the apoC-I peak masses in the CAD HDL subfractions 
were presented at the beginning of this section.  The average apoC-I peak masses for the 
non HDL and protein fractions are shown in Tables 152 and 153 respectively.  
 
 
Table 152. Total CAD cohort Non HDL fraction average apoC-I masses by MALDI. 
 CAD Cohort ApoC-I'1 CAD Cohort ApoC-I1 
Average Mass 6527.18 ± 2.51 6721.61 ± 2.58 
Known Mass 6432.50 6630.60 
Difference 94.68 ± 2.51 91.01 ± 2.58 
 
 
 
Table 153. Total CAD cohort Protein fraction average apoC-I masses by MALDI. 
 CAD Cohort ApoC-I'1 CAD Cohort ApoC-I 
Average Mass 6517.13 ± 2.10 6726.61 ± 9.50 
Known Mass 6432.50 6630.60 
Difference 84.63 ± 2.10 96.01 ± 9.50 
 
 
Apolipoprotein C-I is composed of 57 amino acids and has a molecular weight of 
6630.6 Da as well as a truncated form with a molecular weight of 6432.5 Da.  Several 
mass spectrometry experiments have been carried out which confirm these masses 
experimentally.
169,
 
186, 187 
  Hortin and colleagues at the National Institutes of Health also 
recently identified apoC-I from human serum with a molecular mass of 6630.6 Da and 
apoC-I' with a molecular mass of 6432.5 Da.
188
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 Post-translational modifications refer to the chemical alteration of proteins 
following translation including peptide bond cleavage and derivatization of amino acid 
side chains.  Post-translational modifications result in the attachment or addition of 
biochemical functional groups such as carbohydrates, lipids, phosphates and acetates to 
amino acids; and may also result in structural changes.  The majority of post-
translational modifications are introduced by enzymes.  These modifications are required 
for normal biological function of proteins in many instances, although in other cases the 
role of these modifications is unknown and perhaps detrimental.  Approximately, one-
third of proteins from mammalian cells are phosphorylated.
189
  Phosphorylation is the 
most highly occurring and physiologically significant reversible regulatory modification.  
Protein kinases and phosphatases control cell growth, metabolism, division, motility, and 
differentiation, through selective phosphorylation at plural sites, and dephosphorylation 
of proteins.
190, 189, 191
  Phosphorylation of intracellular proteins serves an important role 
in signal transduction and as a result, the regulation of intracellular physiological 
processes.
192, 193
  Since mass spectrometry measures molecular mass, it is invaluable for 
detecting and characterizing covalent post-translational modifications that involve mass 
changes to amino acids.  Protein phosphorylation is detected by an increase in amino 
acid residue mass of +80 Da.  This mass shift reflects the addition of HPO3 to serine, 
threonine, tyrosine and also histidine.
194
  Acetylation is useful as well in cellular 
regulation including DNA recognition, protein-protein interaction, and protein 
stability.
195
  Acetylation of lysine and serine residues is detected by a characteristic mass 
shift of +42.01 Da.
194
  Cysteine residues, which are involved in cell proliferation, 
differentiation, and apoptosis, can be oxidized to form sulfenic acid (R-SOH), sulfinic 
acid (R-SO2H), and sulfonic acid (R-SO3H) respectively, which are detected by mass 
shifts of +16, +32, and +48 Da.
194
  The oxidation of methionine plays a large role in 
oxidative stress, as well as protein stability, and may undergo a two-electron oxidation to 
methionine sulfoxide.
196
  This oxidation results in a mass shifting of +16Da.
197
  
Additionally, hydroxylation of proline, as well as tyrosine, tryptophan, and 
phenylalanine residues results in a mass shifting of +16Da.
198
  Sulfonation is another 
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post-translational modification which occurs as a result of enzymatic modification of 
proteins.  Sulfonation can occur through several linkage types including esters and 
anhydrides (O-sulfonation), amides, and thioesters (N-sulfonation).  The effects of 
sulfation of threonine and serine residues results in a mass shift of +80 Da.
199
  The 
effects of sulfation of tyrosine also results in a mass shift of +80 Da.
200
   
ApoC-I contains a total of 57 amino acids, and does not contain tyrosine, 
cysteine, or histidine residues.
108
  The mass shifting observed following the analysis of 
the CAD cohort contained an average mass of +90 Da.  Considering the amino acid 
composition of apoC-I, it is possible that this shifting may be a result of post-
translational modifications including phosphorylation, sulfonation, hydroxylation, and 
oxidation.  If phosphorylation is responsible for the mass shifting, ApoC-I contains 7 
serine and 3 threonine (2 in C-Iꞌ) residues which may undergo this particular 
modification.  Phosphorylation results in the addition of a phosphate molecule to a polar 
R group of an amino acid residue.  This in turn can transform a hydrophobic portion of a 
protein in to a polar hydrophilic portion.  It can also introduce a conformational change 
in the structure of the protein through interaction with other protein residues. 
Phosphorylation may explain the ability of apoC-I to stimulate protein kinases in 
apoptosis.  Additionally, apoC-I contains 7 serine and 3 threonine residues which may 
undergo sulfonation.  In sulfonation, a sulfonic acid group is added to an amino acid in 
place of a hydrogen atom.  Additionally, the presence of doublet peaks with mass 
differences of 16 Da could indicate the influences of oxidation and hydroxylation.  
ApoC-I contains 1 methionine residue which may be oxidized to methionine sulfoxide.  
ApoC-I also contains 3 phenylalanine, 1 tryptophan, and 1 proline residues which could 
undergo hydroxylation. 
Isoforms of C apolipoproteins have been identified in biological samples as a 
result of glycosylation and deglycosylation and proteolytic activity at the post-
translational levels.
166, 167, 168
  The truncated apoC-I isoform apoC-I' was first identified 
by Bondarenko and colleagues and lacks Thr-Pro residues from the N terminus.
169  
In 
2006, Wroblewski and colleagues identified a functional polymorphism of apoC-I 
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detected by mass spectrometry.
170
  This polymorphism was found only in individuals of 
American Indian or Mexican ancestry.  Tandem mass spectrometry showed the 
alteration to consist of a T45S variation which forms part of the lipid interacting surface 
of apoC-I.  The Wroblewski study reported the first case of a structural variant of apoC-I 
as well as some protein properties that suggest the functional significance of this residue 
change.  The individuals in this study showing the polymorphism had apoC-I doublets 
for each of the two forms.  
 
 Adduct formation corresponds to the attachment of matrix molecules to analyte 
ions and presents difficulties in MALDI-MS analyses.
201, 202
  Adducts complicate spectra 
and reduce the intensities of ions of interest.  The matrix sinapinic acid (3,5-dimethoxy-
4-hydroxycinnamic acid) was used for MALDI-MS analysis and is specifically useful in 
the analysis of proteins in the mass range of apoC-I and other serum apolipoproteins.  
This matrix is commonly used with the dried droplet method and results in rhomboid 
crystals.  Loboda and colleagues recently investigated adduct formation in MALDI.
203
  
There are two theories of adduct formation which include incomplete cluster evaporation 
and poisoning.  Incomplete evaporation of analyte-matrix clusters is the assumption 
upon which the first theory is based.  Poisoning refers to adduct formation as analyte 
ions go through the dense plume of matrix molecules.  Though the study did not 
incorporate the matrix sinapinic acid it was observed that with matrices DHB and ferulic 
acid, matrix adduct formation in MALDI at elevated pressure occurred due to collisions 
of analyte ions with a dense plume of matrix molecules.  It was also observed that by 
using smaller laser spots, smaller plumes can be generated, resulting in reduced matrix 
adduct formation without changing other experimental conditions. It is highly unlikely 
that the shifting observed in the CAD cohort was due to matrix adducts.  Sinapinic acid 
adducts would predominately be observed with mass shifts corresponding to the addition 
of sodium or potassium ions which collectively and individually have lower masses than 
the adducts observed in the CAD apoC-I peaks.  Additionally, the effect of matrix 
adducts would be expected to be observed in all samples and not solely the CAD 
samples since both cohorts were prepared identically.      
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 Mass spectrometry enabled an in-depth investigation of the HDL subfractions 
from human serum samples following DGU.  In both patient cohorts consisting of 
control individuals and those with coronary artery disease, a distinct difference was 
observed in the apoC-I region of the MALDI spectra.  In all samples of the control 
cohort, it was observed that both forms of apoC-I contained peaks which corresponded 
to the known masses of these proteins.  The control patients had apolipoprotein peaks 
that were extremely close to the known masses of the respective apolipoproteins.  Such 
closeness of the peaks in the control cohort to their known calculated masses indicated 
that there were no interactions between the apolipoproteins and the heavy metal density 
gradient that might alter the weights of the proteins and likewise no fragmentation or 
damage to the apolipoproteins caused by solid phase extraction.  The closeness of the 
peak masses to the known masses also demonstrated the mass accuracy of the 
instrumentation.  
 In all samples of the CAD cohort it was observed that apoC-I forms contained 
peaks with greater masses than the known calculated masses.  Such a finding indicated 
post-translational modifications occurring in the CAD cohort which may be linked to 
CAD, as this diagnosis was the distinguishing difference between the two cohorts.  Mass 
spectral analysis of HDL serum fractions allowed the identification of the isoform 
distribution of apoC-I peaks.  This study has demonstrated the existence of isoforms of 
apoC-I and further variability in the isoform pattern in subjects within the CAD cohort.   
The observation of new isoforms of apoC-I in the mass spectra of subjects with 
CAD compared to those without CAD is a significant finding that may explain some of 
the unique functional properties of HDL.  In the identification of the apoC-I adduct, 
apoC-I1' had a mass difference of 89.97 ± 2.78 Da and apoC-I1 had a mass difference of 
89.87 ± 2.09 Da which are probably due to the attachment of the same adduct.  It is 
possible that the adduct corresponds to phosphorylation of apoC-I' and C-I, which is 
known to be accompanied by a comparable mass shift.
169 
 Post-translational 
modifications such as phosphorylation, are part of common mechanisms for controlling 
protein behavior such as enzyme activation and inhibition.  Interestingly, HDL 
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subclasses enriched in apoC-I as well as apoC-I itself have been shown to induce 
apoptosis in human aortic smooth muscle cells through activation of the neutral 
sphingomyelinase (N-SMase) pathway generating ceramide a key signaling molecule 
that regulates apoptosis.  It is hypothesized that apoC-I activates the N-SMase pathway 
by the stimulation of membrane bound protein kinases.   The observation that post 
translational modifications had occurred in the apoC-I and C-I' peaks in the CAD 
patients, further supports the hypothesis that apoC-I is potentially atherogenic.  An 
alternative hypothesis is that the approximately +90Da mass shift observed may be an 
acidic form of apoC-I due to oxidation, with a methionine residue converted to 
methionine sulfoxide, as seen in the recent and comparable results obtained in apes.
171
  
Likewise, it is important to note that the oxidation of apoC-I in certain CAD individuals, 
was seen predominately in the more buoyant and larger HDL2 subclass of HDL.  As the 
distinguishing characteristic between the two cohorts of individuals was the presence or 
absence of CAD, it is hypothesized that the presence of arterial plaque plays a significant 
role in the modification observed.  The adduct may be due to the interaction of apoC-I 
and apoC-I' with foam cells or macrophages on the arterial wall.  An additional 
hypothesis is that the shifting observed in the CAD cohort may be the result of a genetic 
mutation(s) that may compromise the functionality of apoC-I.
204
  The results obtained 
from MALDI-MS further support the hypothesis that apoC-I is a probable biomarker for 
CAD as suggested by many research studies. 
Interestingly, one patient, patient 49, who has not been diagnosed with CAD despite 
having a family history of the disease, and having apoptotic HDL was included in this 
study.  This patient’s MALDI-MS apoC-I spectra corresponded with those in the CAD 
cohort and showed a mass shift.  This result suggests that this analysis may be an initial 
screening that could indicate the future development of CAD and serve as a biomarker 
for CAD in this individual, as its MALDI spectra showed characteristics as seen in the 
CAD cohort and even displayed evidence of further modifications beyond the mass shift.  
If a mutation of the apoC-I gene is involved in this modification, it is likely that if the 
site of mutation is involved in the LCAT and CETP activity of apoC-I within the HDL 
256 
 
 
 
system, its role in lipoprotein metabolism may be compromised contributing to 
atherogenic or dysfunctional forms of HDL. 
 
CAD Cohort ApoA-I1 MALDI-MS Discussion 
The CAD cohort apoA-I peaks were observed in detail in the mass range 
spanning 27,000 – 30,000m/z.  As also seen in the control cohort, upon closer inspection 
it was observed that the peak in this mass range was shifted.  Due to this shift, this 
apolipoprotein peak was designated as apoA-I1. The masses of apoA-I1 peaks were 
averaged and the standard deviation was calculated at the 95% confidence level.  For the 
CAD cohort the average apoA-I1 mass for all serum fractions was 28466.00 ± 32.09 Da, 
which corresponded to a mass increase of approximately 387Da.  The average apoA-I1 
mass for the non HDL subfraction was 28462.54 ± 102.96 Da, which was 384Da higher 
than the known mass of apoA-I.  The average apoA-I1 mass for the HDL2 and HDL3 
fractions were 28461.62 ± 24.21 Da and 28477.16 ± 92.75 Da, which corresponded to 
mass differences of 383Da and 398 Da respectively.  The average apoA-I1 mass for the 
protein fraction was 28452.53 ± 25.12 Da, which was approximately 374Da higher than 
the known mass of apoA-I.  
As both cohorts showed comparable mass shifting of apoA-I, it is likely that this 
modification is due to biological variables such as those described in the control apoA-I1 
discussion which alone may or may not pose a risk to CAD and or its development.  In 
both patient cohorts consisting of control individuals and those with CAD, a consistent 
mass shift was observed in the apoA-I region of the MALDI-MS spectra.  In all samples 
of the control and CAD cohorts, it was observed that apoA-I contained peaks with 
greater masses than the known mass of this protein.  Such a finding suggests potential 
sample preparation influences on apoA-I mass. Additionally, the shift may be due to 
post-translational modifications occurring in the CAD cohort which may be linked to 
CAD in the CAD cohort, and possibly protected by other HDL associated proteins in the 
control cohort which also showed this shift despite being free of CAD. 
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CAD Cohort CE Analysis Discussion 
The observed elution order of peaks in the electropherograms was: EOF marker, 
human serum albumin, apoC-II/apoC-III, apoA-II,  apoA-I, and apoC-I.  Human serum 
albumin, has a larger molecular weight than HDL apolipoproteins, which resulted in its 
lower mobility.  ApoC-I is the smallest protein in molecular mass which resulted in its 
relatively high mobility.  There were few striking differences between serum non HDL, 
HDL2, HDL3, and protein subfractions for the two patient cohorts.  The composition of 
each individual subfraction in regards to apolipoprotein composition and peak areas 
remained relatively consistent over both patient cohorts.  Both samples contained a 
greater ratio of apoA-I to apoC-I in the more buoyant HDL2 fraction.  ApoA-I was most 
abundant in the HDL2 subfractions in both samples.  The CAD cohort showed more 
comparable apoA-I concentrations between the HDL2 and HDL3 fractions than the 
control cohort.  ApoC-I was most abundant in the HDL3 subfraction.  The ratio of apoA-
I to apoC-I was observed to be higher in the HDL2 subfraction as also observed in the 
control cohort. The average corrected peak area values for each fraction are shown in 
Table 165 for the CAD cohort. 
Albumin was most abundant in the HDL3 subfraction followed by the bottom or 
protein fraction.  Human serum albumin is not a structural part of HDL particles, 
however, it was commonly detected in HDL3 fractions after preparative 
ultracentrifugation.  Human serum albumin has the capacity to bind cholesterol as well 
as free fatty acids in the blood stream.  It is likely that albumin was also attached to 
lipoprotein particles prior to purification, which may have contributed to the peak shape 
variability observed in the lipoprotein profiles.   
  In the CAD cohort, apoA-I had the highest mobility in the non HDL fraction and 
the lowest mobility in the HDL3 fraction.  ApoC-I had the highest mobility in the protein 
fraction and lowest in the HDL2 subfraction.  Human serum albumin had the highest 
mobility in the non HDL fraction and lowest in the protein fraction though both albumin 
and apoC-I had constant mobilities that were comparable to their corresponding 
commercial standards.  Overall, the fluctuations in mobilities were consistent across both 
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cohorts, and may be influenced by a number of factors, the most pertinent of which may 
be the presence of other sample constituents and contaminants. The average 
electrophoretic mobility values for each fraction are shown in Table 154 for the CAD 
cohort. 
 
Table 154.  Average electrophoretic mobilities for the non HDL, HDL2, HDL3, and 
protein fractions from 200µL serum samples from the CAD cohort. 
Serum Fraction Average ApoA-I 
Mobility 
Average ApoC-I 
Mobility 
Average HSA 
Mobility 
Non HDL -28.029 ± 1.239 -31.206 ± 0.236 -20.295 ± 0.314 
HDL2 -28.018 ± 0.603 -31.099 ± 0.159 -20.224 ± 0.308 
HDL3 -27.416 ± 1.875 -31.123 ± 0.305 -20.261 ± 0.590 
Protein -27.499 ± 1.709 -31.293 ± 0.874 -20.146 ± 1.216 
Overall Average -27.422 ± 1.516 -31.215 ± 0.425 -20.864 ± 0.969 
 
 
Overall, the MALDI-MS data correlated fairly well with capillary electrophoresis 
with the exception of HDL2 fractions which consistently showed detectable human 
serum albumin peaks by CE while consistently showing no detectable human serum 
albumin by MALDI-MS.  The control patients did not show apoA-I in the protein 
fraction and likewise, the CAD patients were less likely to have any detectable 
apolipoprotein peaks in the non HDL fraction.  The consistent observation that CE 
fractions containing human serum albumin did not contain albumin by MS indicated that 
the proteins identified as human serum albumin by CE based upon their electrophoretic 
mobilities were most likely misidentified.  As MALDI-MS is a more sensitive analytical 
technique, it is highly possible that the true identity of serum components can be 
measured more confidently by MALDI-MS. 
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The corrected peak areas and concentrations of apolipoproteins reported, were 
lower than normal serum concentrations for apos A-I and C-I, with apoA-I having 
substantially low concentrations.  Such values are likely the result of dextran sulfate 
precipitation as apolipoproteins are also present in the apoB-containing lipoproteins, 
sample loss following DGU, sample excision, delipidation and desalting, and Speed-Vac 
evaporation.  The most probable explanation for such loss is likely attributed to solid 
phase extraction, it is likely that apos are retained in the stationary phase.  Quantitation 
using the current methodology will require additional research and development beyond 
the scope of this study. 
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Table 155.  Clinical studies result summary 
Patient ApoC-Iꞌ ApoC-I Oxidation SAA1 Unknowns Risk Factors Medical 
1-NonCAD        
3-NonCAD    HDL3 HDL3   
7-NonCAD Low in HDL3       
13-NonCAD Low in HDL3     Hypertension  
14-NonCAD        
16-NonCAD      Hypertension  
24-NonCAD      Hypertension  
 
25-NonCAD 
Low in HDL2 
Nearly depleted 
in HDL3 
   
HDL3 
  
Hypertension 
 
 
49 
Modified 
Nearly depleted 
in HDL2 and 
HDL3 
 
Modified 
 HDL3 
Protein 
  
Family History 
 
 
10-CAD 
 
Modified 
Modified 
Nearly 
Depleted in 
HDL3 and 
Protein 
 
non-HDL 
 
non-HDL 
 
HDL3 
Protein 
 Stent, Angina, 
Angioplasty 
 
41-CAD 
Modified 
 
Nearly depleted  
in Protein 
Modified 
Nearly 
depleted in 
Protein 
  
Protein 
 
Protein 
Hypertension 
Tobacco 
Stent, Angina, 
Angioplasty 
 2
6
1
 
 
Table 155.  (Continued) 
Patient ApoC-Iꞌ ApoC-I Oxidation SAA1 Unknowns Risk Factors Medical 
 
84-CAD 
 
 
Modified 
 
 
Modified 
   
HDL2 
Protein 
Hypertension 
Diabetes 
Tobacco 
Family History 
Stent, Angina, 
Angioplasty, 
Congestive 
Heart Failure 
143-CAD Modified 
Oxidized in 
HDL2 and HDL3 
Modified 
Oxidized in 
HDL2 
HDL2 
HDL3 
   
Hypertension 
 
146-CAD Modified Modified   Protein Hypertension  
170-CAD  
Modified 
 
Modified 
   Hypertension 
Tobacco 
 
195-CAD Modified 
Nearly depleted 
in HDL3 
 
Modified 
    
Hypertension 
Angina, CABG 
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Collaborative Studies 
 The collaborative studies, served to further assist in the characterization and 
elucidation of serum subfraction composition.  Likewise, these collaborations provided 
information that was useful in determining the biological functions of a novel 
atherogenic HDL phenotype in a group of adults with CAD.  Clinical lipid levels were 
provided by Scott & White Hospital (Temple, TX), apoptosis levels were provided by 
the Chatterjee Laboratory at Johns Hopkins University (Baltimore, MD), and CETP and 
PLTP transfer rates were provided by Roar Biomedical (New York, NY).   
 
Patient Lipid Levels  
Lipid levels were analyzed by standard methods in the Clinical Chemistry 
Laboratory at Scott & White Hospital (Temple, TX).  Lipid levels are included in the 
traditional risk factors for CAD and include total cholesterol, triglycerides, high density 
lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C).   
High and low density lipoprotein cholesterol levels along with triglyceride, and 
Lipoprotein(a) levels cumulatively comprise the total cholesterol count which is 
obtained through blood testing.  Total cholesterol levels <200 mg/dL are desirable and 
put individuals at relatively low risk of heart disease.  Total cholesterol levels ranging 
between 200 – 239 mg/dL are categorized as borderline to high risk and may require 
medication, while total cholesterol levels >240 mg/dL are considered high risk and are 
associated with twice the risk of heart disease.   
High HDL-C levels are desired due to their atheroprotective benefits.  Low HDL-
C levels, identified as <40 mg/dL for men and <50 mg/dL for women, put individuals at 
greater risk for heart disease.  The average levels for men range from 40 – 50 mg/dL 
and for women from 50 – 60mg/dL.  An HDL cholesterol level ≥60 mg/dL provides 
protection against heart disease.  
 The lower an individual’s LDL cholesterol, the lower their risk of heart attack 
and stroke.  Levels <100 mg/dL are optimal while levels ranging from 100 – 129 mg/dL 
are near and or above optimal.  LDL cholesterol levels ranging from 130 – 159 mg/dL 
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are borderline high.  LDL cholesterol levels ranging between 160 – 189 mg/dL are 
considered high, while levels ≥190 mg/dL are extremely high.   
Triglyceride is a form of fat, and oftentimes, individuals with high triglyceride 
levels have high total cholesterol levels including high LDL-C levels and low HDL-C 
levels.  Many individuals have high triglyceride levels due to obesity, physical 
inactivity, alcohol consumption, smoking, and/or diet.  Triglyceride levels <150 mg/dL 
are considered normal while levels between 150 – 199 mg/dL are considered 
borderline.  Triglyceride levels between 200 – 499 mg/dL are high with levels >500 
mg/dL considered very high.   
The control cohort patient lipid levels are shown in Table 156 in addition to the 
true mean CETP values at the 95% confidence level.  The total cholesterol levels range 
from 135 – 226 mg/dL, with a cohort average total cholesterol of 184.43 ± 28 mg/dL.  
Patients 3 and 13 have levels above 200 mg/dL which put them at borderline high risk.  
Their risk however also depends on other risk factors and their measurements in those 
other areas.  The triglyceride levels for the control patient cohort range from 49 – 124 
mg/dL, with a cohort average of 86.43 ± 25 mg/dL.  All patients have normal levels 
which are classified as below 150mg/dL.  The HDL-C levels range from 61 – 89 mg/dL, 
with a cohort average of 74.29 ± 9 mg/dL.  All levels are above 60 mg/dL, which 
regardless of gender is optimal for a reduced risk of heart disease.  The LDL-C levels 
range from 55 – 130 mg/dL, with a cohort average 91.86 ± 23 mg/dL.  As seen with the 
total cholesterol levels, there are a few patients whose levels are in the near to above 
optimal range, including patients 3, 13, and 14, whose levels are 130 mg/dL, 115 mg/dL, 
and 108 mg/dL, respectively.   
 
Table 156.  Control patient cohort lipid levels. 
Patient 
Total 
Cholesterol 
(mg/dL) 
Triglycerides 
(mg/dL) 
HDL-C 
(mg/dL) 
LDL-C 
(mg/dL) 
1 155 94 62 74 
3 226 124 71 130 
7 185 70 76 95 
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 Table 156.  (Continued) 
Patient 
Total 
Cholesterol 
(mg/dL) 
Triglycerides 
(mg/dL) 
HDL-C 
(mg/dL) 
LDL-C 
(mg/dL) 
14 194 124 61 108 
16 135 49 70 55 
24 151 60 64 75 
25 173 97 89 65 
Average 183 86 74 92 
Standard Deviation 34 30 11 28 
True Mean 183 ± 28 86 ± 25 74 ± 9 92 ± 23 
 
 The CAD cohort patient lipid levels are shown in Table 157.  The total 
cholesterol levels range from 168 – 205 mg/dL with a cohort average of 183.57 ± 19 
mg/dL, and with the highest HDL-C levels being lower than the highest HDL-C levels in 
the control cohort.  Patients 41, 146, and 195 have levels in the 200mg/dL range 
however.  The triglyceride levels for the CAD patient cohort were slightly higher than 
the control cohort, ranging from 69 – 155mg/dL, with a cohort average of 111.86 ± 26 
mg/dL. Patient 10 is the only patient whose triglyceride level is borderline high.  The 
HDL-C levels range from 56 – 108 mg/dL, with a cohort average of 83.86 ± 17 mg/dL.  
Patient 41 has levels in the upper 50s however none of the patients show extremely low 
values.  Patients 146 and 195 show HDL cholesterol levels above 100 mg/dL.  The LDL 
cholesterol levels range from 53 – 120 mg/dL which are lower than those observed from 
the control cohort, with a cohort average of 81.29 ± 19 mg/dL.  There are two patients 
whose levels are in the near to above optimal range, including patients 41, and 49, whose 
levels are 120 mg/dL and 115 mg/dL.   
 
 
Table 157.  CAD patient cohort lipid levels. 
Patient 
Total 
Cholesterol 
(mg/dL) 
Triglycerides 
(mg/dL) 
HDL-C 
(mg/dL) 
LDL-C 
(mg/dL) 
10 168 155 84 53 
41 204 140 56 120 
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 Table 157.  (Continued) 
Patient 
Total 
Cholesterol 
(mg/dL) 
Triglycerides 
(mg/dL) 
HDL-C 
(mg/dL) 
LDL-C 
(mg/dL) 
84 180 95 78 89 
146 205 106 102 82 
170 161 108 69 70 
195 206 110 108 82 
Average 184 112 84 81 
Standard Deviation 21 28 18 21 
True Mean 184 ±19 112 ± 26 84 ± 17 81 ± 19 
 
 
 Patient 49, whose lipid levels are shown in Figure 158; has total cholesterol that 
is comparable to both cohort averages and within the desirable range.  Their triglycerides 
are higher than both cohort averages yet still normal by definition. Their HDL-C levels 
are lower than both cohort averages yet in the desirable range.  Lastly, their LDL-C 
levels are in the near and or above optimal range. 
 
 
 Table 158. Patient 49 lipid levels.  
Patient 
Total 
Cholesterol 
(mg/dL) 
Triglycerides 
(mg/dL) 
HDL-C 
(mg/dL) 
LDL-C 
(mg/dL) 
49 184 74 57 116 
 
 
 In regards to the CAD cohort lipid levels, particularly the HDL-C levels, many of 
the CAD patients have high HDL-C levels.  It is this occurrence of accelerated CAD in 
patients despite high HDL-C and normal lipid levels that is at the center of the 
atherogenic HDL investigation.  It is hypothesized that despite high serum levels of 
HDL-C, at the metabolic level, there are functional and structural errors preventing HDL 
from adequately shuttling cholesterol to the liver.   The closeness of both cohort lipid 
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levels also further support the fact that CAD diagnosis based upon coronary angiography 
is the distinguishing difference between these two groups of patients. 
 
Smooth Muscle Cell Apoptosis 
Immunoaffinity chromatography was performed using anti-apoC-I microbeads in 
order to obtain apoC-I depleted serum subfractions and apoC-I enriched serum as 
described in the methods chapter.   The apoptosis analyses reported here were performed 
to investigate the hypothesis that apoptotic effects of HDL on aortic smooth muscle cells 
were attributed to apoC-I enriched HDL.  
 Immunospecific DGU was utilized to investigate the differential effects of the 
apoC-I depleted and enriched lipoproteins on the aortic smooth muscle cell cultures.  
Aortic smooth muscle cells play a critical role in preventing the progression and 
complications of atherosclerosis, by providing a supportive structural role as part of the 
fibrous cap that sequesters the lipid core and prevents the rupture of atherosclerotic 
plaque.
205
  The results shown in Figure 180 compare both the commercial procedure 
(CP) and in-laboratory procedure (LP) described in the methods chapter.  Minimal 
apoptosis was observed with apoC-I depleted HDL subfractions.  In contrast, apoC-I 
enriched whole serum released from the immunoaffinity chromatography beads caused a 
15 - 20% increase in aortic smooth muscle cell apoptosis.  Figure 180 shows the results 
obtained from the apoptosis samples which used serum from CAD patient 10.    The first 
two bars correspond to apoC-I depleted HDL2 and HDL3 respectively using the in-
laboratory method described in the methods chapter.  There were less than 5% apoptotic 
cells in these apoC-I depleted HDL subfractions.  The third and fourth bars correspond 
to the apoC-I depleted HDL2 and HDL3 respectively using the commercial method 
described in the methods chapter.  There was a further decrease in the percent of 
apoptotic cells using the commercial method that correlated to roughly 1% apoptotic 
cells, showing a slightly greater efficiency with the commercial microbeads compared to 
the in-laboratory conjugated microbeads.  Lastly, the fifth and sixth bars correspond to 
the apoC-I enriched unfractionated serum corresponding to the in-laboratory and 
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commercial methods respectively.  There was an increase in the number of apoptotic 
cells when treated with recovered apoC-I enriched serum, roughly 17% of apoptotic cells 
from the in-laboratory method and roughly 20% apoptotic cells from the commercial 
method.  As also seen with the depleted samples from the two methods, the recovered 
apoC-I enriched serum from the commercial method was shown to be more efficient in 
recovering apoC-I from serum.  The results of the preliminary studies with CAD patient 
10, showed a direct relationship between apoptosis and apoC-I enriched HDL.  Such a 
relationship was also observed by Kolmakova and colleagues in their apoptosis 
studies.
106
 
 
 
 
 
 
 
 
 
 
Figure 180.  Apoptosis results following the treatment of aortic smooth muscle cell 
cultures with apoC-I enriched and depleted serum from CAD patient 10 using both in-
laboratory (LP) and commercial (CP) immunoprecipitation procedures. 
 
 
Following the preliminary apoptosis results presented above, it was apparent that 
there was a direct correlation between apoptosis and apoC-I enrichment.  The next step 
involved assessing the apoptosis levels of patients with and without CAD, to identify 
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any further relationships.  Fractionated serum was submitted to Johns Hopkins to assess 
aortic smooth muscle cell apoptosis levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 181.  Apoptosis results following the treatment of aortic smooth muscle cell 
cultures with CAD (black), non-CAD (light grey) and patient 49 (dark grey) non-HDL, 
HDL2, HDL3, and protein subfractions. 
 
 
 Figure 181 shows the aortic smooth muscle cell apoptosis levels induced by 
serum from each patient included in this study.  There was a distinct difference in 
apoptosis between the two cohorts, with the CAD cohort having substantially higher 
levels.  It was observed that CAD patient 146 induced the greatest percentage of 
apoptosis with approximately 50% apoptosis.  The CAD patients 10, 41, 84 also induced 
nearly as high of a percentage as patient 146, with values ranging between 40 – 45% 
apoptosis.  Of the CAD cohort patient 143 induced the least percentage of apoptosis, 
with approximately 25%.  In the control cohort, it was observed that overall, there were 
lower apoptosis levels compared to the CAD cohort.  Patient 1 induced the greatest 
percentage of apoptosis of the cohort with approximately 25% apoptosis.  The MALDI-
         CAD Patient 
Patient 49 
Non-CAD Control 
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MS analysis of patient 1 identified the presence of the inflammatory marker, SAA1, 
which may contribute to the apoptosis induced by this subject.  The lowest percentage of 
apoptosis was induced by patient 24 who induced approximately 2% apoptosis.  
Additionally, patient 49 induced a substantially high percentage of apoptosis which was 
comparable to the degree of apoptosis observed in the CAD cohort patients. 
The preliminary results from the apoptosis study with CAD patient 10 showed a 
direct correlation between apoptosis of aortic smooth muscle cells and the concentration 
of apoC-I.  Similarly, the results obtained showing substantially greater apoptosis 
percentages amongst the CAD cohort, further support the idea that these patients are 
inducing such apoptosis due to their apoC-I composition as these subjects all contained 
the apoC-I isoforms. It is highly probably that apoC-I in individuals with CAD is 
modified in a way that is detrimental to the arterial wall.  Previous apoptosis studies 
involving apoC-I enriched HDL from infant chord blood showed substantial apoptosis 
and provided key insight into the mechanisms by which this occurs.
206
  It was based 
upon these previous findings by Kolmakova and colleagues that experiments were 
carried out in order to ascertain the role of apoC-I in this process.  In previous 
experiments investigating apoC-I in apoptosis, it was observed that commercial apoC-I 
and apoC-I enriched HDL from low birth weight infants induced apoptosis 5 to 25 fold, 
compared to control cells, and apoC-I-poor HDL.   More importantly, however, it was 
seen that the mechanism of action by apoC-I was mediated through the recruitment of 
neutral sphingomyelinase (N-SMase), generating ceramide and activating cytochrome c 
release as well as caspase.  It is hypothesized that this mechanism may contribute to 
unstable plaque that is more susceptible to rupture, leading to thrombosis, myocardial 
infarction, and death.  It is also possibly that the adducts consistently observed in the 
mass spectra of CAD patients influence the stimulation of one or more membrane bound 
protein kinases by apoC-I which in turn activates neutral sphingomyelinase in human 
aortic smooth muscle cells. 
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Transfer Protein Assays 
Cholesteryl ester transfer protein (CETP) and phospholipid transfer protein 
(PLTP) activity were measured by collaborators at Roar Biomedical Inc. (New York, 
NY) utilizing a commercial assay on both patient cohorts.  The intravascular metabolism 
of lipid components of HDL is regulated by enzymes such as cholesteryl ester transfer 
protein (CETP) and phospholipid transfer protein (PLTP).  Consequently, HDL lipids 
represent complex mixtures of multiple molecular species of phospholipids, cholesteryl 
esters, triacylglycerols, and partial glycerides which differ in their fatty acid 
composition, in addition to free cholesterol and lipophilic vitamins.  The abundance of 
individual molecular species of cholesteryl ester in HDL reflects esterification of free 
cholesterol by LCAT, but equal removal of HDL cholesteryl ester by cellular receptors, 
primarily by scavenger receptor class B type 1 (SR-B1), and by CETP, which transfers 
cholesteryl ester to apoB-containing particles including VLDL, VLDL remnants, and 
LDL in exchange for triglycerides.   
 
Cholesteryl Ester Transfer Protein Assay    __________________________________
Cholesteryl ester transfer protein (CETP), transfers neutral lipids from HDL to 
VLDL and is present in human serum.  CETP plays an important role in lipoprotein 
metabolism and influences the reverse cholesterol transport pathway.  As key 
determinants of core lipid abundance and composition, LCAT and CETP activities 
regulate the maturation of nascent HDL to spherical particles, and thereby modulate 
HDL heterogeneity and function.  The Roar CETP Activity Assay is useful for 
measuring the CETP activity in human serum.   The Roar CETP Activity Assay Kit uses 
a proprietary substrate that enables the detection of CETP-mediated transfer of neutral 
lipid from the substrate to a physiological acceptor.  The transfer activity results in an 
increase in fluorescence intensity and is further described in the methods chapter.  For 
the CETP assay, a standard curve was prepared by making serial dilutions of the donor 
molecule in isopropanol and subsequently recording the fluorescence intensity of each 
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dilution, using isopropanol alone as a blank.  The standard curve for the CETP assay is 
shown in Figure 182.   
 
 
 
Figure 182.  CETP standard curve. 
 
 
The fluorescence intensity values of the standard curve were applied directly to 
the results to express activity of the plasma sample as described in the methods chapter.  
The results from the CETP activity assay are shown in Tables 159 and 160 in addition to 
the true mean CETP values at the 95% confidence level. 
 
 
Table 159.  CETP assay results for the control cohort 
Patient 
pMoles 
Transferred 
pMoles 
transferred/µL/hr 
Average 
FIU 
Transferred 
FIU 
1 104 69 3550 1686 
3 115 77 3707 1843 
7 133 89 3943 2079 
13 92 61 3389 1525 
14 143 96 4081 2217 
y = 13364x + 300.12 
R² = 0.9991 
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Table 160.  (Continued) 
Patient 
pMoles 
Transferred 
pMoles 
transferred/µL/hr 
Average 
FIU 
Transferred 
FIU 
16 135 90 3975 2111 
24 170 113 4431 2567 
25 128 85 3869 2005 
Average 128 85 3868 2004 
Standard 
Deviation 24 16 324 324 
True Mean 128 ± 20 85 ± 14 
3868 ± 
271 2004 ± 271 
 
 
In the control cohort, there was an average of 128 ± 20 pMoles transferred, 85 ± 
14 pMoles transferred/all/hr, 3868 ± 271 average fluorescence intensity units, and 2004 
± 271 transferred fluorescence intensity units.  The highest CETP activity was observed 
in patient 24, who had a transfer rate of 113 pMoles/µL/hour and the lowest CETP 
activity was observed in patient 13 who had a transfer rate of 61 pMoles/µL/hour.   
 
Table 161.  CETP assay results for the CAD cohort 
Patient 
pMoles 
Transferred 
pMoles 
transferred/µL/hr 
Average 
FIU 
Transferre
d FIU 
10 104 69 3550 1686 
41 137 91 3991 2127 
49 128 85 3871 2007 
84 54 36 2887 1023 
143 138 92 4005 2141 
146 147 98 4125 2261 
170 92 61 3395 1531 
195 48 32 2811 947 
Average 106 71 3579 1715 
Standard 
Deviation 39 26 512 512 
True Mean 106 ± 32 71 ± 21 
3579 ± 
429 1715 ± 429   
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In the CAD cohort, there was an average of 106 ± 32 pMoles transferred, 71 ± 21 
pMoles transferred/µL/hr, 3579 ± 429 fluorescence intensity units, and 1715 ± 429 
fluorescence intensity units transferred.  It was seen that the highest CETP activity was 
observed in patient 146, who had a transfer rate of 98 pMoles/µL/hour and the lowest 
CETP activity was observed in patient 195 who had a transfer rate of 32 
pMoles/µL/hour.  It is worth noting that patient 195, who had the lowest CETP activity 
was also a low birth weight infant and possesses apoC-I enriched HDL.  It is known that 
apoC-I is an inhibitor of CETP and this inhibition may be responsible for the 
substantially lower CETP transfer rate observed from patient 195.  Compared to the 
control cohort, the CAD cohort had slightly lower average CETP activity, as this cohort 
contained unanimous apoC-I isoforms, there may be a direct correlation between their 
lower CETP rates and apoC-I composition.  Interestingly, research has shown a link 
between low CETP activity and protection from CAD.  It is probable that the CETP 
lower activity observed in the CAD cohort, is an attempt by the body to attenuate plaque 
progression. 
               ________________________________________
 
Ex Vivo Cholesteryl Ester Transfer Protein Assay 
The Roar Ex Vivo CETP Activity Assay is useful for evaluating non-reversible 
and reversible inhibitors on plasma CETP activity.  The assay is not affected by changes 
in HDL concentration or other endogenous lipoproteins.  The difference between the 
RB-EVAK and RB-CETP is that with the EVAK assay, the concentration of serum is 
200µL with 5µL substrate compared to 0.5µL serum in 200µL substrate with the RB-
CETP assay.  The EVAK dilutes serum less, and when reversible inhibitors are present 
the EVAK is the preferred assay.  The standard curve used for this assay is shown in 
Figure 183.  The results for the patient samples from this assay are shown in Tables 161 
and 162 in addition to the true mean CETP values at the 95% confidence level. 
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Figure 183.  EVAK standard curve. 
 
 
Table 162. EVAK results for the control cohort. 
Patient 
pMoles 
Transferred 
pMoles 
transferred/µL/hr 
Average 
FIU 
Transferred 
FIU 
1 84 9 8006 1669 
3 104 12 7489 1987 
7 90 10 8000 1768 
13 87 10 8315 1722 
14 129 14 7724 2396 
16 139 15 8099 2544 
24 11 1 10187 512 
25 98 11 8311 1902 
Average 93 10 8266 1813 
Standard 
Deviation 39 4 824 614 
True Mean 93 ± 32 10 ± 4 
8266 ± 
689 1813 ± 513 
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The control cohort had an average 93 ± 32 pMoles transferred, 10 ± 4 pMoles 
transferred/µL/hr, 8266 ± 689 fluorescence intensity units, and 1813 ± 513 transferred 
fluorescence intensity units.  The highest rate was observed in patient 16 with a rate of 
15 pMoles transferred/µL/hr.  The lowest rate was observed in patient 24 with a rate of 1 
pMoles transferred/µL/hr. 
 
 
Table 163. EVAK results for the CAD cohort. 
Patient 
pMoles 
Transferred 
pMoles 
transferred/µL/hr Average FIU 
Transferred 
FIU 
10 50 6 6256 1137 
41 56 6 13335 1224 
49 100 11 7407 1931 
84 52 6 6605 1154 
143 90 10 7445 1760 
146 135 15 8535 2484 
170 176 20 14755 3134 
195 29 3 5776 795 
Average 86 10 8764 1702 
Standard 
Deviation 29 3 5776 795 
True Mean 86 ± 42 10 ± 5 8764 ± 3387 1702 ± 792 
 
 
The CAD cohort had an average 86 ± 42 pMoles transferred, 10 ± 5 pMoles 
transferred/µL/hr, 8764 ± 3387 fluorescence intensity units, and 1702 ± 792 transferred 
fluorescence intensity units.  The highest rate was observed in patient 170 with a rate of 
20 pMoles/transferred/µL/hr.  The lowest rate was observed in patient 195 with a rate of 
3 pMoles transferred/µL/hr.  The EVAK assay provides a 96% serum volume analysis as 
it does not dilute serum to the extent of the CETP assay. This large percentage of 
undiluted serum results in the inclusion of all factors that may affect the CETP at 
physiological concentration, in addition to reversible inhibitors such as apoC-I. 
Interestingly, patient 195 maintained the lowest CETP transfer rate in the CAD cohort 
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with the EVAK assay which is not affected by changes in HDL concentration or other 
endogenous lipoproteins.   
Recent studies have supported an interest in CETP inhibition in vivo by means of 
either anti-CETP immunotherapy, antisense oligoneluceotides, or specific 
pharmacological inhibitors.
207, 208, 209
  Studies have also shown that small anti-CETP 
molecules in human populations demonstrate that CETP inhibition markedly increases 
HDL-C levels and also decreases LDL-C levels.
58, 210, 211
  In addition to intervention 
studies utilizing exogenous substances, studies have shown that plasma CETP levels can 
be modulated by endogenous factors including the apolipoprotein content of lipoproteins 
in circulation.
212, 213,
 
214
 ApoC-I has been identified as a potent inhibitor of CETP 
activity,
215
 and unlike other apolipoprotein inhibitors this candidate has been shown to 
have the ability to decrease CETP activity in vivo using mouse models.
98, 102
  ApoC-I can 
suppress CETP-mediated lipid transfer in a concentration dependent manner.
215
  Thus 
variation in apoC-I concentration may be a determinant of neutral lipid exchange in 
human plasma.  Though it is known that apoC-I is a major physiological inhibitor of 
CETP in plasma, the molecular mechanism of the blockade remains under investigation.  
The transfer reaction that takes place involving CETP is a complex reaction consisting of 
at least two rate determining steps.  In the first step, CETP binds to lipoproteins through 
electrostatic interactions with negative charges localized at the lipoprotein surface.
216, 217
  
Next, following a CETP conformational change, one neutral lipid molecule binds to a 
hydrophobic site in the C-terminus of the protein prior to being transferred to an electron 
acceptor.
218, 219
  Studies have reported mainly two ways by which the CETP-mediated 
transfer reaction is blocked.  CETP inhibition may be a result of insufficient or excessive 
binding between CETP and the lipoprotein surface, as it has been shown that both 
weak
217, 220
 and strong
217, 219
 CETP-lipoprotein interactions significantly inhibit the lipid 
transfer reaction.  Another way by which CETP may be inhibited is through the blockade 
of the neutral lipid binding site, resulting in abnormal production of irreversibly 
associated CETP-lipoprotein complexes.
221,
 
222
  Dumont and colleagues recently studied 
the effect of apoC-I on the lipid transfer process and indicated that the inhibitory 
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property of apoC-I is in a direct link with its electrostatic charge properties and its ability 
to produce significant changes in CETP-lipoprotein interactions.
223
   In all cases the 
addition of apoC-I was accompanied by a marked inhibition of the lipid transfer 
reaction.  It was determined that CETP inhibition by HDL is the consequence of a direct 
and specific property of apoC-I, because apoC-I-poor HDL displayed a much weaker 
ability to block the lipid transfer reaction in the HDL concentration ranges studied.   
Additionally, it appeared that the inhibitory effect of human apoC-I is a direct 
consequence of its unique electrostatic properties that lead to alteration of the HDL-
CETP interactions.  The elucidation of the molecular mechanism of CETP inhibition by 
apoC-I may help identify new mechanisms of CETP blockade.  Kinetic studies have 
shown that the CETP reaction in plasma is dependent on the amount and the specific 
activity of CETP, as well as on the concentrations and properties of lipoprotein 
substrates such as HDL.
224,
 
225
 Dumont and colleagues observed that the inhibitory 
potential of apoC-I is dependent on the amount of HDL and not CETP added.
223 
These 
observations suggest that apoC-I may inhibit CETP through its ability to modify the 
HDL substrate, rather than through a specific blockade of the CETP molecule.   In vitro 
studies examining the electrostatic properties of apoC-I showed that apoC-I is able to 
produce a significant change in HDL electronegativity which is recognized today as a 
leading factor in determining the strength of CETP-HDL interactions and the velocity of 
CETP transfer activity.
226
  Overall, it appears as though the inhibition of CETP activity 
by apoC-I depends in part on the electrostatic properties of apoC-I which have the ability 
to shift HDL toward lower electronegativity.  It is very likely that apoC-I mediated 
alteration in the binding of CETP to lipoproteins may result in fewer cholesteryl ester 
transfers in human plasma. 
  ________________________________
 
Phospholipid Transfer Protein Assay 
The content of phospholipid molecular species in the HDL particle surface can 
be modulated by transfer or exchange with cell membranes and lipoprotein facilitated by 
PLTP, and by the actions of plasma and lipoprotein-associated phospholipases, HL, and 
278 
 
 
 
EL.  The Roar PLTP Activity Assay Kit also includes proprietary substrates to detect 
PLTP mediated transfer of the fluorescent substrate and is performed similarly to the 
CETP assay. For the PLTP assay, a standard curve was prepared by making serial 
dilutions of the donor molecule in isopropanol and subsequently recording the 
fluorescence intensity of each dilution, using isopropanol alone as a blank.  The standard 
curve for the PLTP Assay is shown in Figure 184. 
 
 
 
Figure 184. PLTP standard curve. 
 
 
  The fluorescence intensity values of the standard curve were applied directly to 
the results to express activity of the plasma sample as described in the methods chapter.  
The results of the PLTP assay are shown in Tables 163 and 164 in addition to the true 
mean CETP values at the 95% confidence level. 
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Table 164. PLTP assay results for the control cohort     
Patient 
pMoles 
Transferred 
pMoles 
transferred/µL/hr 
Average 
FIU 
Transferred 
FIU 
1 14.3 11.4 2525 1435 
3 17.6 14.1 2789 1699 
7 16.3 13 2686 1596 
13 21.4 17.2 3092 2002 
14 13.5 10.8 2462 1372 
16 11.1 8.9 2274 1184 
24 16.9 13.5 2733 1643 
25 13.4 10.8 2461 1371 
Average 15.6 12.5 2628 1538 
Standard 
Deviation 3.2 2.6 253 253 
True Mean 15.6 ± 2.7 12.5 ± 2.1 
2628 ± 
211 1538 ± 211 
 
 
 The control cohort had an average 15.6 ± 2.7 pMoles transferred, 12.5 ± 2.1 
pMoles transferred/µL/hr, 2628 ± 211 fluorescence intensity units, and 1538 ± 211 
transferred fluorescence intensity units.  The highest PLTP rate was observed in patient 
13 with a rate of 17.2 pMoles transferred/µL/hr.  The lowest rate was observed in patient 
16 with a rate of 8.9 pMoles transferred/µL/hr. 
 
 
 
Table 165. PLTP assay results for the CAD cohort     
Patient 
pMoles 
Transferred 
pMoles 
transferred/µL/hr 
Average 
FIU 
Transferred 
FIU 
10 23.7 18.9 3267 2177 
41 23.3 18.6 3238 2148 
49 12.7 10.1 2400 1310 
84 12.7 10.2 2405 1315 
143 12.3 9.8 2369 1279 
146 26.3 21 3475 2385 
170 27 21.6 3539 2439 
195 12.3 9.8 2367 1277 
Average 19 15 2883 1791 
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Table 166. (Continued)     
Patient 
pMoles 
Transferred 
pMoles 
transferred/µL/hr 
Average 
FIU 
Transferred 
FIU 
Standard 
Deviation 6.8 5.5 541 539 
True Mean 19 ± 5.7 15 ± 4.6 
2883 ± 
452 1791 ± 451 
 
 
The CAD cohort had an average 19 ± 5.7 pMoles transferred, 15 ± 4.6 pMoles 
transferred/µL/hr, 2883 ± 452 fluorescence intensity units, and 1791 ± 451 transferred 
fluorescence intensity units.  The highest PLTP rate was observed in patient 170 with a 
rate of 21.6 pMoles transferred/µL/hr.  The lowest PLTP rate was observed in patients 
195 and 143 with a rate of 9.8 pMoles transferred/µL/hr.   
The influence of transfer protein rates on CAD risk is complex and it has been 
shown that both increased and decreased rates of PLTP pose risk in human studies.
227, 
228,
 
229
  The importance of this transfer protein centers around its function in mediating 
the transfer and exchange of phospholipids between lipoproteins
230,
 
231
 and its role in the 
conversion of HDL in a time and concentration dependent manner.
232,
 
233
  PLTP can 
mediate the conversion of HDL into larger and smaller particles
234,
 
235
 and generate the 
efficient and preferred cholesterol acceptor, pre-β HDL, in the process.236  Other notable 
functions which also affect CAD risk and overall health include the ability of PLTP to 
bind and transfer unesterified cholesterol
237,
 
238
 and α-tocopherol239 among lipoprotein 
particles and cells.  α-Tocopherol is the most potent antioxidant form of vitamin E, and 
circulates in plasma bound to lipoproteins playing a major role in preventing lipoprotein 
oxidation and maintaining endothelial function.
85, 240,
 
241,
 
242
   Interestingly, this protein 
can also alter the anti-oxidative potentials of lipoprotein particles.
239
  Recently it was 
reported that PLTP was increased in patients with systemic and acute inflammatory 
response
243,
 
244
 associating PLTP with inflammatory activity.   This relationship between 
inflammation and PLTP is significant since there is supporting evidence regarding the 
relationship between inflammation and atherogenesis.
245
  Additionally, PLTP has been 
implicated in human atherosclerosis, where it has been detected both on macrophage 
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foam cells and on the extracellular matrix.
246
 Consistent with this implication, increased 
presence of PLTP has been found in arterial smooth muscle cells and macrophages in 
atherosclerotic lesions and is increased with cholesterol loading of macrophages.
238
  
PLTP activity has been shown to increase in conjunction with other independent risk 
factors for CAD such as cigarette smoking
247,
 
248 
excessive alcohol intake
249
 and over 
consumption of the diterpenes present in filtered coffee.
247 
  
Similar to the results from both cohorts included in this study showing slightly 
higher PLTP levels in the CAD cohort, Schlitt and colleagues also studied PLTP rates in 
CAD and control subjects.
229  
This study demonstrated for the first time that plasma 
PLTP levels were higher in CAD subjects than controls, and this difference was found to 
be independent of other risk factors.  Many possible explanations may result in the 
relationship between plasma PLTP activity and CAD.  One possible explanation is that 
high PLTP activity may decrease HDL concentrations in line with this possibility,  
overexpression of PLTP in mouse models have been shown to decrease HDL levels. 
250
  
A second explanation for the PLTP and CAD relationship is that high PLTP activity may 
increase TRL concentrations.  Previous studies with mice have demonstrated that PLTP 
deficiency in mice resulted in reduced production and levels of TRL and a decrease in 
atherosclerosis.
251
  Thirdly, high PLTP activity may provide a state of prolipoprotein 
oxidation.  Recent work has shown a significant increase in vitamin E content of VLDL 
and LDL in PLTP deficient mice compared to normal PLTP activity control mice.
252,
 
253
  
Thus it is highly probable that PLTP activity in CAD subjects may promote TRL 
oxidation.  Lastly, high plasma PLTP activity may transfer more oxidized phospholipids 
from TRL to HDL, which may subsequently become less protective against 
atherosclerosis than normal HDL.  Studies supporting this hypothesis have shown that 
PLTP deficient mice have decreased ability of HDL to inhibit LDL oxidation in artery 
wall cell cultures.
229
  Further studies investigating PLTP will be needed as recent studies 
have been mainly hypothesis generating and not proving.  The finding that PLTP activity 
is a risk factor for CAD will need to be confirmed by prospective studies.  If proven, 
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PLTP activity may serve as a therapeutic target and be identified as a biomarker for 
CAD. 
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CHAPTER IV 
  
CONCLUSIONS 
   
 Density gradient ultracentrifugation, capillary electrophoresis, and MALDI-MS, 
were used to assess two cohorts of serum samples obtained from CAD patients and non-
CAD control patients. These methods collectively provided significant clinical 
information regarding human serum subfractions and their corresponding 
apolipoproteins, including apolipoprotein composition, electrophoretic mobilities, 
molecular weights, post-translational modifications, and isoforms.  
 Methods for obtaining accurate serum high density lipoprotein subfractions using 
DGU were investigated and improved.  This was accomplished through the modification 
and correction of the defined cut points previously used to obtain the HDL subfractions.  
Excised serum fractions were re-spun following gravimetric density determination to 
determine where these cut fractions would appear on the lipoprotein density profile.  
Upon re-spinning it was discovered that samples were minimally contaminated with 
neighboring fractions. The excised fractions however, did possess the correct densities 
despite the minimal contamination.  The fact that the subfractions were obtained using a 
heavy metal solute system, demonstrated feasibility, accuracy, and precision of the 
method.  The dense protein or bottom fraction of the serum sample was found to be 
composed of HDL3 and protein in some patients.  This fraction contained a volume of 
less than 60µL and was below the seam of the polycarbonate UC tube making adequate 
UC separation of this fraction difficult.  In the future, it would be beneficial to invest in a 
longer UC rotor in order to utilize longer UC tubes to achieve a complete and improved 
separation of this particular region.  Likewise, modification of the concentration of the 
heavy metal Cs2CdY density gradient solute may also provide a better separation of the 
HDL subclasses and perhaps even obtain baseline resolution within the HDL subclasses. 
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Methods for the secondary analysis of subfractions were also developed through 
the use of commercial apolipoprotein standards.  The solid phase extraction protocol 
with the C18 cartridge for delipidation and desalting of the lipoprotein fraction was 
investigated.  Four 100µL 0.1% TFA in acetonitrile elutions were collected to ensure 
high recovery of the apolipoproteins and verified by MALDI-MS analysis.  It was found 
that only the first 100µL elution contained analytes.  In the future, it would be beneficial 
to investigate other methods of delipidation that would remove more human serum 
albumin from the samples prior to secondary analysis as this protein was found in 
substantial quantities in the HDL fractions. 
 Capillary electrophoresis was used to analyze the serum subfractions from the 
two patient cohorts and to confirm the elution pattern following solid phase extraction.  
The protein compositions of the four individual serum subfractions were uniform 
throughout the patient samples and cohorts.  The electrophoretic mobilities of the 
apolipoproteins were observed for the two cohorts and various serum subfractions.  The 
electrophoretic mobility of apoA-I fluctuated minimally depending on the serum fraction 
and other sample constituents.  There were also no distinct differences observed between 
the two patient cohorts in terms of electrophoretic mobilities and peak shapes.  In the 
future it would be beneficial to explore the use of larger serum volumes for capillary 
electrophoresis analysis to better visualize less abundant apolipoproteins and to enable 
quantitation of apolipoproteins.   
Serum fractions were analyzed by MALDI-MS as a qualitative analytical 
method.  Increased sensitivity and resolution were obtained using the Voyager STR 
instrument.  MALDI-MS analysis provided the most valuable information regarding 
apoC-I.  It was observed in the CAD patient samples from every serum subfraction 
analyzed, that there was a shift in the mass to charge ratio corresponding to apoC-I and 
apoC-I , the truncated form of the protein.  This shift was approximately 90amu higher 
than the known mass of this protein, and was not observed in any of the control patient 
samples, whose apoC-I and apoC-I peaks were at the known masses for these two 
proteins.  In addition to the shifting, some of the CAD patients demonstrated further 
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modifications indicative of oxidative processes. One patient, who did not have diagnosed 
CAD, displayed MALDI-MS spectra identical to those in the CAD cohort; such a 
spectral pattern suggests that this individual will develop CAD in the future. These 
observations strongly supported the hypothesis that some forms of apoC-I are potentially 
atherogenic. In the future, it would be beneficial to fragment the apoC-I peaks to identify 
the modifications to this protein as there was variation in the masses of the CAD cohort 
apoC-I peaks. 
The bottom or protein fraction was analyzed by the methodologies described 
previously to evaluate any loss of apolipoproteins during the ultracentrifugation spin 
especially considering the contamination of the protein fraction with HDL3.  The 
capillary electrophoresis and MALDI-MS results of this fraction indicated that it was 
composed predominantly of human serum albumin.  However, apoA-I and apoC-I were 
also detected in the mass spectra of some CAD patient protein fractions.  It was 
hypothesized that the apolipoproteins present in this fraction were from mixing with the 
HDL3 fraction; however, they could also be from apolipoproteins present in the free 
form or as nascent HDL.  Based on the analysis, however, very minimal loss of 
apolipoproteins occurred during the ultracentrifugation spin. 
HDL enriched in apoC-I is an emerging risk factor for CAD.  Some subjects with 
this risk factor have elevated HDL-cholesterol levels and were initially perceived to have 
a lower risk of CAD based upon their lipid levels.  In collaborative studies with Johns 
Hopkins, it was observed that apoC-I enriched HDL fractions and apoC-I enriched 
serum induced apoptosis of aortic smooth muscle cells.  Interestingly, these apoC-I 
enriched biological samples were from a CAD patient with the modified apoC-I mass 
peaks.  It is probable that this modification may in turn be influencing the stimulation of 
one or more membrane bound protein kinases which in turn activate the neutral 
sphingomyelinase pathway inducing apoptosis of human aortic smooth muscle cells and 
could be due to a genetic mutation that could compromise apoC-I function. 
  Transfer protein tests were performed for both cohorts of patients.  Cholesteryl 
ester transfer protein (CETP) rates were lower in the CAD cohort compared to the 
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control cohort.  The CAD patient with the lowest of all CETP transfer rates was also a 
low birth weight infant with apoC-I enriched HDL.  This finding correlated with the 
known fact that apoC-I is an inhibitor of CETP.  It is unknown, however, whether this 
inhibition contributes to CAD development or is a protective response to halt or decrease 
CAD development.  Phospholipid transfer protein (PLTP) rates were also assessed from 
the two cohorts and resulted in higher transfer rates in the CAD cohort. 
 Overall, the wide array of methods utilized provided information that was 
frequently supported by the other methods.  Analyzing the serum subfractions from two 
cohorts of clinically different patients enabled a closer look into the composition of HDL 
serum subfractions.  Novel apoC-I isoforms were identified through MALDI-MS 
analysis in all CAD cohort patients.  This modified protein also proved to be apoptotic in 
collaborative clinical studies.  Through the incorporation of several methods and studies, 
it was elucidated that apoC-I has the capability of being modified post-translationally 
and subsequently influences apoptosis of aortic smooth muscle cells, ultimately leading 
to the destabilization of atherosclerotic plaque and acceleration of CAD. 
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